Salt-inducible kinase inhibitory compound and pharmaceutical composition containing same

A novel compound inhibiting SIK1, SIK2, and SIK3 effectively addresses the limitations of current SIK inhibitors by simultaneously targeting all three isoforms, enhancing anti-inflammatory responses in macrophages by suppressing inflammatory cytokines and promoting IL-10 production.

WO2024242169A1PCT designated stage expired Publication Date: 2024-11-28TANABE PHARMA CORP

Patent Information

Application Number
PCT/JP2024/018995
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2024-05-23
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current SIK inhibitors are ineffective in targeting all three isoforms (SIK1, SIK2, and SIK3) simultaneously, which is crucial for demonstrating drug efficacy in macrophages, as inhibition of both SIK1 and SIK2, and especially all three, is necessary to suppress inflammatory cytokines and promote anti-inflammatory cytokines effectively.

Method used

Development of a novel compound represented by formula (I), which effectively inhibits all three SIK isoforms (SIK1, SIK2, and SIK3), allowing for the suppression of inflammatory cytokines and promotion of anti-inflammatory cytokines, thereby inducing a specific macrophage phenotype.

Benefits of technology

The compound achieves significant inhibition of SIK1, SIK2, and SIK3, leading to reduced production of inflammatory cytokines like TNF-α and increased production of anti-inflammatory cytokine IL-10, demonstrating improved drug efficacy in macrophages.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018995_28112024_PF_FP_ABST
    Figure JP2024018995_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention addresses the problem of providing: a novel compound capable of effectively inhibiting all of SIK1, SIK2, and SIK3; and a pharmaceutical composition containing the same. Provided is a compound represented by formula (I): [in the formula, each symbol is as described in the description] or a pharmacologically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Salt-inducible kinase inhibitor compounds and pharmaceutical compositions containing the same

[0001] The present invention relates to salt-inducible kinase inhibitor compounds and pharmaceutical compositions containing same.

[0002] Salt-inducible kinases (SIKs) belong to the AMP-activated protein kinase (AMPK) family and are primarily involved in the regulation of energy response-related physiological processes such as gluconeogenesis and lipid metabolism. The SIK family consists of three isoforms, SIK1, SIK2, and SIK3, all of which are believed to act as metabolic mediators. SIKs exhibit autophosphorylation and play an important role in regulating adrenal cortical function under high salt or adrenocorticotropic hormone (ACTH) stimulation.

[0003] The SIK family consists of three members: SIK1, SIK2, and SIK3, all of which are widely expressed. SIK1 mRNA expression is regulated by multiple stimuli, including high salt intake, ACTH signaling, glucagon signaling, depolarization of excitable cells, and circadian rhythms. On the other hand, SIK2 and SIK3 expression is constitutive in tissues where these kinases are expressed. In humans, SIK2 and SIK3 are ubiquitously expressed, with SIK2 being most highly expressed in adipose tissue and SIK3 in the brain. Furthermore, these SIK family members are dysregulated in various cancers, including ovarian cancer, breast cancer, prostate cancer, and lung cancer, suggesting that SIK plays an important role in the development and progression of cancer.

[0004] SIK controls a novel molecular switch that regulates macrophage polarization. Pharmacological inhibition of SIK induces a macrophage phenotype characterized by high secretion of anti-inflammatory cytokines such as interleukin (IL)-10 and extremely low secretion of pro-inflammatory cytokines such as tumor necrosis factor-α. However, it was unclear which of the three isoforms, SIK1, SIK2, and SIK3, is the appropriate target. Non-Patent Document 1 addressed this issue, showing that in a study using mouse macrophages, macrophages in which both SIK1 and SIK2 were inactivated suppressed the production of pro-inflammatory cytokines (TNF-α, IL-12p40) and promoted the production of anti-inflammatory cytokines (IL-10) upon stimulation with lipopolysaccharide (LPS), compared with macrophages in which only SIK2 was inactivated. This indicates that the inhibition of both SIK1 and SIK2 is important for efficacy compared with the inhibition of SIK2 alone. In addition, a SIK1 / 2 / 3 inhibitor (structure: In macrophages in which all of SIK1, SIK2, and SIK3 were inhibited by adding a compound having the formula (HG-9-91-01), TNF-α and IL-12p40 production was suppressed and anti-inflammatory cytokine (IL-10) production was promoted compared to SIK1- and SIK2-inactivated macrophages, demonstrating that inhibiting all of SIK1, SIK2, and SIK3 is the most important factor for demonstrating pharmacological efficacy in macrophages.

[0005] Patent Documents 1 to 5 disclose compounds that exhibit a certain degree of SIK inhibitory activity.

[0006] International Publication No. WO 2019 / 105886 International Publication No. WO 2019 / 238424 International Publication No. WO 2020 / 239658 International Publication No. WO 2020 / 239660 Chinese Patent Application Publication No. 115448881

[0007] Darling NJ, Toth R, Arthur JS, and Clark K. Inhibition of SIK2 and SIK3 during differentiation enhances the anti-inflammatory phenotype of macrophages. Biochem J. 2017; 474(4): 521-537

[0008] It has been suggested that it is important for SIK inhibitor compounds useful as pharmaceuticals to inhibit all of SIK1, SIK2 and SIK3, and there is a need to develop compounds that can effectively inhibit all of such SIK1, SIK2 and SIK3.

[0009] An objective of the present invention is to provide a novel compound that can effectively inhibit all of SIK1, SIK2 and SIK3, and a pharmaceutical composition containing the same.

[0010] As a result of the investigation, it was found that the problem can be solved by the following specific means.

[0011] One embodiment of the present invention is a compound represented by the following formula (I): [In the formula, R 1 represents a cyano group, a C optionally substituted with 1 to 3 halogen atoms, 1-4 alkyl group or R 1a C optionally substituted with 1 to 3 substituents independently selected from 1-4 an alkoxy group, where R 1a is a halogen atom; a cyano group, a halogen atom, and C 1-4 a 5- or 6-membered monocyclic aromatic heterocyclic group which may be substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups; a 4-membered monocyclic aliphatic heterocyclic group; a hydroxyl group; 3-4 a cycloalkyl group; and a phenyl group, wherein L is a single bond, C 1-4 Alkylene group or C 2-4 is an alkenylene group, R 2 is R 2a is a 5-membered monocyclic aromatic heterocyclic group optionally substituted with 2a is R2b C optionally substituted with 1 to 4 substituents independently selected from 1-5 an alkyl group or a 5-membered monocyclic aliphatic heterocyclic group, wherein R 2b is a hydroxyl group; C optionally substituted with a hydroxyl group 3-4 Cycloalkyl group; halogen atom; C 1-4 an alkoxy group; a 4- to 6-membered monocyclic aliphatic heterocyclic group optionally substituted with 1 to 3 substituents independently selected from the group consisting of a halogen atom and an oxo group; an oxo group; 1-4 an amino group optionally substituted with an alkyl group; a phenyl group; a 5-membered monocyclic aromatic heterocyclic group; and C 1-4 alkylsulfonyl group, R 3 is a hydrogen atom or C optionally substituted with 1 to 3 halogen atoms 1-4 is an alkoxy group, R 4 is C optionally substituted with 1 to 3 halogen atoms 1-4 is an alkoxy group, R 5 is a hydrogen atom, and R 6 is a hydrogen atom; a C substituted with a halocyclopropyl group 1-4 an alkyl group; or a cyclopropyl group substituted with 1 to 2 halogen atoms; or R 5 and R 6 together with the nitrogen atom to which they are attached form an azetidine ring (wherein the azetidine ring is a C 1-4 C optionally substituted with an alkyl group, a hydroxyl group, or 1 to 2 halogen atoms 1-4 substituted with 1 to 2 substituents independently selected from the group consisting of an alkoxy group, a cyano group, and an amino group; or 4 and R 6 is R 4 together with the benzene ring to which it is attached to form a tetrahydroisoquinolin-1-one ring (wherein the ring is 1-4or a pharmaceutically acceptable salt thereof.

[0012] Another embodiment of the present invention is a pharmaceutical composition comprising, as an active ingredient, the compound of formula (I) or a pharmaceutically acceptable salt thereof. This pharmaceutical composition is used for the prevention or treatment of various diseases and / or associated symptoms that can be improved by inhibition of salt-inducible kinase (SIK), or for improving the prognosis of such diseases and / or associated symptoms.

[0013] Another embodiment of the present invention is a pharmaceutical comprising, as an active ingredient, the compound of formula (I) or a pharmacologically acceptable salt thereof. This pharmaceutical is used for preventing or treating various diseases and / or associated symptoms that can be improved by salt-inducible kinase (SIK) inhibition, or for improving the prognosis of such diseases and / or associated symptoms. Another embodiment of the present invention is use of the compound of formula (I) or a pharmacologically acceptable salt thereof for the manufacture of an agent for preventing or treating various diseases and / or associated symptoms that can be improved by salt-inducible kinase (SIK) inhibition. Another embodiment of the present invention is a method for preventing or treating various diseases and / or associated symptoms that can be improved by salt-inducible kinase (SIK) inhibition, comprising administering to a patient a therapeutically effective amount of the compound of formula (I) or a pharmacologically acceptable salt thereof. Another embodiment of the present invention is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of various diseases and / or symptoms associated therewith that can be ameliorated by inhibition of salt-inducible kinase (SIK), or for use in improving the prognosis of such diseases and / or symptoms associated therewith.

[0014] According to one embodiment of the present invention, there are provided novel compounds that can effectively inhibit all of SIK1, SIK2 and SIK3, and pharmaceutical compositions containing the same.

[0015] [Definition of each group used in this specification] The definition of each group used in this specification will be described in detail below. Unless otherwise specified, each group has the following definition. In this specification, when describing the number of carbon atoms constituting a certain group, the notation "C1-C6" may be used instead of "1 to 6 carbon atoms". Furthermore, when describing the number of atoms constituting a certain ring, the notation "3 to 6-membered" may be used instead of "3 to 6 atoms constituting the ring".

[0016] When a compound has an acidic functional group and / or a basic functional group in the compound, it can form a salt. Examples of such salts include metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, etc.

[0017] As used herein, examples of a "halogen atom" include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom. In one embodiment, the halogen atom may be a fluorine atom.

[0018] In this specification, the term "alkyl group" (including the "alkyl" portion in the definition) refers to a straight or branched alkyl group having 1 to 6 carbon atoms, and examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, and 3,3-dimethylbutyl. 1-5 The term "alkyl group" refers to an alkyl group having 1 to 5 carbon atoms. 1-4 The "alkyl group" is an alkyl group having 1 to 4 carbon atoms. When the alkyl group has a substituent, the substituent may be present at any substitutable position, and when there are two or more substituents, the respective substituents may be the same or different. For example, -CH 2 CON (CH 3 ) 2 corresponds to an oxo group; and an alkyl group substituted with an amino group substituted with two methyl groups.

[0019] In the present specification, the term "alkylene group" (including the "alkylene" portion in the definition) refers to a linear or branched alkylene group having 1 to 4 carbon atoms, for example, -CH 2 -, -(CH 2 ) 2 -, -(CH 2 ) 3 -, -(CH 2 ) 4 -, -CH(CH 3 ) -, -C(CH 3 ) 2 -, -CH(C 2 H 5 ) -, -CH(C 3 H 7 )-,-CH(CH(CH 3 ) 2 )-,-(CH(CH 3 )) 2 -, -CH 2 -CH(CH 3 ) -, -CH(CH 3 )-CH 2 - are listed.

[0020] In the present specification, the term "alkenylene group" (including the "alkenylene" portion in the definition) refers to a straight or branched alkenylene group having 2 to 4 carbon atoms, such as -CH=CH-, -CH 2 -CH=CH-, -CH=CH-CH 2 -, -CH 2 -CH=CH-CH 2 -, -CH 2 -CH 2 -CH=CH-, -CH=CH-CH 2 -CH 2 -, -CH=CH-CH=CH-.

[0021] As used herein, the term "alkoxy group" (including the "alkoxy" portion in the definition) refers to a straight-chain or branched-chain alkoxy group having 1 to 4 carbon atoms, and examples thereof include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert-butoxy. When the alkoxy group has a substituent, the substituent may be located at any substitutable position, and when there are two or more substituents, the respective substituents may be the same or different.

[0022] As used herein, the term "cycloalkyl group" (including the "cycloalkyl" portion in the definition) refers to a monocyclic cycloalkyl group having 3 to 4 carbon atoms, and examples include cyclopropyl and cyclobutyl. The cycloalkyl group can have one bond at any substitutable position. When the cycloalkyl group has a substituent, the substituent can be located at any substitutable position, and when there are two or more substituents, the substituents may be the same or different. As used herein, the term "halocyclopropyl group" refers to a cyclopropyl group substituted with 1 to 3 halogen atoms.

[0023] As used herein, the term "monocyclic aliphatic heterocyclic group" (including the "monocyclic aliphatic heterocyclic" portion in the definition) refers to a saturated or partially unsaturated 4- to 6-membered monocyclic aliphatic heterocyclic group containing, in addition to carbon atoms, 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur as ring-constituting atoms. Here, "partially unsaturated" means that the ring contains a double bond in part. Examples of monocyclic aliphatic heterocyclic groups include azetidinyl (azetidine ring), oxetanyl, thietanyl, tetrahydrothienyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, oxazolinyl, oxazolidinyl, pyrazolinyl, pyrazolidinyl, thiazolinyl, thiazolidinyl, tetrahydroisothiazolyl, tetrahydrooxazolyl, tetrahydroisoxazolyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydropyridinyl, dihydrothiopyranyl, tetrahydropyrimidinyl, tetrahydropyridazinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, and thiomorpholinyl. Monocyclic aliphatic heterocyclic groups can have one bond at any substitutable position, and may have a bond on either a carbon atom or a nitrogen atom. In addition, when the monocyclic aliphatic heterocyclic group has a substituent, the substituent can be present at any substitutable position, and can be present on any of the carbon atoms, nitrogen atoms, or sulfur atoms as ring members. When there are two or more substituents, each substituent may be the same or different. For example, The structure of corresponds to a monocyclic aliphatic heterocyclic group substituted with two oxo groups.

[0024] In the present specification, examples of the "monocyclic aromatic heterocyclic group" (including the "monocyclic aromatic heterocyclic" portion in the definition) include monocyclic aromatic heterocyclic groups containing, in addition to carbon atoms, 1 to 4 heteroatoms, which may be the same or different, selected from nitrogen atoms, oxygen atoms, and sulfur atoms, and having 5 to 6 ring atoms. Examples of the "monocyclic aromatic heterocyclic group" include thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and the like. The monocyclic aromatic heterocyclic group can have one bond at any substitutable position, and the bond may be on either the carbon atom or the nitrogen atom. Furthermore, when the monocyclic aromatic heterocyclic group has a substituent, the substituent may be present at any substitutable position, and may be present on either a carbon atom or a nitrogen atom as a ring member. When there are two or more substituents, the respective substituents may be the same or different.

[0025] [Compounds represented by formula (I) or pharmaceutically acceptable salts thereof] The compounds represented by formula (I) or pharmaceutically acceptable salts thereof, which are one embodiment of the present invention, include the following aspects.

[0026] As an embodiment (1), the compound represented by the following formula (I): [In the formula, R 1 represents a cyano group, a C optionally substituted with 1 to 3 halogen atoms, 1-4 alkyl group or R 1a C optionally substituted with 1 to 3 substituents independently selected from 1-4 an alkoxy group, where R 1a is a halogen atom; a cyano group, a halogen atom, and C 1-4 a 5- or 6-membered monocyclic aromatic heterocyclic group which may be substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups; a 4-membered monocyclic aliphatic heterocyclic group; a hydroxyl group; 3-4a cycloalkyl group; and a phenyl group, wherein L is a single bond, C 1-4 Alkylene group or C 2-4 is an alkenylene group, R 2 is R 2a is a 5-membered monocyclic aromatic heterocyclic group optionally substituted with 2a is R 2b C optionally substituted with 1 to 4 substituents independently selected from 1-5 an alkyl group or a 5-membered monocyclic aliphatic heterocyclic group, 2b is a hydroxyl group; C optionally substituted with a hydroxyl group 3-4 Cycloalkyl group; halogen atom; C 1-4 an alkoxy group; a 4- to 6-membered monocyclic aliphatic heterocyclic group optionally substituted with 1 to 3 substituents independently selected from the group consisting of a halogen atom and an oxo group; an oxo group; 1-4 an amino group optionally substituted with an alkyl group; a phenyl group; a 5-membered monocyclic aromatic heterocyclic group; and C 1-4 alkylsulfonyl group, R 3 is a hydrogen atom or C optionally substituted with 1 to 3 halogen atoms 1-4 is an alkoxy group, R 4 is C optionally substituted with 1 to 3 halogen atoms 1-4 is an alkoxy group, R 5 is a hydrogen atom, and R 6 is a hydrogen atom; a C substituted with a halocyclopropyl group 1-4 an alkyl group; or a cyclopropyl group substituted with 1 to 2 halogen atoms; or R 5 and R 6 together with the nitrogen atom to which they are attached form an azetidine ring (wherein the azetidine ring is a C 1-4 C optionally substituted with an alkyl group, a hydroxyl group, or 1 to 2 halogen atoms 1-4substituted with 1 to 2 substituents independently selected from the group consisting of an alkoxy group, a cyano group, and an amino group; or 4 and R 6 is R 4 together with the benzene ring to which it is attached to form a tetrahydroisoquinolin-1-one ring (wherein the ring is 1-4 and a pharmaceutically acceptable salt thereof.

[0027] In the above aspect (1), R 1 C which may be substituted with 1 to 3 halogen atoms 1-4 The alkyl group is preferably —CHF 2 , -CH 2 CH 2 CH 2 CH 3 , or -CH 2 CH 2 CH (CH 3 ) 2 In the above aspect (1), R 1 R 1a C optionally substituted with 1 to 3 substituents independently selected from 1-4 The alkoxy group is preferably —OCH 3 , -OCH 2 CH 3 , -OCHF 2 , -OCH 2 CHF 2 , -OCH 2 CF 3 , -OCH(CH 3 ) 2 , -OCH 2 CH 2 OH, -OCH 2 CH 2 CH 2 OH, -OCH 2 CH 2 CH 2 CH 2 OH, -OCH 2 CH 2 CH (CH 3 ) OH, is.

[0028] In the above aspect (1), L is preferably a single bond or -CH=CH-. 2 The 5-membered monocyclic aromatic heterocyclic group represented by the formula: is preferably a pyrazolyl group, a triazolyl group, or an isothiazolyl group. 2 is a 5-membered monocyclic aromatic heterocyclic group represented by 2a When substituted with 2a is preferably —CH 3 , -CHF 2 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CF 3 , -CH 2 CHF 2 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -CH 2 CH (CH 3 ) 2 , -CH 2 CH (CH 3 ) OH, —CH 2 C(CH 3 ) 2 OH, -CH 2 CH(OH)CF 3 , -CH 2 CH 2 CH (CH 3 ) OH, —CH 2 CH 2 C(CH 3 ) 2 OH, -CH 2 CH(OH)CH 2 CH 3 , -CH 2 CH 2 OCH 3 , -CH 2 CH 2 CH 2 OCH 3 , -CH 2 CH 2 OCH 2 CH 3 , -CH2 CON (CH 3 ) 2 , -CH 2 CH 2 CON (CH 3 ) 2 , -CH 2 CH 2 N (CH 3 ) 2 , -CH 2 CH 2 SO 2 CH 3 , In the above aspect (1), R 2 is a 5-membered monocyclic aromatic heterocyclic group represented by 2a When substituted with, the position of the substituent may be any substitutable position, but is preferably located on a ring atom two ring atoms away from the ring carbon atom to which L is attached, and more preferably, is located on the ring atom two ring atoms away from the ring carbon atom to which L is attached. It exists at the position.

[0029] In the above aspect (1), R 3 C which may be substituted with 1 to 3 halogen atoms 1-4 The alkoxy group is preferably —OCH 3 , or -OCHF 2 In the above aspect (1), R 4 C which may be substituted with 1 to 3 halogen atoms 1-4 The alkoxy group is preferably —OCH 3 , or -OCHF 2 is.

[0030] In the above aspect (1), R 6 C substituted with a halocyclopropyl group, 1-4 The alkyl group is preferably In the above aspect (1), R 6 The cyclopropyl group substituted with 1 to 2 halogen atoms, represented by is.

[0031] In the above aspect (1), R 5 and R 6The substituted azetidine ring formed together with the nitrogen atom to which they are attached preferably has a methyl group, —CHF 2 , -CF 3 , hydroxyl group, —OCHF 2 , a cyano group, and an amino group, and more preferably is.

[0032] In the above aspect (1), R 4 and R 6 But, R 4 The tetrahydroisoquinolin-1-one ring formed together with the benzene ring to which is attached is preferably substituted with one or two methyl groups at the 4-position of the ring.

[0033] As an embodiment (2), R 1 is a cyano group, C optionally substituted with 1 to 3 halogen atoms 1-4 C optionally substituted with an alkyl group or 1 to 3 halogen atoms 1-4 is an alkoxy group, L is a single bond, R 2 is a substituent R 2b’ C optionally substituted with 1-4 a pyrazolyl group optionally substituted with an alkyl group, 2b’ represents a hydroxyl group, 1 to 3 halogen atoms, C 1-4 R is independently selected from the group consisting of an alkoxy group, and a hydroxyl-substituted cyclobutyl group; 3 C optionally substituted with 1 to 3 halogen atoms 1-4 is an alkoxy group, R 4 C optionally substituted with 1 to 3 halogen atoms 1-4 is an alkoxy group, R 5 is a hydrogen atom, and R 6 is a hydrogen atom; C substituted with a halocyclopropyl group 1-4 an alkyl group; or a cyclopropyl group substituted with 1 to 2 halogen atoms; or R 4 and R 6 is R 4is attached to a benzene ring to form a tetrahydroisoquinolin-1-one ring (wherein the 4-position of the ring is 1-4 The compound according to the above aspect (1) or a pharmacologically acceptable salt thereof may be mentioned.

[0034] As an embodiment (3), R 1 C optionally substituted with a cyano group, 1 to 3 fluorine atoms 1-2 C optionally substituted with an alkyl group or 1 to 3 fluorine atoms 1-2 is an alkoxy group, L is a single bond, R 2 is a substituent R 2b’’ C optionally substituted with 1-3 a pyrazolyl group optionally substituted with an alkyl group, 2b’’ are independently selected from the group consisting of a hydroxyl group, 1 to 3 fluorine atoms, a methoxy group, and a hydroxyl-substituted cyclobutyl group; R 3 is a methoxy group optionally substituted with 1 to 3 fluorine atoms, and R 4 is a methoxy group optionally substituted with 1 to 3 fluorine atoms, and R 5 is a hydrogen atom, and R 6 is a hydrogen atom; a methyl group substituted with a fluorocyclopropyl group; or a cyclopropyl group substituted with one to two fluorine atoms; or R 4 and R 6 is R 4 is taken together with the benzene ring to which it is attached to form a tetrahydroisoquinolin-1-one ring (wherein the 4-position of the ring is substituted with 1 to 2 methyl groups), or a pharmaceutically acceptable salt thereof.

[0035] As an embodiment (4), R 1 is a cyano group, -CHF 2 , -OCHF 2 , or -OC 2 H 5 The compound according to any one of the above aspects (1) to (3) or a pharmacologically acceptable salt thereof is exemplified.

[0036] As an embodiment (5), R 2 -L-, where R 2a But -CH 3 , -CHF 2 , -CH 2 CH 3 , -CH 2 CF 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 OCH 3 , -CH 2 CH (CH 3 ) OH, or a 3-hydroxycyclobutylmethyl group. Examples of the compound include the compound according to any one of the above aspects (1) to (4) or a pharmacologically acceptable salt thereof.

[0037] As the above aspect (6), R 3 But, -OCH 3 , or -OCHF 2 The compound according to any one of the above aspects (1) to (5) or a pharmacologically acceptable salt thereof is exemplified.

[0038] As the above aspect (7), R 4 But, -OCH 3 , or -OCHF 2 and R 5 is a hydrogen atom, and R 6 is a hydrogen atom, or or R 4 and R 6 is R 4 is attached to a benzene ring to form a tetrahydroisoquinolin-1-one ring (wherein the 4-position of the ring is 3 and a compound according to any one of the above aspects (1) to (6), or a pharmacologically acceptable salt thereof, which forms a compound represented by the formula (I) or (II),

[0039] As the above aspect (8), R 1is a cyano group, -CHF 2 , or -OCHF 2 , or -OC 2 H 5 and R 2 -L-, where R 2a But -CH 3 , -CHF 2 , -CH 2 CH 3 , -CH 2 CF 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 OCH 3 , -CH 2 CH (CH 3 ) OH, or a 3-hydroxycyclobutylmethyl group, R 3 But, -OCH 3 , or -OCHF 2 and R 4 But, -OCH 3 , or -OCHF 2 and R 5 is a hydrogen atom, and R 6 is a hydrogen atom, or or R 4 and R 6 is R 4 is attached to a benzene ring to form a tetrahydroisoquinolin-1-one ring (wherein the 4-position of the ring is 3 and a compound according to the above aspect (3) or a pharmacologically acceptable salt thereof, which forms a compound represented by the formula (1) or (2),

[0040] As an aspect (9), the following: or a pharmacologically acceptable salt thereof. All of these specific compounds are encompassed by the compounds of formula (I) above.

[0041] As an aspect (9-2), the following: or a pharmacologically acceptable salt thereof. All of these specific compounds are encompassed by the compounds of formula (I) above.

[0042] When the compound of formula (I) contains optical isomers (enantiomers, diastereomers), stereoisomers, positional isomers, or rotational isomers, these are also contained in the compound of formula (I), and each of them can be obtained as a single product by known synthesis methods and separation methods (e.g., concentration, solvent extraction, column chromatography, recrystallization, etc.).

[0043] The compound of formula (I) may be appropriately converted into a prodrug, and such an embodiment is also included within the scope of the present invention. The prodrug may be converted into the compound of formula (I) under physiological conditions, as described in "Drug Development," Vol. 7, Molecular Design, pp. 163-198, Hirokawa Shoten, 1990.

[0044] The compound of formula (I) may be any of a hydrate, a non-hydrate, a solvate, and a non-solvate. In addition, the compound of formula (I) may be a compound containing an isotope (e.g., 2 H. 3 H. 11 C. 14 C. 18 F. 35 S. 125 The compound may be a compound labeled or substituted with an isotope, such as I, and a compound labeled or substituted with an isotope can be used, for example, as a tracer (PET tracer) used in positron emission tomography (PET), and can be useful in fields such as medical diagnosis. 1 H 2H The deuterium-converted product converted to (D) is also included in the compound of formula (I).

[0045] Tautomers are also encompassed by the compounds of formula (I).

[0046] [Method for Producing Compounds] (General Synthesis Approach) The compounds of formula (I) or intermediate compounds thereof can be produced, for example, by the following methods A to K. These methods and steps may be combined with each other. For example, methods and steps can be combined such that steps 1 to 4 of synthesis method A are carried out after steps 1 and 2 of synthesis method D. The method for producing the compounds is not limited to these.

[0047] In the synthesis methods A to K, PG1 represents a protecting group of a carboxylic acid, and PG2 represents a protecting group of an amide. Ra and Rb each independently represent a hydrogen atom or an alkyl, or both are bonded to each other to form an alkylene group. X represents a halogen atom. LG represents a leaving group. R 1 ' is an optionally substituted C 1-4 is an alkyl group, and R 2 is R 2 -L, and other symbols have the same meanings as above.

[0048] The starting compounds used in Synthesis Methods A to K can be produced by the methods described in the Reference Examples below or by methods similar thereto. Alternatively, commercially available starting compounds may be used.

[0049] Synthesis method A [wherein each symbol has the same meaning as defined above. However, in general formulae [A-2′], [A-3′], [A-4] and [A-5], R 2 and / or R 5 includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxy.

[0050] The compound of general formula [A-2] can be obtained by a coupling reaction between a compound of general formula [A-1] and a compound of general formula [A-1']. The reaction can be carried out in the presence of a palladium catalyst and a base in an appropriate solvent, with or without a ligand. The reaction time varies depending on the starting materials, solvent, and reaction temperature used, but is usually 30 minutes to 24 hours. Examples of palladium catalysts include tetrakis(triphenylphosphine)palladium(0), palladium(II) acetate, palladium(II) chloride, tris(benzylideneacetone)dipalladium(0), 1,1-bis(diphenylphosphine)ferrocene-palladium(II) dichloride, and 1,1-bis(di-tert-butylphosphino)ferrocene-palladium(II) dichloride. Examples of bases include tripotassium phosphate, potassium carbonate, potassium fluoride, cesium fluoride, triethylamine, and N,N-diisopropylethylamine. Examples of the ligand include triphenylphosphine, tri(O-tolyl)phosphine, 2-(dicyclohexylphosphino)-2',4',6'-triisopropyl-1,1'-biphenyl (XPhos), 2-(dicyclohexylphosphino)-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (BrettPhos), 2-(dicyclohexylphosphino)-2,6-diisopropoxy-1,1' -biphenyl (RuPhos), 2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl (tBuXPhos), 2-(dicyclohexylphosphino)-2',6'-dimethoxybiphenyl (SPhos), 2-(dicyclohexylphosphino)-2'-(N,N-dimethylamino)biphenyl (DavePhos), tri-ortho-tolylphosphine, 2-(dicyclohexylphosphino)biphenyl, 2-(di-tert-butylphosphino)biphenyl, 2-(di-tert-butylphosphino)-1,1-binaphthyl, tri-tert-butylphosphine, tri-tert-butylphosphonium tetrafluoroborate, etc. Reagents in which the above-mentioned palladium catalyst and a ligand form a complex may also be used.The solvent may be any solvent that does not affect the reaction, and examples thereof include ethers such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as toluene and xylene; amides such as N,N-dimethylformamide and N-methyl-2-pyrrolidone; or mixed solvents of these organic solvents with water. This reaction proceeds favorably at room temperature to 150°C, particularly at 40°C to 120°C.

[0051] The compound of general formula [A-3] can be obtained, for example, by either of the following two methods. Method 1: The compound of general formula [A-3] can be obtained by deprotection of the compound of general formula [A-2] with an acid. The reaction can be carried out using an appropriate acid in an appropriate solvent. The reaction time varies depending on the raw materials, solvent, and reaction temperature used, but is usually 30 minutes to 24 hours. Examples of acids include hydrochloric acid and trifluoroacetic acid. Any solvent that does not affect the reaction can be used, and examples include alcohols such as methanol and ethanol; ethers such as tetrahydrofuran and 1,4-dioxane; esters such as ethyl acetate; and chlorinated hydrocarbons such as dichloromethane and chloroform. This reaction preferably proceeds at a temperature between 0°C and 60°C, particularly at room temperature. Method 2: The compound of general formula [A-3] can be obtained by hydrolysis of the compound of general formula [A-2]. The reaction can be carried out in an appropriate solvent in the presence of a suitable base. The reaction time varies depending on the raw materials, solvent, and reaction temperature used, but is usually 30 minutes to 24 hours. Examples of the base include alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, and potassium hydroxide. Any solvent may be used as long as it does not affect the reaction, and examples include alcohols such as methanol and ethanol; ethers such as tetrahydrofuran and 1,4-dioxane; water, or a mixture thereof. This reaction proceeds suitably at a temperature between 0°C and 100°C, particularly between room temperature and 60°C.

[0052] The compound of general formula [A-4] can be obtained by, for example, any of the following three methods. Method 1: The compound of general formula [A-4] can be obtained by a condensation reaction between a compound of general formula [A-3] and a compound of general formula [A-2']. The reaction can be carried out using a condensing agent in the presence of a suitable base in a suitable solvent. The reaction time varies depending on the raw materials and solvent used, and the reaction temperature, but is usually 30 minutes to 24 hours. Examples of condensing agents include 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC.HCl), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU), 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methylmorpholinium chloride hydrate (DMT-MM), and 2-chloro-1-methylpyridinium iodide. The reaction may be accelerated by adding 1-hydroxybenzotriazole (HOBt). Examples of bases include triethylamine, N,N-diisopropylethylamine, and pyridine. Any solvent that does not affect the reaction may be used, including, for example, ethers such as tetrahydrofuran and 1,4-dioxane; amides such as N,N-dimethylformamide and N-methyl-2-pyrrolidone; and chlorinated hydrocarbons such as chloroform and dichloromethane. This reaction proceeds favorably at temperatures between 0°C and 100°C, particularly between room temperature and 60°C. Method 2: A compound of general formula [A-4] can be obtained by converting a compound of general formula [A-3] into an acid halide using a halogenating agent and then reacting the acid halide with a compound of general formula [A-2']. The reaction can be carried out using a halogenating agent in the presence of a suitable base in an appropriate solvent. The reaction time varies depending on the starting materials, solvent, and reaction temperature used, but is usually 30 minutes to 24 hours. Examples of halogenating agents include thionyl chloride, oxalyl chloride, and phenylphosphonyl dichloride.Any solvent may be used as long as it does not affect the reaction, and examples thereof include ethers such as tetrahydrofuran and 1,4-dioxane; chlorinated hydrocarbons such as dichloromethane, 1,2-dichloroethane, and chloroform; and amines such as pyridine. This reaction proceeds favorably at temperatures between 0°C and 100°C, particularly between room temperature and 60°C. Method 3: A compound of general formula [A-4] can be obtained by converting a compound of general formula [A-3] into a mixed acid anhydride and then reacting it with a compound of general formula [A-2']. The reaction can be carried out in an appropriate solvent in the presence of a base using a reagent that forms a mixed acid anhydride. The reaction time varies depending on the starting materials, solvent, and reaction temperature used, but is usually 30 minutes to 24 hours. Examples of reagents that form a mixed acid anhydride include methyl chlorocarbonate, ethyl chlorocarbonate, isopropylthiocarbonyl chloride, and pivaloyl chloride. Examples of bases include triethylamine, N,N-diisopropylethylamine, pyridine, and N-methylmorpholine. Any solvent may be used as long as it does not affect the reaction, and examples thereof include tetrahydrofuran, chloroform, N,N-dimethylformamide, N-methyl-2-pyrrolidone, etc. This reaction proceeds preferably at a temperature of −20° C. to 100° C., particularly 0° C. to room temperature.

[0053] The compound of general formula [A-5] can be obtained by coupling reaction of the compound of general formula [A-4] with the compound of general formula [A-3']. The reaction temperature, time, and reagents and solvents used are the same as those in the first step.

[0054] In the synthesis method A, the compound of the general formula [A-2′] and / or [A-3′] is R 2 and / or R 5 In some cases, a compound having a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl may be used. In this case, a compound of the general formula [A-5] (wherein R 2 and / or R 5The protecting group of R can be removed (the group corresponding to R includes a protecting group of a functional group such as a carboxylic acid, an amine, or a hydroxyl). The deprotection can be carried out by a conventional method such as reduction, hydrolysis, or acid treatment depending on the type of the protecting group to be removed. 2 In the case where the compound of the general formula [A-5] is a group containing an amide bond (—CONR′R″), R 2 The target compound can be obtained by deprotecting a compound of the general formula [A-5] in which the group corresponding to the formula (I) contains an ester bond (-COOPG1), followed by amidation.

[0055] Synthesis method A' [wherein each symbol has the same meaning as defined above. However, in general formulae [A'-1'], [A-3'], [A-4] and [A-5], R 2 and / or R 5 includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxy.

[0056] The compound of general formula [A-4] is obtained by a coupling reaction between a compound of general formula [A-1] and a compound of general formula [A'-1']. The reaction temperature and time, as well as the reagents and solvents used, are the same as those in the first step of synthesis method A. The compound of general formula [A-5] is obtained by a coupling reaction between a compound of general formula [A-4] and a compound of general formula [A-3']. The reaction temperature and time, as well as the reagents and solvents used, are the same as those in the first step of synthesis method A.

[0057] In the synthesis method A′, the compound of the general formula [A′-1′] and / or [A-3′] is R 2 and / or R 5 In some cases, a compound having a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl may be used. In this case, a compound of the general formula [A-5] (wherein R 2 and / or R 5 (wherein the group corresponding to the formula (I) includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl) can be removed. The deprotection can be carried out by a conventional method such as reduction, hydrolysis, or acid treatment depending on the type of protecting group to be removed.

[0058] Synthesis method B [wherein each symbol has the same meaning as defined above. However, in general formulae [A-2′], [A-3′], [B-1], [B-2] and [A-5], R 2 and / or R 5 includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxy.

[0059] The compound of general formula [B-1] is obtained by a coupling reaction between the compound of general formula [A-2] obtained by synthesis method A and the compound of general formula [A-3']. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the first step of synthesis method A. The compound of general formula [B-2] is obtained by deprotection of the carboxylic acid of the compound of general formula [B-1]. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the second step of synthesis method A. The compound of general formula [A-5] is obtained by an amidation reaction between the compound of general formula [B-2] and the compound of general formula [A-2']. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the third step of synthesis method A.

[0060] In the synthesis method B, the compound of the general formula [A-2′] and / or [A-3′] is R 2 and / or R 5 In some cases, a compound having a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl may be used. In this case, a compound of the general formula [A-5] (wherein R 2 and / or R 5 (wherein the group corresponding to the formula (I) includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl) can be removed. The deprotection can be carried out by a conventional method such as reduction, hydrolysis, or acid treatment depending on the type of protecting group to be removed.

[0061] Synthesis method C [wherein each symbol has the same meaning as defined above. However, in general formulae [C-1′], [C-1], [A-4] and [A-5], R 2 and / or R 5 includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxy.

[0062] The compound of general formula [C-1] can be obtained by a coupling reaction between a compound of general formula [A-4] and bis-pinacolatodiboron. The reaction can be carried out using a palladium catalyst in the presence of a base in an appropriate solvent. The reaction time varies depending on the starting materials, solvent, and reaction temperature used, but is usually 30 minutes to 24 hours. Examples of palladium catalysts include tetrakis(triphenylphosphine)palladium(0), palladium(II) acetate, palladium(II) chloride, tris(benzylideneacetone)dipalladium(0), 1,1-bis(diphenylphosphine)ferrocene-palladium(II) dichloride, and 1,1-bis(di-tert-butylphosphino)ferrocene-palladium(II) dichloride. Examples of bases include tripotassium phosphate, potassium carbonate, potassium fluoride, cesium fluoride, and potassium acetate. Any solvent may be used as long as it does not affect the reaction, and examples thereof include ethers such as 1,4-dioxane and 1,2-dimethoxyethane; aromatic hydrocarbons such as toluene and xylene; and amides such as N,N-dimethylformamide and N-methyl-2-pyrrolidone. This reaction proceeds favorably at room temperature to 150°C, particularly at 60°C to 100°C. The compound of general formula [A-5] can be obtained by a coupling reaction between a compound of general formula [C-1] and a compound of general formula [C-1']. The reaction temperature and time, as well as the reagents and solvents used, are the same as those used in the first step of synthesis method A.

[0063] In the synthesis method C, the compound of the general formula [C-1′] and / or [A-4] is R 2 and / or R 5 In some cases, a compound having a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl may be used. In this case, a compound of the general formula [A-5] (wherein R 2 and / or R 5 (wherein the group corresponding to the formula (I) includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl) can be removed. The deprotection can be carried out by a conventional method such as reduction, hydrolysis, or acid treatment depending on the type of protecting group to be removed.

[0064] Synthesis method D [wherein each symbol has the same meaning as defined above, provided that in general formulae [A'-1'], [A-3'], [D-1'], [D-3], [D-4] and [D-5], R 1 ', and / or R 2 and / or R 5 includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxy.

[0065] The compound of general formula [D-2] can be obtained by O-demethylation of the compound of general formula [D-1]. The reaction can be carried out in a suitable solvent using boron tribromide, aluminum chloride, or the like. The reaction time varies depending on the raw materials, solvent, and reaction temperature used, but is usually 30 minutes to 24 hours. The solvent may be any solvent that does not affect the reaction, and examples thereof include ethers such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as toluene and xylene; acetonitrile; and chlorinated hydrocarbons such as dichloromethane, chloroform, and 1,2-dichloroethane. This reaction proceeds favorably at temperatures from -80°C to 50°C, particularly from -20°C to room temperature. The compound of general formula [D-3] can be obtained by O-demethylation of the compound of general formula [D-1'] (R 1 '=CHF 2 In this case, CF 2 BrPO(OEt) 2The compound of formula [D-2] can be obtained by O-alkylation of the compound of formula [D-3] using a base (using a base). The reaction can be carried out in a suitable solvent in the presence of a base. The reaction time varies depending on the starting materials, solvent, and reaction temperature used, but is usually 30 minutes to 24 hours. Examples of the base include inorganic bases such as potassium carbonate, cesium carbonate, sodium hydroxide, and potassium hydroxide, and alkoxides such as potassium tert-butoxide and sodium tert-butoxide. Any solvent that does not affect the reaction can be used, and examples include ethers such as 1,4-dioxane and 1,2-dimethoxyethane; aromatic hydrocarbons such as toluene and xylene; acetonitrile; amides such as N,N-dimethylformamide and N-methyl-2-pyrrolidone; and mixtures of these organic solvents with water. This reaction proceeds favorably at temperatures between -20°C and 150°C, particularly between 60°C and 100°C. The compound of general formula [D-4] is obtained by a coupling reaction between a compound of general formula [D-3] and a compound of general formula [A'-1']. The reaction temperature and time, as well as the reagents and solvents used, are the same as those in the first step of synthesis method A. The compound of general formula [D-5] is obtained by a coupling reaction between a compound of general formula [D-4] and a compound of general formula [A-3']. The reaction temperature and time, as well as the reagents and solvents used, are the same as those in the first step of synthesis method A.

[0066] In the synthesis method D, the compounds of the general formula [A'-1'], and / or [A-3'], and / or [D-1'] are 1 ', and / or R 2 and / or R 5 In some cases, a compound having a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl may be used. In this case, a compound of the general formula [D-5] (wherein R 1 ', and / or R 2 and / or R 5 (wherein the group corresponding to the formula (I) includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl) can be removed. The deprotection can be carried out by a conventional method such as reduction, hydrolysis, or acid treatment depending on the type of protecting group to be removed.

[0067] Synthesis method E [wherein each symbol has the same meaning as defined above, provided that in general formulae [A'-1'], [A-3'], [D-1'], [D-5], [E-1] and [E-2], R 1 ', and / or R 2 and / or R 5 includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxy.

[0068] The compound of general formula [E-1] can be obtained by a coupling reaction between a compound of general formula [D-2] and a compound of general formula [A'-1']. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the first step of synthesis method A. The compound of general formula [E-2] can be obtained by a coupling reaction between a compound of general formula [E-1] and a compound of general formula [A-3']. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the first step of synthesis method A. The compound of general formula [D-5] can be obtained by an O-alkylation reaction of a compound of general formula [E-2] using a compound of general formula [D-1']. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the second step of synthesis method D.

[0069] In the synthesis method E, the compound of the general formula [A'-1'] and / or [A-3'] and / or [D-1'] is R 1 ', and / or R 2 and / or R 5 In some cases, a compound having a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl may be used. In this case, a compound of the general formula [D-5] (wherein R 1 ', and / or R 2 and / or R 5 (wherein the group corresponding to the formula (I) includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl) can be removed. The deprotection can be carried out by a conventional method such as reduction, hydrolysis, or acid treatment depending on the type of protecting group to be removed.

[0070] Synthesis method F [wherein each symbol has the same meaning as defined above. However, in general formulae [A-2′], [C-1′], [D-3], [D-5], [F-1], [F-2], [F-3] and [F-4], R 1 ', and / or R 2 and / or R 5 includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxy.

[0071] A compound of general formula [F-1] can be obtained by a coupling reaction between a compound of general formula [D-3] and a compound of general formula [A-1']. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the first step of synthesis method A. A compound of general formula [F-2] can be obtained by a coupling reaction between a compound of general formula [F-1] and bis-pinacolate diboron. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the first step of synthesis method C. A compound of general formula [F-3] can be obtained by a coupling reaction between a compound of general formula [F-2] and a compound of general formula [C-1']. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the first step of synthesis method A. A compound of general formula [F-4] can be obtained by deprotection of the carboxylic acid of a compound of general formula [F-3]. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the second step of synthesis method A. The compound of general formula [D-5] can be obtained by an amidation reaction between the compound of general formula [F-4] and the compound of general formula [A-2']. The reaction temperature, time, and reagents and solvents used are the same as those in the third step of synthesis method A.

[0072] In the synthesis method F, the compounds of the general formula [A-2′], [C-1′], and / or [D-3] are 1 ', and / or R 2 and / or R 5 In some cases, a compound having a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl may be used. In this case, a compound of the general formula [D-5] (wherein R 1 ', and / or R 2 and / or R 5(wherein the group corresponding to the formula (I) includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl) can be removed. The deprotection can be carried out by a conventional method such as reduction, hydrolysis, or acid treatment depending on the type of protecting group to be removed.

[0073] Synthesis method G [wherein each symbol has the same meaning as defined above, provided that in general formulae [A-2′], [A-3′], [D-1′], [D-5], [F-3], [F-4] and [G-2], R 1 ', and / or R 2 and / or R 5 includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxy.

[0074] The compound of general formula [G-1] can be obtained by a coupling reaction between a compound of general formula [D-2] and a compound of general formula [A-1']. The reaction temperature and time, as well as the reagents and solvents used, are the same as those in the first step of synthesis method A. The compound of general formula [G-2] can be obtained by a coupling reaction between a compound of general formula [G-1] and a compound of general formula [A-3']. The reaction temperature and time, as well as the reagents and solvents used, are the same as those in the first step of synthesis method A. The compound of general formula [F-3] can be obtained by a coupling reaction between a compound of general formula [D-1'] (R 1 '=CHF 2 In this case, CF 2 BrPO(OEt) 2 The compound of general formula [G-2] is obtained by an O-alkylation reaction using a carboxylic acid of the compound of general formula [G-3]. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the second step of synthesis method D. The compound of general formula [F-4] is obtained by deprotection of the carboxylic acid of the compound of general formula [F-3]. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the second step of synthesis method A. The compound of general formula [D-5] is obtained by an amidation reaction of the compound of general formula [F-4] with the compound of general formula [A-2']. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the third step of synthesis method A.

[0075] In the synthesis method G, the compounds of the general formula [A-2′] and / or [A-3′] and / or [D-1′] are1 ', and / or R 2 and / or R 5 In some cases, a compound having a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl may be used. In this case, a compound of the general formula [D-5] (wherein R 1 ', and / or R 2 and / or R 5 (wherein the group corresponding to the formula (I) includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl) can be removed. The deprotection can be carried out by a conventional method such as reduction, hydrolysis, or acid treatment depending on the type of protecting group to be removed.

[0076] Synthesis method H [wherein each symbol has the same meaning as defined above. However, in general formulae [A-2′], [D-1′], [D-5], [E-2], [G-2], and [H-1], R 1 ', and / or R 2 and / or R 5 includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxy.

[0077] The compound of general formula [H-1] can be obtained by deprotection of the carboxylic acid of the compound of general formula [G-2]. The reaction temperature and time, as well as the reagents and solvents used, are the same as those in the second step of synthesis method A. The compound of general formula [E-2] can be obtained by an amidation reaction between the compound of general formula [H-1] and the compound of general formula [A-2']. The reaction temperature and time, as well as the reagents and solvents used, are the same as those in the third step of synthesis method A. The compound of general formula [D-5] can be obtained by amidation of the compound of general formula [D-1'] (R 1 '=CHF 2 In this case, CF 2 BrPO(OEt) 2 The reaction temperature and time, as well as the reagents and solvents used, are the same as in the second step of Synthesis Method D.

[0078] In the synthesis method H, the compounds of the general formula [A-2′], [D-1′], and / or [G-2] are1 ', and / or R 2 and / or R 5 In some cases, a compound having a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl may be used. In this case, a compound of the general formula [D-5] (wherein R 1 ', and / or R 2 and / or R 5 (wherein the group corresponding to the formula (I) includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl) can be removed. The deprotection can be carried out by a conventional method such as reduction, hydrolysis, or acid treatment depending on the type of protecting group to be removed.

[0079] Synthesis method I [wherein each symbol has the same meaning as defined above, provided that in general formulae [A-2′], [A-3′], [D-1′], [D-4], [D-5] and [E-1], R 1 ', and / or R 2 and / or R 5 includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxy.

[0080] The compound of general formula [I-1] can be obtained by deprotection of the carboxylic acid of the compound of general formula [G-1]. The reaction temperature and time, as well as the reagents and solvents used, are the same as those in the second step of synthesis method A. The compound of general formula [E-1] can be obtained by an amidation reaction between the compound of general formula [I-1] and the compound of general formula [A-2']. The reaction temperature and time, as well as the reagents and solvents used, are the same as those in the third step of synthesis method A. The compound of general formula [D-4] can be obtained by amidation of the compound of general formula [D-1'] (R 1 '=CHF 2 In this case, CF 2 BrPO(OEt) 2The compound of general formula [D-5] can be obtained by a coupling reaction between a compound of general formula [D-4] and a compound of general formula [A-3']. The reaction temperature, time, and reagents and solvents used are the same as those in the second step of synthesis method D. The compound of general formula [D-6] can be obtained by a coupling reaction between a compound of general formula [D-7] and a compound of general formula [A-3']. The reaction temperature, time, and reagents and solvents used are the same as those in the first step of synthesis method A.

[0081] In the synthesis method I, the compounds of the general formula [A-2′], [A-3′], and / or [D-1′] are 1 ', and / or R 2 and / or R 5 In some cases, a compound having a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl may be used. In this case, a compound of the general formula [D-5] (wherein R 1 ', and / or R 2 and / or R 5 (wherein the group corresponding to the formula (I) includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl) can be removed. The deprotection can be carried out by a conventional method such as reduction, hydrolysis, or acid treatment depending on the type of protecting group to be removed.

[0082] Synthesis method J [wherein PG2 represents an amide protecting group, and the other symbols are as defined above.] However, in general formulae [A-3'] and [J-3], R 2 includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxy.

[0083] A compound of general formula [J-1] is obtained by a coupling reaction between a compound of general formula [A-1] and a compound of general formula [J-1']. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the first step of synthesis method A. A compound of general formula [J-2] is obtained by deprotection of a compound of general formula [J-1]. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the second step of synthesis method A. A compound of general formula [J-3] is obtained by a coupling reaction between a compound of general formula [J-2] and a compound of general formula [A-3']. The reaction temperature and time, as well as the reagents and solvents used, are the same as in the first step of synthesis method A.

[0084] In the synthesis method J, the compound of the general formula [A-3′] is 2 In some cases, a compound having a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl may be used. In this case, a compound of the general formula [J-3] (wherein R 2 (wherein the group corresponding to the formula (I) includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl) can be removed. The deprotection can be carried out by a conventional method such as reduction, hydrolysis, or acid treatment depending on the type of protecting group to be removed.

[0085] Synthesis method K [wherein PG2 represents an amide protecting group, and the other symbols are as defined above.] However, in general formulae [A-3'], [K-1] and [J-3], R 2 includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxy.

[0086] The compound of general formula [K-1] is obtained by a coupling reaction between a compound of general formula [J-1] and a compound of general formula [A-3']. The reaction temperature and time, as well as the reagents and solvents used, are the same as those in the first step of synthesis method A. The compound of general formula [J-3] is obtained by deprotection of the compound of general formula [K-1]. The reaction temperature and time, as well as the reagents and solvents used, are the same as those in the second step of synthesis method A.

[0087] In the synthesis method K, the compound of the general formula [A-3′] is 2In some cases, a compound having a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl may be used. In this case, a compound of the general formula [J-3] (wherein R 2 (wherein the group corresponding to the formula (I) includes a protecting group for a functional group such as carboxylic acid, amine, or hydroxyl) can be removed. The deprotection can be carried out by a conventional method such as reduction, hydrolysis, or acid treatment depending on the type of protecting group to be removed.

[0088] The starting compounds in the above-described methods can be produced by known methods and / or methods similar to those described in the Examples below. Introduction of protecting groups to functional groups and removal of functional group protecting groups can be carried out with reference to known methods (e.g., PROTECTIVE GROUPS in ORGANIC SYNTHESIS (Theodora W. Greene, Peter G.M. Wuts)). The compounds of the present embodiment and intermediate compounds produced by the above-described methods can be further structurally converted into other target compounds or intermediates by methods described in the Examples below and / or known methods, or a combination thereof. When the compounds of the present embodiment and intermediate compounds produced by the above-described methods are racemic, the individual enantiomers can be separated by standard separation techniques, including chiral column chromatography.

[0089] The compound of formula (I) produced by the above-mentioned method can be purified to any desired purity by applying conventional purification means, such as concentration, extraction, chromatography, reprecipitation, recrystallization, etc. Furthermore, if necessary, it can be converted into a pharmacologically acceptable salt by treating it with an acid or base in an appropriate solvent (water, alcohol, ether, etc.). Furthermore, the obtained compound of the present invention or a pharmacologically acceptable salt thereof can be converted into a hydrate or solvate by treating it with water, a water-containing solvent, or other solvent.

[0090] The compounds of the above embodiments of the present invention, or pharmaceutically acceptable salts thereof, include racemates, stereoisomers, and mixtures of these compounds, including isotopically and radiolabeled compounds. Such isomers can be isolated by standard separation techniques, including fractional crystallization and chiral column chromatography. The compounds of the above embodiments of the present invention also include enantiomers or diastereomers. Diastereomeric mixtures can be separated into their individual diastereomers based on their physical / chemical differences, using methods well known in the art, such as chromatography and / or fractional crystallization. Enantiomers can be separated by chiral column chromatography or by converting the enantiomeric compounds into a diastereomeric mixture by reacting them with an appropriate optically active compound, separating the diastereomers, and then converting the individual diastereomers into their corresponding enantiomers. The compounds of the above embodiments of the present invention may be any isomer, including diastereomers, enantiomers, and mixtures thereof.

[0091] SIK controls a new molecular switch that controls macrophage polarization. Pharmacological inhibition of SIK induces a macrophage phenotype characterized by high secretion of anti-inflammatory cytokines such as interleukin (IL)-10 and extremely low secretion of pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α). Non-Patent Document 1 showed that inhibiting all of SIK1, SIK2, and SIK3 is the most important factor for demonstrating pharmacological efficacy in macrophages. The compound of formula (I) or a pharmacologically acceptable salt thereof according to the above embodiment can effectively inhibit all of SIK1, SIK2, and SIK3. For example, the compound of formula (I) or a pharmacologically acceptable salt thereof according to the above embodiment exhibits a 50% inhibitory concentration (IC ) of SIK1, SIK2, and SIK3 in an SIK inhibitory activity evaluation system (Experimental Example 1) described in the Examples below. 50) are all less than 20 nM. There are several methods for evaluating SIK inhibitory activity, such as the evaluation method described in the Examples below and the method described in International Publication No. 2019 / 105886. Those skilled in the art can appropriately select an appropriate evaluation system. In addition, depending on the evaluation system, the 50% inhibitory concentration (IC 50 Those skilled in the art will understand that the value of ) can vary.

[0092] The compound of formula (I) or a pharmaceutically acceptable salt thereof in the above embodiment can suppress the production of inflammatory cytokines such as tumor necrosis factor α (TNF-α).

[0093] In a preferred embodiment, the compound of formula (I) or a pharmacologically acceptable salt thereof in the above embodiment has little or no risk of producing reactive metabolites. After a foreign substance, such as a pharmaceutical, is taken into the body, its chemical structure changes through metabolism, resulting in the generation of highly reactive intermediates, such as electrophilic compounds and free radicals, which can manifest or enhance toxicity. The resulting metabolites are called reactive metabolites, and this series of processes is called metabolic activation, and extensive research has been conducted on this topic. Reactive metabolites often irreversibly bond covalently with in vivo macromolecules (e.g., proteins and nucleic acids) and have been thought to cause allergies, hepatotoxicity, tissue necrosis, mutagenicity, and carcinogenicity. Avoiding reactive metabolites is extremely important from the perspective of pharmaceutical safety. The generation of reactive metabolites can be evaluated, for example, by a trapping test using glutathione (GSH) as described in the Examples below.

[0094] The compound of formula (I) or a pharmaceutically acceptable salt thereof according to the above embodiment can be used as a pharmaceutical for preventing or treating various diseases and / or symptoms associated therewith that can be improved by salt-inducible kinase (SIK) inhibition in patients, preferably mammals (e.g., mice, rats, hamsters, rabbits, cats, dogs, cows, sheep, monkeys, humans, etc.), or for improving the prognosis of these diseases and / or symptoms associated therewith.

[0095] [Pharmaceutical Composition] Another embodiment of the present invention is a pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. This pharmaceutical composition may further comprise a pharmaceutically acceptable carrier. This pharmaceutical composition can be used for preventing or treating various diseases and / or associated symptoms that can be improved by salt-inducible kinase (SIK) inhibition, or for improving the prognosis of such diseases and / or associated symptoms.

[0096] That is, the pharmaceutical composition of this embodiment includes the following aspects: Aspect (10) includes a pharmaceutical composition containing, as an active ingredient, the compound according to any one of Aspects (1) to (9) above or a pharmacologically acceptable salt thereof.

[0097] Aspect (11) includes the pharmaceutical composition according to aspect (10) above, which is used for the prevention or treatment of various diseases and / or symptoms associated therewith that can be improved by inhibition of salt-inducible kinase (SIK), or for improving the prognosis of such diseases and / or symptoms associated therewith.

[0098] Aspect (12) includes the pharmaceutical composition according to aspect (10) above, which is an agent for preventing or treating a disease selected from inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases associated with disorders of cartilage metabolic turnover, congenital cartilage malformations, diseases associated with disorders of bone metabolic turnover, diseases associated with excessive secretion of TNF-α, interferon, IL-6, IL-12, and / or IL-23, respiratory diseases, endocrine and / or metabolic diseases, cardiovascular diseases, skin diseases, and diseases associated with abnormal angiogenesis.

[0099] In embodiment (13), the present invention relates to rheumatoid arthritis, osteoarthritis, psoriatic arthritis, chronic inflammatory demyelinating polyneuropathy, ulcerative colitis, Crohn's disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 1 diabetes, type 2 diabetes, pancreatitis, systemic lupus erythematosus, cutaneous lupus erythematosus, central nervous system lupus, lupus nephritis, and antiphospholipid antibodies. syndrome, chronic kidney disease, acute kidney injury, sarcoidosis, systemic sclerosis, localized scleroderma, Sjogren's syndrome, ANCA-associated vasculitis, immune complex-mediated small vessel vasculitis, polyarteritis nodosa, Kawasaki disease, Takayasu's vasculitis, giant cell arteritis, idiopathic inflammatory myopathies (polymyositis, dermatomyositis, inclusion body myositis), IgG4-related disease, juvenile Still's disease, pelvic inflammatory disease, psoriasis, pustular psoriasis, atopic dermatitis, asthma, and an example of the pharmaceutical composition according to aspect (10) above, which is an agent for preventing or treating a disease selected from allergic rhinitis, relapsing polychondritis, mixed connective tissue disease, graft-versus-host disease, idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, chronic obstructive pulmonary disease, myelofibrosis, multiple sclerosis, cerebral infarction, ischemic stroke, Alzheimer's disease, Parkinson's disease, depression, developmental epilepsy, Meniere's disease, narcolepsy, macrophage activation syndrome, sepsis, pulmonary hypertension, dyslipidemia, Behçet's disease, uveitis, osteoporosis, bone fracture, osteosarcoma, heart failure, hypertrophic cardiomyopathy, atherosclerosis, female pregnancy syndrome, ovarian cancer, breast cancer, prostate cancer, malignant lymphoma, leukemia, multiple myeloma, lung cancer, granuloma annulare, esophageal cancer, colorectal cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, melanoma, and secondary hemophagocytic lymphohistiocytosis.

[0100] Aspect (14) includes the pharmaceutical composition according to aspect (10) above, which is an agent for preventing or treating a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, primary biliary cholangitis, primary sclerosing cholangitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjögren's syndrome, psoriasis, pustular psoriasis, Behcet's disease, ovarian cancer, and acute myeloid leukemia.

[0101] Aspect (15) includes the pharmaceutical composition according to aspect (10) above, which is an agent for preventing or treating a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjögren's syndrome, pustular psoriasis, and Behcet's disease.

[0102] As used herein, "prevention" includes preventing the onset of a disease (either an entire condition or one or more conditions) and delaying the onset of the disease. A "prophylactically effective amount" refers to a dose of a compound of formula (I) sufficient to achieve this purpose.

[0103] As used herein, "treatment" includes curing a disease (all or one or more pathological conditions), ameliorating the disease, and inhibiting the progression of the severity of the disease. A "therapeutically effective amount" refers to a dose of the compound of formula (I) sufficient to achieve such a purpose.

[0104] Examples of the form of the pharmaceutical composition include tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, buccal tablets, etc.), pills, powders, granules, capsules (including soft capsules and microcapsules), syrups, liquids, emulsions, suspensions, controlled-release preparations (e.g., immediate-release preparations, sustained-release preparations, sustained-release microcapsules), aerosols, films (e.g., orally disintegrating films, oral mucosal patch films), injections (e.g., subcutaneous injections, intravenous injections (e.g., bolus), intramuscular injections, intraperitoneal injections), drip infusions, transdermal preparations, ointments, lotions, patches, suppositories (e.g., rectal suppositories, vaginal suppositories), pellets, nasal preparations, pulmonary preparations (inhalants), and eye drops.

[0105] As used herein, the term "pharmaceutically acceptable carrier" refers to any of a variety of carriers commonly used in the field of pharmaceutical formulation technology.

[0106] Specific examples of "pharmaceutically acceptable carriers" in solid preparations include excipients (e.g., lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light anhydrous silicic acid, etc.), lubricants (e.g., magnesium stearate, talc, colloidal silica, etc.), binders (e.g., crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, sucrose, gelatin, methylcellulose, sodium carboxymethylcellulose, etc.), and disintegrants (e.g., starch, carboxymethylcellulose, carboxymethylcellulose calcium, sodium carboxymethylstarch, L-hydroxypropylcellulose, etc.).

[0107] Liquid preparations may contain solvents (e.g., water for injection, isotonic saline, alcohol, propylene glycol, macrogol, sesame oil, etc.), solubilizing agents (e.g., polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, triethanolamine, sodium carbonate, sodium citrate, etc.), suspending agents (e.g., surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, glycerin monostearate, etc.; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, etc.), isotonic agents (e.g., glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol, etc.), buffers (e.g., buffer solutions such as phosphates and citrates, etc.), and soothing agents (e.g., benzyl alcohol, etc.).

[0108] If necessary, formulation additives such as preservatives (e.g., paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, sorbic acid, etc.), antioxidants (e.g., sulfites, ascorbic acid, α-tocopherol, etc.), colorants, sweeteners, etc. may be further added.

[0109] The pharmaceutical composition of this embodiment may be prepared by adding the compound of the above embodiment in a proportion of typically 0.01 to 99% (w / w), preferably 0.1 to 85% (w / w), based on the total amount of the formulation, although this may vary depending on the dosage form, administration method, carrier, etc. The pharmaceutical composition may be prepared by a method conventionally used in the field of formulation technology, depending on the form. The pharmaceutical composition of this embodiment may be formed into a sustained-release formulation containing the active ingredient.

[0110] The relationship between SIK and various diseases is described in, for example, the following documents:・Darling NJ, Cohen P. Nuts and bolts of the salt-inducible kinases (SIKs). Biochem J. 2021 Apr 16;478(7):1377-1397. ・Fu Y, Ma G, Zhang Y, Wang W, Shi T, Zhu J, Zhang J, Huang Z, Chen J. HG-9-91-01 Attenuates Murine Experimental Colitis by Promoting Interleukin-10 Production in Colonic Macrophages Through the SIK / CRTC3 Pathway. Inflamm Bowel Dis. 2021 Oct 20;27(11):1821-1831. ・Lombardi MS, Gillieron C, Berkelaar M, Gabay C. Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesis. PLoS One. 2017 Oct 3;12(10):e0185426. ・Taub M. Salt Inducible Kinase Signaling Networks: Implications for Acute Kidney Injury and Therapeutic Potential. Int J Mol Sci. 2019 Jun 30;20(13):3219. ・Chen F, Chen L, Qin Q, Sun X. Salt-Inducible Kinase 2: An Oncogenic Signal Transmitter and Potential Target for Cancer Therapy. Front Oncol. 2019 Jan 22;9:18. ・Wein MN, Foretz M, Fisher DE, Xavier RJ, Kronenberg HM.Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential. Trends Endocrinol Metab. 2018 Oct;29(10):723-735. ・Sasaki T, Takemori H, Yagita Y, Terasaki Y, Uebi T, Horike N, Takagi H, Susumu T, Teraoka H, ​​Kusano K, Hatano O, Oyama N, Sugiyama Y, Sakoda S, Kitagawa K. SIK2 is a key regulator for neuronal survival after ischemia via TORC1-CREB. Neuron. 2011 Jan 13;69(1):106-19.

[0111] Another embodiment of the present invention is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of various diseases and / or symptoms associated therewith that can be ameliorated by inhibition of salt-inducible kinase (SIK), or for use in improving the prognosis of such diseases and / or symptoms associated therewith, and includes the following aspects:

[0112] Aspect (16) includes the compound according to any one of Aspects (1) to (9) above, or a pharmacologically acceptable salt thereof, for use in the prevention or treatment of various diseases and / or symptoms associated therewith that can be improved by inhibition of salt-inducible kinase (SIK), or for use in improving the prognosis of such diseases and / or symptoms associated therewith.

[0113] Aspect (17) includes the compound according to any one of Aspects (1) to (9) above, or a pharmaceutically acceptable salt thereof, for use in the prophylaxis or treatment of a disease selected from inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases associated with impaired cartilage metabolic turnover, congenital cartilage malformations, diseases associated with impaired bone metabolic turnover, diseases associated with excessive secretion of TNF-α, interferon, IL-6, IL-12, and / or IL-23, respiratory diseases, endocrine and / or metabolic diseases, cardiovascular diseases, skin diseases, and diseases associated with abnormal angiogenesis.

[0114] In embodiment (18), the present invention is directed to the treatment of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, chronic inflammatory demyelinating polyneuropathy, ulcerative colitis, Crohn's disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 1 diabetes, type 2 diabetes, pancreatitis, systemic lupus erythematosus, cutaneous lupus erythematosus, central nervous system lupus, lupus nephritis, antiphospholipid antibody syndrome, chronic Renal impairment, acute kidney injury, sarcoidosis, systemic sclerosis, localized scleroderma, Sjögren's syndrome, ANCA-associated vasculitis, immune complex-mediated small vessel vasculitis, polyarteritis nodosa, Kawasaki disease, Takayasu's vasculitis, giant cell arteritis, idiopathic inflammatory myopathies (polymyositis, dermatomyositis, inclusion body myositis), IgG4-related disease, juvenile Still's disease, pelvic inflammatory disease, psoriasis, pustular psoriasis, atopic dermatitis, asthma, allergic rhinitis, recurrent polyarteritis Chondritis, mixed connective tissue disease, graft-versus-host disease, idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, chronic obstructive pulmonary disease, myelofibrosis, multiple sclerosis, cerebral infarction, ischemic stroke, Alzheimer's disease, Parkinson's disease, depression, developmental epilepsy, Meniere's disease, narcolepsy, macrophage activation syndrome, sepsis, pulmonary hypertension, dyslipidemia, Behcet's disease, uveitis, osteoporosis, fractures, osteosarcoma, heart failure, hypertrophic The compound or a pharmaceutically acceptable salt thereof according to any one of the above aspects (1) to (9) can be used for the prophylaxis or treatment of a disease selected from cardiomyopathy, atherosclerosis, female pregnancy syndrome, ovarian cancer, breast cancer, prostate cancer, malignant lymphoma, leukemia, multiple myeloma, lung cancer, granuloma annulare, esophageal cancer, colon cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, melanoma, and secondary hemophagocytic lymphohistiocytosis.

[0115] Aspect (19) includes the compound according to any one of Aspects (1) to (9) above, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, primary biliary cholangitis, primary sclerosing cholangitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjogren's syndrome, psoriasis, pustular psoriasis, Behcet's disease, ovarian cancer, and acute myeloid leukemia.

[0116] Aspect (20) includes the compound according to any one of Aspects (1) to (9) above, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjögren's syndrome, pustular psoriasis, and Behcet's disease.

[0117] Furthermore, another embodiment of the present invention is a method for preventing or treating various diseases and / or symptoms associated therewith that can be improved by inhibition of salt-inducible kinase (SIK), which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and includes the following aspects:

[0118] Aspect (21) includes a method for preventing or treating various diseases and / or symptoms associated therewith that can be improved by inhibition of salt-inducible kinase (SIK), comprising administering to a patient a therapeutically effective amount of the compound according to any one of Aspects (1) to (9) above or a pharmacologically acceptable salt thereof.

[0119] Aspect (22) includes a method for preventing or treating a disease selected from inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases associated with disorders of cartilage turnover, congenital cartilage malformations, diseases associated with disorders of bone turnover, diseases associated with hypersecretion of TNF-α, interferon, IL-6, IL-12, and / or IL-23, respiratory diseases, endocrine and / or metabolic diseases, cardiovascular diseases, skin diseases, and diseases associated with abnormal angiogenesis, comprising administering to a patient a therapeutically effective amount of a compound according to any one of Aspects (1) to (9) above, or a pharmaceutically acceptable salt thereof.

[0120] In aspect (23), there is provided a method for treating rheumatoid arthritis, osteoarthritis, psoriatic arthritis, chronic inflammatory demyelinating polyneuropathy, ulcerative colitis, Crohn's disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, type 1 diabetes, type 2 diabetes, which comprises administering to a patient a therapeutically effective amount of the compound according to any one of the above aspects (1) to (9) or a pharmacologically acceptable salt thereof. Diarrhea, pancreatitis, systemic lupus erythematosus, cutaneous lupus erythematosus, central nervous system lupus, lupus nephritis, antiphospholipid syndrome, chronic kidney disease, acute kidney injury, sarcoidosis, systemic sclerosis, localized scleroderma, Sjogren's syndrome, ANCA-associated vasculitis, immune complex-mediated small vasculitis, polyarteritis nodosa, Kawasaki disease, Takayasu's vasculitis, giant cell arteritis, idiopathic inflammatory myopathies (polymyositis, dermatomyositis, inclusion body myositis), IgG4-related disease , juvenile Still's disease, pelvic inflammatory disease, psoriasis, pustular psoriasis, atopic dermatitis, asthma, allergic rhinitis, relapsing polychondritis, mixed connective tissue disease, graft-versus-host disease, idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, chronic obstructive pulmonary disease, myelofibrosis, multiple sclerosis, cerebral infarction, ischemic stroke, Alzheimer's disease, Parkinson's disease, depression, developmental epilepsy, Meniere's disease, narcolepsy, macrophage activation syndrome, and ulcerative colitis. and methods for preventing or treating a disease selected from the group consisting of hypertension, pulmonary hypertension, dyslipidemia, Behcet's disease, uveitis, osteoporosis, bone fractures, osteosarcoma, heart failure, hypertrophic cardiomyopathy, atherosclerosis, female pregnancy loss, ovarian cancer, breast cancer, prostate cancer, malignant lymphoma, leukemia, multiple myeloma, lung cancer, granuloma annulare, esophageal cancer, colon cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, melanoma, and secondary hemophagocytic lymphohistiocytosis.

[0121] Aspect (24) includes a method for preventing or treating a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, primary biliary cholangitis, primary sclerosing cholangitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjogren's syndrome, psoriasis, pustular psoriasis, Behcet's disease, ovarian cancer, and acute myeloid leukemia, comprising administering to a patient a therapeutically effective amount of the compound according to any one of Aspects (1) to (9) above, or a pharmacologically acceptable salt thereof.

[0122] Aspect (25) includes a method for preventing or treating a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjogren's syndrome, pustular psoriasis, and Behcet's disease, comprising administering to a patient a therapeutically effective amount of the compound according to any one of Aspects (1) to (9) above, or a pharmacologically acceptable salt thereof.

[0123] Another embodiment of the present invention is use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for producing an agent for preventing or treating various diseases and / or symptoms associated therewith that can be improved by salt-inducible kinase (SIK) inhibition, or an agent for improving the prognosis of such diseases and / or symptoms associated therewith, and includes the following aspects.

[0124] Aspect (26) includes use of the compound according to any one of Aspects (1) to (9) above or a pharmaceutically acceptable salt thereof for the manufacture of an agent for preventing or treating various diseases and / or symptoms associated therewith that can be improved by inhibition of salt-inducible kinase (SIK), or an agent for improving the prognosis of such diseases and / or symptoms associated therewith.

[0125] Aspect (27) includes use of a compound according to any one of Aspects (1) to (9) above, or a pharmaceutically acceptable salt thereof, for the manufacture of an agent for the prophylaxis or treatment of a disease selected from inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases associated with impaired cartilage metabolic turnover, congenital cartilage malformations, diseases associated with impaired bone metabolic turnover, diseases associated with excessive secretion of TNF-α, interferon, IL-6, IL-12, and / or IL-23, respiratory diseases, endocrine and / or metabolic diseases, cardiovascular diseases, skin diseases, and diseases associated with abnormal angiogenesis.

[0126] In embodiment (28), the present invention relates to a method for treating rheumatoid arthritis, osteoarthritis, psoriatic arthritis, chronic inflammatory demyelinating polyneuropathy, ulcerative colitis, Crohn's disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 1 diabetes, type 2 diabetes, pancreatitis, systemic lupus erythematosus, cutaneous lupus erythematosus, central nervous system lupus, lupus nephritis, antiphospholipid antibody syndrome, and chronic renal failure. Acute kidney injury, sarcoidosis, systemic sclerosis, localized scleroderma, Sjögren's syndrome, ANCA-associated vasculitis, immune complex-mediated small vessel vasculitis, polyarteritis nodosa, Kawasaki disease, Takayasu's vasculitis, giant cell arteritis, idiopathic inflammatory myopathies (polymyositis, dermatomyositis, inclusion body myositis), IgG4-related disease, juvenile Still's disease, pelvic inflammatory disease, psoriasis, pustular psoriasis, atopic dermatitis, asthma, allergic rhinitis, relapsing polychondritis , mixed connective tissue disease, graft-versus-host disease, idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, chronic obstructive pulmonary disease, myelofibrosis, multiple sclerosis, cerebral infarction, ischemic stroke, Alzheimer's disease, Parkinson's disease, depression, developmental epilepsy, Meniere's disease, narcolepsy, macrophage activation syndrome, sepsis, pulmonary hypertension, dyslipidemia, Behcet's disease, uveitis, osteoporosis, fractures, osteosarcoma, heart failure, hypertrophic cardiomyopathy, atherosclerosis, pulmonary arterial hypertension, pulmonary fibrosis, pulmonary stenosis, pulmonary arterial hypertension, pulmonary fibrosis, pulmonary arterial hypertension ... and use of the compound according to any one of the above aspects (1) to (9) or a pharmaceutically acceptable salt thereof for the manufacture of an agent for the prophylaxis or treatment of a disease selected from rheumatic arteriosclerosis, female pregnancy syndrome, ovarian cancer, breast cancer, prostate cancer, malignant lymphoma, leukemia, multiple myeloma, lung cancer, granuloma annulare, esophageal cancer, colon cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, melanoma, and secondary hemophagocytic lymphohistiocytosis.

[0127] Aspect (29) includes use of the compound according to any one of Aspects (1) to (9) above or a pharmaceutically acceptable salt thereof for the manufacture of an agent for the prophylaxis or treatment of a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, primary biliary cholangitis, primary sclerosing cholangitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjogren's syndrome, psoriasis, pustular psoriasis, Behcet's disease, ovarian cancer, and acute myeloid leukemia.

[0128] Aspect (30) includes use of the compound according to any one of Aspects (1) to (9) above or a pharmacologically acceptable salt thereof for the manufacture of an agent for the prophylaxis or treatment of a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjögren's syndrome, pustular psoriasis, and Behcet's disease.

[0129] (Regarding Administration Subjects) The compound of formula (I) or a pharmaceutical composition containing the same in the above embodiment can be safely administered to a patient. As used herein, the term "patient" refers to an animal, preferably a mammal (e.g., mouse, rat, hamster, rabbit, cat, dog, cow, sheep, monkey, human, etc.), and particularly a human.

[0130] (Regarding Administration Route) The compound of formula (I) of the above embodiment or a pharmaceutical composition containing the same may be administered orally or parenterally (e.g., intravenously, intramuscularly, subcutaneously, intraorganly, intranasally, intradermally, by instillation, intracerebrally, intrarectally, intravaginally, intraperitoneally, and administration to a lesion).

[0131] The dosage of the compound of formula (I) or a pharmaceutical composition containing the compound of formula (I) in the above embodiment varies depending on the subject, the route of administration, and the age and symptoms of the subject, but is not particularly limited. For example, the dosage is 1 to 1000 mg of the active ingredient per dose when administered orally, and 0.1 to 1000 mg when administered parenterally.

[0132] Injection dose levels range, for example, from about 0.1 mg / kg / hour to at least 10 mg / kg / hour for about 1 to about 120 hours, particularly 24 to 96 hours. A bolus of about 0.1 mg / kg to about 10 mg / kg or more may be administered to achieve adequate steady-state levels. The maximum total dose is expected to not exceed about 1 g / day for a 40-80 kg human patient.

[0133] Treatment regimens for the prevention and / or treatment of long-term conditions, such as degenerative conditions, typically span several months or years, and therefore oral administration is preferred for patient convenience and tolerability. For oral administration, a typical regimen is one to four times daily, particularly one to three times daily, typically one to two times daily, and most typically once daily. Alternatively, for long-acting drugs, typical regimens for oral administration are once every two weeks, once weekly, and once daily. Specifically, the dosing regimen can be every 1 to 14 days, more specifically every 1 to 10 days, even more specifically every 1 to 7 days, and most specifically every 1 to 3 days.

[0134] Transdermal doses are typically selected to provide blood levels similar to or lower than those achieved with injection doses.

[0135] (Use as a prodrug) The compound of formula (I) in the above embodiment can also be used in the form of a prodrug. A prodrug of the compound of formula (I) refers to a compound that is converted to the compound of formula (I) by a reaction with an enzyme, gastric acid, or the like under physiological conditions in a living body, i.e., a compound that is converted to the compound of formula (I) by enzymatic oxidation, reduction, hydrolysis, or the like, or a compound that is converted to the compound of formula (I) by hydrolysis, etc., with gastric acid, or the like. Prodrugs of the compound of formula (I) include compounds in which the amino group of the compound of formula (I) is acylated, alkylated or phosphorylated [e.g., compounds in which the amino group of the compound of formula (I) is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated or tert-butylated, etc.]; compounds in which the hydroxyl group of the compound of formula (I) is acylated, alkylated, phosphorylated or borated [e.g., compounds in which the hydroxyl group of the compound of formula (I) is acetylated, palmitoylated, propanoylated or pivaloyloxymethylated, etc.]; Examples of compounds include compounds in which the carboxyl group of the compound of formula (I) is esterified, amidated, or phenylated (e.g., compounds in which the carboxyl group of the compound of formula (I) is ethyl-esterified, phenyl-esterified, carboxymethyl-esterified, dimethylaminomethyl-esterified, pivaloyloxymethyl-esterified, ethoxycarbonyloxyethyl-esterified, phthalidyl-esterified, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-esterified, cyclohexyloxycarbonylethyl-esterified, or methylamidated). These compounds can be produced from the compound of formula (I) by methods known per se. Furthermore, prodrugs of the compound of formula (I) may be those that are converted into the compound of formula (I) under physiological conditions, as described in "Drug Development," Vol. 7, Molecular Design, pp. 163 to 198, Hirokawa Shoten, 1990.

[0136] (Combination with Other Drugs) The compound of formula (I) can be used in combination with other drugs to prevent or treat the target disease, and excellent preventive and / or therapeutic effects can be expected from the combination with other drugs. Furthermore, such combination therapy can be expected to reduce the dose of other drugs, thereby reducing their side effects. Drugs that can be used in combination with the compound of formula (I) (hereinafter abbreviated as "combined drugs") can be appropriately selected taking into account the type of disease and the severity of the symptoms of the patient. Examples of the combined drugs include: immunomodulators such as azathioprine, corticosteroids (e.g., prednisolone or dexamethasone), cyclophosphamide, cyclosporine, voclosporin, tacrolimus, mycophenolate mofetil, muromonab-CD3 (OKT3, e.g., Orthoclone (registered trademark)), ATG, aspirin, acetaminophen, ibuprofen, naproxen, and piroxicam; - drugs for the treatment of arthritis (e.g. rheumatoid arthritis), such as azathioprine, corticosteroids (e.g. prednisolone or dexamethasone), cyclophosphamide, cyclosporine, tacrolimus, mycophenolate mofetil, muromonab-CD3 (OKT3, e.g. Orthoclone®), ATG, aspirin, acetaminophen, ibuprofen, naproxen, piroxicam, tofacitinib, baricitinib, upadacitinib, filgotinib, tocilizumab; - agents for the treatment of proliferative disorders, such as methotrexate, leucovorin, adriamycin, prednisone, bleomycin, cyclophosphamide, 5-fluorouracil, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, doxorubicin, tamoxifen, toremifene, megestrol acetate, anastrozole, goserelin, anti-HER2 monoclonal antibodies (e.g., Herceptin®), capecitabine, raloxifene hydrochloride, EGFR inhibitors (e.g., Iressa®, Tarceva®, Erbitux®), VEGF inhibitors (e.g., Avastin®), proteasome inhibitors (e.g., Velcade®), Gleevec® and hsp90 inhibitors (e.g., 17-AAG);agents for the treatment of autoimmune diseases, such as glucocorticoids, cytostatics (e.g., purine analogs), alkylating agents (e.g., nitrogen mustards (cyclophosphamide), nitrosoureas, and others), antimetabolites (e.g., methotrexate, azathioprine, and mercaptopurine), cytotoxic antibiotics (e.g., dactinomycin, anthracyclines, mitomycin C, bleomycin, and mithramycin), antibodies (e.g., anti-CD20, anti-CD25, or anti-CD3 (OTK3) monoclonal antibodies, Atgam® and Thymoglobulin®), cyclosporine, tacrolimus, rapamycin (sirolimus), interferons (e.g., IFN-β), TNF-binding proteins (e.g., infliximab, etanercept, or adalimumab), mycophenolate, fingolimod, and myriocin; - agents for the treatment of transplant rejection, such as calcineurin inhibitors (e.g., cyclosporine or tacrolimus (FK506)), mTOR inhibitors (e.g., sirolimus, everolimus), antiproliferative agents (e.g., azathioprine, mycophenolic acid), corticosteroids (e.g., prednisolone, hydrocortisone), antibodies (e.g., monoclonal anti-IL-2Rα receptor antibodies, basiliximab, daclizumab), polyclonal anti-T cell antibodies (e.g., antithymocyte globulin (ATG), antilymphocyte globulin (ALG));- beta2-adrenergic receptor agonists (e.g., salbutamol, levalbuterol, terbutaline, and bitolterol), epinephrine (inhaled or tablet), anticholinergics (e.g., ipratropium bromide), glucocorticoids (oral or inhaled), long-acting beta2-agonists (e.g., salmeterol, formoterol, bambuterol, and sustained-release oral albuterol), combinations of inhaled steroids and long-acting bronchodilators (e.g., fluticasone / salmeterol, budesonide) / formoterol), leukotriene antagonists and synthesis inhibitors (e.g., montelukast, zafirlukast and zileuton), mediator release inhibitors (e.g., cromoglycate and ketotifen), biomodulators of IgE responses (e.g., omalizumab), antihistamines (e.g., cetirizine, cinnarizine, fexofenadine) and vasoconstrictors (e.g., oxymetazoline, xylometazoline, naphazoline and tramazoline) for the treatment of asthma and / or rhinitis and / or COPD; - agents for the treatment of inflammatory bowel diseases, such as glucocorticoids (e.g., prednisone, budesonide), synthetic disease-modifying immunomodulators (e.g., methotrexate, leflunomide, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine and cyclosporine), biologic disease-modifying immunomodulators (infliximab, adalimumab, rituximab, ustekinumab, guselkumab, mirikizumab and abatacept); - human monoclonal antibodies (belimumab (Benlysta) agents for the treatment of systemic lupus erythematosus (SLE) or lupus nephritis (LN), such as fluticasone (fluconazole), anifrolumab (Safnerol), disease-modifying antirheumatic drugs (DMARDs) such as antimalarials (e.g., Plaquenil, hydroxychloroquine), immunosuppressants (e.g., methotrexate and azathioprine), cyclophosphamide and mycophenolate, immunosuppressants and analgesics such as cyclosporine, voclosporin, nonsteroidal anti-inflammatory drugs, opiates (e.g., dextropropoxyphene and co-codamol), opioids (e.g., hydrocodone, oxycodone, MS Contin, or methadone), and fentanyl Duragesic transdermal patches;- medications for treating psoriasis such as topical treatments such as baths, moisturizers, medicated creams and ointments containing coal tar, dithranol (anthralin), corticosteroids like desoximetasone (Topicort™), fluocinonide, vitamin D3 analogues (e.g. calcipotriol), argan oil, and retinoids (etretinate, acitretin, tazarotene), systemic treatments such as methotrexate, cyclosporine, retinoids, thioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumarates, or biologics such as Amebiv™, Enbrel™, Humira™, Remicade™, Raptiva™, ustekinumab (an IL-12 and IL-23 signaling blocker) and secukinumab (an IL-17 signaling blocker); - agents for treating allergic reactions, such as, but not limited to, antihistamines (e.g., cetirizine, diphenhydramine, fexofenadine, levocetirizine), glucocorticoids (e.g., prednisone, betamethasone, beclomethasone, dexamethasone), epinephrine, theophylline or antileukotrienes (e.g., montelukast or zafirlukast), anticholinergics and decongestants;

[0137] The administration form of the concomitant drug is not particularly limited, and the compound of formula (I) and the concomitant drug can be combined at the time of administration. For example, the compound of formula (I) and the concomitant drug can be administered in the following forms: (1) administration of a preparation containing the compound of formula (I) and the concomitant drug in combination; (2) simultaneous or separate administration of two preparations obtained by separately formulating the compound of formula (I) and the concomitant drug via the same administration route; (3) simultaneous or separate administration of two preparations obtained by separately formulating the compound of formula (I) and the concomitant drug via different administration routes. The preferred form can be appropriately selected depending on the actual situation in the medical field.

[0138] A preparation containing the compound of formula (I) in combination with a concomitant drug can be appropriately prepared by a person skilled in the art in accordance with the pharmaceutical composition containing the compound of formula (I) described above.

[0139] The dosage of the concomitant drug can be appropriately selected based on the clinically used dose. The compounding ratio of the compound of formula (I) to the concomitant drug can be appropriately selected depending on the disease or symptoms of the subject, the administration route, the type of the concomitant drug used, etc. Usually, it can be appropriately determined based on the general clinical dose of the concomitant drug used in accordance with the actual situation in medical practice.

[0140] The present invention will be explained in more detail below using Reference Examples and Examples relating to the synthesis of the compound of formula (I), and Test Examples relating to the activity of the compound of formula (I). However, these are merely illustrative, and the present invention is not limited thereto. In the structural formulae of the Reference Examples and Examples below, the notations "or1" and "or2" indicate that the carbon atom to which they are attached has been confirmed to have a single configuration, but its absolute configuration has not been confirmed. The notation "wavy line" indicates that in a compound having two or more asymmetric carbon atoms, the stereochemistry of the carbon atom to which they are attached is a mixture of R- and S-configurations, and the notation "solid line" attached to an asymmetric carbon atom indicates a racemic mixture.

[0141] Here, typical abbreviations used in the following Reference Examples and Examples are explained. (List of Abbreviations) DMSO: dimethyl sulfoxide ESI: electrospray ionization g: gram HATU: O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate HOBt: 1-hydroxybenzotriazole HPLC: high performance liquid chromatography M: molar concentration mmol: millimole MS: mass spectrometry NMR: nuclear magnetic resonance p-: para tert-: tertiary TFA: trifluoroacetic acid WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride

[0142] Reference Example 1: Synthesis of 1-acetyl-6-bromoindazole-4-carbaldehyde 6-Bromo-1H-indazole-4-carbaldehyde (500 mg) was dissolved in tetrahydrofuran (11 mL), and pyridine (0.20 mL), acetic anhydride (0.23 mL), and 4-dimethylaminopyridine (27 mg) were added, followed by stirring at room temperature overnight. After completion of the reaction, the reaction mixture was diluted with ethyl acetate and washed twice with 1N hydrochloric acid and once with saturated brine. Sodium sulfate was added to the organic layer, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The residue was suspended and washed with diisopropyl ether to obtain the title compound (524 mg) as a white powder. MS (ESI) m / z: 267.1 / 269.1 [M+H]+

[0143] Reference Example 2: Synthesis of 4-methylbenzenesulfonate [(3R)-3-hydroxybutyl] Under ice-cooling, p-toluenesulfonyl chloride (1.2 g) and triethylamine (1.2 mL) were added to a solution of (3R)-butane-1,3-diol (500 mg) in dichloromethane (10 mL), and the mixture was stirred at room temperature under a nitrogen atmosphere for 19 hours. After completion of the reaction, water was added to the reaction mixture, which was then extracted with chloroform. Sodium sulfate was added to the separated organic layer, and the mixture was filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (hexane:ethyl acetate = 90:10 to 50:50) to obtain the title compound (701 mg) as a colorless oil. MS (ESI) m / z: 244.8 [M+H]+

[0144] Reference Example 3: Synthesis of 4-bromo-1-(oxetan-3-ylmethyl)pyrazole Under ice-cooling, sodium hydride (60%, dispersed in liquid paraffin) (90 mg) was added to a solution of 4-bromo-1H-pyrazole (300 mg) in N,N-dimethylformamide (5.0 mL), and the mixture was stirred at room temperature under a nitrogen atmosphere for 15 minutes. After that, 3-(bromomethyl)oxetane (370 mg) was added and the mixture was stirred for an additional 3 hours. After the reaction was completed, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The separated organic layer was washed with saturated brine, sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 80:20 to 50:50) to give the title compound (355 mg) as a colorless oil. MS (ESI) m / z: 216.9 / 218.9 [M+H]+

[0145] Reference Example 4: Synthesis of 2-[(4-bromopyrazol-1-yl)methyl]-1,3-oxazole Potassium carbonate (846 mg) was added to a mixture of 4-bromo-1H-pyrazole (300 mg), 2-(chloromethyl)oxazole (288 mg), and acetonitrile (3.0 mL), and the mixture was heated and stirred at 60°C for 3 hours. After completion of the reaction, the reaction mixture was diluted with chloroform, and insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (hexane:ethyl acetate = 80:20 to 50:50) to obtain the title compound (303 mg) as a colorless oil. MS (ESI) m / z: 227.7 / 229.7 [M+H]+

[0146] Reference Example 5: Synthesis of 4-bromo-1-[(3-fluorooxetan-3-yl)methyl]pyrazole To a solution of 4-bromo-1H-pyrazole (100 mg) in N,N-dimethylformamide (2.0 mL), sodium hydride (60%, dispersed in liquid paraffin) (33 mg) was added under ice-cooling, and the mixture was stirred at room temperature for 15 minutes. (3-fluorooxetan-3-yl)methyl p-toluenesulfonate (195 mg) was added, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed twice with saturated brine, separated using a Phase-Separator®, and concentrated under reduced pressure. The residue was purified twice by silica gel column chromatography (hexane:ethyl acetate = 90:10 to 70:30) to obtain the title compound (131 mg) as a colorless oil. MS (ESI) m / z: 234.9 / 236.9 [M+H]+

[0147] Reference Example 6: Synthesis of 4-iodo-1-(oxolan-3-ylmethyl)pyrazole A mixture of 4-iodo-1H-pyrazole (200 mg), potassium carbonate (428 mg), 3-(bromomethyl)tetrahydrofuran (0.15 mL), and N-methyl-2-pyrrolidone (5.2 mL) was heated and stirred at 80°C for 4 hours. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layer was then washed with water and saturated brine, magnesium sulfate was added, and the mixture was stirred. Insoluble matter was then removed by filtration. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 80:20 to 45:55) to give the title compound (175 mg) as a colorless oil. MS (ESI) m / z: 278.8 [M+H]+

[0148] Reference Example 7: Synthesis of 4-iodo-1-(oxolan-2-ylmethyl)pyrazole A mixture of 4-iodo-1H-pyrazole (200 mg), potassium carbonate (428 mg), tetrahydrofurfuryl bromide (0.18 mL), and N-methyl-2-pyrrolidone (5.2 mL) was heated and stirred at 80°C for 3 hours. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. Magnesium sulfate was added to the resulting organic layer, and after stirring, insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 80:20 to 50:50) to obtain the title compound (231 mg) as a colorless oil. MS (ESI) m / z: 278.9 [M+H]+

[0149] Reference Example 8: Synthesis of 4-iodo-1-[(3S)-oxolan-3-yl]pyrazole A mixture of 4-iodo-1H-pyrazole (360 mg), cesium carbonate (807 mg), p-toluenesulfonic acid [(3R)-tetrahydrofuran-3-yl] (300 mg), and N,N-dimethylformamide (6.2 mL) was heated and stirred at 80°C for 5 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, sodium sulfate was added, and the mixture was stirred. Insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by column chromatography using an NH silica gel column and a Si silica gel column in series (hexane:ethyl acetate = 85:15 to 60:40) to obtain the title compound (291 mg) as a white powder. MS (ESI) m / z: 264.8 [M+H]+

[0150] Reference Example 9: Synthesis of 2-bromo-6-(difluoromethoxy)-N-(2-propenyl)benzamide 2-Bromo-6-(difluoromethoxy)benzoic acid (1.5 g) was dissolved in dichloromethane (9.8 mL), and oxalyl dichloride (1.3 mL) and one drop of DMF were added, followed by stirring at room temperature for 2 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure and then subjected to azeotropic distillation three times with toluene. The resulting residue was dissolved in dichloromethane (9.8 mL), and allylamine hydrochloride (552 mg) was added, followed by stirring under ice cooling. Triethylamine (3.4 mL) and dichloromethane (9.8 mL) were added, followed by stirring at room temperature for 1 hour. After completion of the reaction, water was added to the reaction mixture, which was then extracted twice with chloroform. The combined organic layers were washed sequentially with saturated aqueous ammonium chloride and saturated brine, and sodium sulfate was added. Filtration was performed, and the filtrate was concentrated under reduced pressure to obtain the title compound (1.5 g) as a white powder. MS (ESI) m / z: 306.0 / 308.0 [M+H]+

[0151] Reference Example 10: Synthesis of tert-butyl N-[2-bromo-6-(difluoromethoxy)benzoyl]-N-(2-propenyl)carbamate 2-Bromo-6-(difluoromethoxy)-N-(2-propenyl)benzamide (1.5 g) described in Reference Example 9 was dissolved in dichloromethane (9.8 mL), and di-tert-butyl dicarbonate (2.1 g), triethylamine (0.82 mL), and 4-dimethylaminopyridine (60 mg) were added and stirred at room temperature overnight. After completion of the reaction, the reaction solution was diluted with ethyl acetate and washed twice with saturated aqueous ammonium chloride and once with saturated brine, followed by addition of sodium sulfate. Filtration and concentration of the filtrate under reduced pressure gave the title compound (2.2 g) as an orange oil. MS (ESI) m / z: 350.1 / 352.0 [M-tBu+H]+

[0152] Reference Example 11: Synthesis of tert-butyl 8-(difluoromethoxy)-4-methyl-1-oxoisoquinoline-2-carboxylate Tert-butyl N-[2-bromo-6-(difluoromethoxy)benzoyl]-N-(2-propenyl)carbamate (2.2 g), palladium(II) acetate (110 mg), and tetrabutylammonium chloride (1.5 g) described in Reference Example 10 were dissolved in N,N-dimethylformamide (20 mL), and N,N-diisopropylethylamine (1.7 mL) was added, followed by stirring at 80°C under a nitrogen atmosphere for 2 hours. Palladium(II) acetate (219 mg) was added, and the mixture was stirred at 80°C under a nitrogen atmosphere for 3 hours. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted twice with a mixed solvent of hexane:ethyl acetate = 1:1. The organic layers were combined, washed sequentially with saturated aqueous ammonium chloride and saturated brine, and sodium sulfate and activated carbon were added, followed by standing. Filtration was performed, and the filtrate was concentrated under reduced pressure to obtain the title compound (1.6 g) as a pale yellow oil. MS (ESI) m / z: 270.1 [M-tBu+H]+

[0153] Reference Example 12: Synthesis of tert-butyl 4-bromo-2-fluoro-6-methoxybenzoate To a solution of tert-butyl 4-bromo-2,6-difluorobenzoate (15 g) in tetrahydrofuran (110 mL), 5 M sodium methoxide methanol solution (11 mL) was added under ice cooling, and the mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and saturated aqueous ammonium chloride solution was added to the resulting residue, followed by extraction twice with ethyl acetate. The organic layer was separated using a Phase-Separator (registered trademark) and concentrated under reduced pressure. The concentrated residue was purified by silica gel column chromatography (hexane:ethyl acetate = 100:0 to 90:10) to obtain the title compound (9.0 g) as a white powder. MS (ESI) m / z: 248.7 / 250.7 [M+H-tBu]+

[0154] Reference Example 13: Synthesis of tert-butyl 4-bromo-2-hydroxy-6-methoxybenzoate To a solution of 2-(methylsulfonyl)ethanol (3.6 mL) in N,N-dimethylformamide (49 mL), sodium hydride (60%, dispersed in liquid paraffin) (2.7 g) was added under ice cooling and stirred for 30 minutes, followed by the addition of a solution of tert-butyl 4-bromo-2-fluoro-6-methoxybenzoate (9.0 g) described in Reference Example 12 in N,N-dimethylformamide (24 mL). The reaction mixture was stirred at room temperature for 2 days, and then 1N hydrochloric acid (70 mL) was added under ice cooling, followed by extraction twice with ethyl acetate. The organic layer was washed twice with water and once with saturated brine, followed by addition of sodium sulfate, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified twice by silica gel column chromatography (hexane:ethyl acetate = 100:0 to 90:10) to give the title compound (6.1 g) as a colorless oil. MS (ESI) m / z: 246.7 / 248.7 [M+H-tBu]+

[0155] Reference Example 14: Synthesis of tert-butyl 4-bromo-2-(difluoromethoxy)-6-methoxybenzoate To a solution of tert-butyl 4-bromo-2-hydroxy-6-methoxybenzoate (6.1 g) described in Reference Example 13 in acetonitrile (29 mL) and water (29 mL), potassium hydroxide (11 g) was added portionwise under ice-cooling, and the mixture was stirred for 10 minutes. Diethyl (bromodifluoromethyl)phosphonate (7.6 g) was added dropwise under ice-cooling, and the mixture was stirred at room temperature for 2 hours. Water was added to the reaction solution, which was then extracted twice with ethyl acetate. Sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate=100:0 to 80:20) to give the title compound (5.1 g) as a colorless oil. MS (ESI) m / z: 297.5 / 299.5 [M+H-tBu]+

[0156] Reference Example 15: Synthesis of 4-bromo-2-(difluoromethoxy)-6-methoxybenzoic acid TFA (33 mL) was added to a solution of tert-butyl 4-bromo-2-(difluoromethoxy)-6-methoxybenzoate (10 g) described in Reference Example 14 in dichloromethane (94 mL), and the mixture was stirred at room temperature for 6 hours. The reaction mixture was concentrated under reduced pressure, and then toluene (50 mL) was added to the residue, followed by further concentration under reduced pressure. The concentrated residue was suspended and washed with hexane to obtain the title compound (8.0 g) as a white powder. MS (ESI) m / z: 296.7 / 298.7 [M+H]+

[0157] Reference Example 16: Synthesis of 4-bromo-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide To a suspension of 4-bromo-2-(difluoromethoxy)-6-methoxybenzoic acid (8.0 g) described in Reference Example 15 in dichloromethane (90 mL), oxalyl dichloride (11 mL) and N,N-dimethylformamide (0.21 mL) were added under ice cooling and stirred at room temperature for 1.5 hours. The reaction solution was concentrated under reduced pressure, and then triethylamine (19 mL) and (1R,2S)-2-fluorocyclopropan-1-amine hydrochloride (4.5 g) were added to a solution of the residue in dichloromethane (90 mL), and the mixture was stirred at room temperature for 2 hours. Water was added to the reaction solution, and the mixture was extracted with dichloromethane. The organic layer was separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 90:10 to 50:50) to obtain the title compound (6.9 g) as a white powder. MS (ESI) m / z: 353.8 / 355.8 [M+H]+

[0158] Reference Example 17: Synthesis of 2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide A suspension of 4-bromo-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (3.0 g), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (692 mg), potassium acetate (2.5 g), and bis(pinacolato)diboron (2.6 g) in 1,4-dioxane (21 mL) was purged with nitrogen and stirred at 100°C for 2 hours. Insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 90:10 to 50:50) to give the title compound (1.9 g) as a brown viscous material. MS (ESI) m / z: 401.9 [M+H]+

[0159] Reference Example 18: Synthesis of 6-bromo-3-iodo-1H-indazole-4-carbonitrile 6-Bromo-1H-indazole-4-carbonitrile (2.0 g) was dissolved in N,N-dimethylformamide (20 mL) and stirred under ice-cooling. Potassium hydroxide (2.5 g) and iodine (6.9 g) were added, and the mixture was stirred under ice-cooling for 30 minutes, followed by stirring at room temperature for 88 hours. After completion of the reaction, an aqueous sodium thiosulfate solution (50 mL) was added to the reaction solution under ice-cooling, and the mixture was stirred at room temperature for 1 hour. Water (150 mL) was added, and the mixture was stirred at room temperature for 1 hour. The solid was collected by filtration and washed with an excess amount of water to obtain the title compound (2.8 g) as a pale brown powder. MS (ESI) m / z: 345.9 / 347.9 [M-H]-

[0160] Reference Example 19: Synthesis of 6-bromo-3-iodo-2-methylindazole-4-carbonitrile 6-Bromo-3-iodo-1H-indazole-4-carbonitrile (2.8 g) described in Reference Example 18 was suspended in ethyl acetate (82 mL) and stirred under ice-cooling. Trimethyloxonium tetrafluoroborate (1.7 g) was added, and the mixture was stirred at room temperature for 90 hours. After completion of the reaction, saturated aqueous sodium bicarbonate solution (30 mL) and water (50 mL) were added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour. The solid was collected by filtration and washed with an excess amount of water to obtain the title compound (2.7 g) as a pale brown powder. MS (ESI) m / z: 361.7 / 363.7 [M+H]+

[0161] Reference Example 20: Synthesis of 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide A mixture of 6-bromo-3-iodo-2-methylindazole-4-carbonitrile (129 mg) described in Reference Example 19, 2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (172 mg) described in Reference Example 17, water (0.36 mL), potassium carbonate (99 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (29 mg), and 1,4-dioxane (3.6 mL) was heated and stirred under a nitrogen atmosphere at 100°C for 4 hours. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was then separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=70:30 to 0:100) to obtain the title compound (73 mg) as a pale yellow oil. MS (ESI) m / z: 508.8 / 510.8 [M+H]

[0162] Reference Example 21: Synthesis of 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (3.5 g) described in Reference Example 20, bis(pinacolato)diboron (2.1 g), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (560 mg), and potassium acetate (2.0 g) were suspended in 1,4-dioxane (17 mL) and stirred at 95°C under a nitrogen atmosphere for 3 hours. After completion of the reaction, the reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 30:70 to 0:100) to obtain the title compound (2.1 g) as an orange oil. MS (ESI) m / z: 557.4 [M+H]+

[0163] Reference Example 22: Synthesis of 6-bromo-3-iodo-4-methoxy-1H-indazole 6-Bromo-4-methoxy-1H-indazole (16 g) was dissolved in N,N-dimethylformamide (150 mL) and stirred under ice-cooling. Potassium hydroxide (14 g) and iodine (35 g) were added, and the mixture was stirred overnight at room temperature. After the reaction was completed, an aqueous solution of sodium thiosulfate (100 mL) was added to the reaction solution under ice-cooling, and water (700 mL) was added, followed by stirring at room temperature for 1 hour. The solid was collected by filtration and washed with an excess amount of water to obtain the title compound (24 g) as a pale brown powder. MS (ESI) m / z: 352.9 / 354.8 [M+H]+

[0164] Reference Example 23: Synthesis of 6-bromo-3-iodo-4-methoxy-2-methylindazole 6-Bromo-3-iodo-4-methoxy-1H-indazole (12 g) described in Reference Example 22 was suspended in ethyl acetate (161 mL), trimethyloxonium tetrafluoroborate (5.7 g) was added, and the mixture was stirred at room temperature for 14 hours. After completion of the reaction, saturated aqueous sodium bicarbonate solution (100 mL) and water (50 mL) were added to the reaction mixture. After stirring at room temperature for 2 hours, the organic layer was separated, and the aqueous layer was extracted twice with a mixed solvent of chloroform:methanol = 10:1. The combined organic layers were added with sodium sulfate and filtered. The filtrate was concentrated, and the resulting residue was purified by NH silica gel column chromatography (hexane:ethyl acetate = 90:10 to 75:25), followed by suspension washing with diisopropyl ether to obtain the title compound (9.1 g) as a pale brown powder. MS (ESI) m / z: 366.7 / 368.7 [M+H]+

[0165] Reference Example 24: Synthesis of 4-(6-bromo-4-methoxy-2-methylindazol-3-yl)-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide A mixture of 6-bromo-3-iodo-4-methoxy-2-methylindazole (100 mg) described in Reference Example 23, 2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (131 mg) described in Reference Example 17, water (0.27 mL), potassium carbonate (75 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (22 mg), and 1,4-dioxane (2.7 mL) was heated and stirred under a nitrogen atmosphere at 100°C for 4 hours. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was then separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=70:30 to 0:100) to obtain the title compound (86 mg) as a pale yellow oil. MS (ESI) m / z: 513.9 / 515.8 [M+H]

[0166] Reference Example 25: Synthesis of N-[(1R,2S)-2-fluorocyclopropyl]-2-hydroxy-6-methoxybenzamide To a suspension of 2-hydroxy-6-methoxy-benzoic acid (5.0 g) in dichloromethane (30 mL), 1,1'-carbonyldiimidazole (4.8 g) was added and the mixture was stirred at room temperature for 45 minutes. Then, (1R,2S)-2-fluorocyclopropan-1-amine hydrochloride (3.5 g) and triethylamine (5.0 mL) were added to the reaction mixture and stirred at room temperature for 15 hours. 1N hydrochloric acid was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was washed with saturated aqueous sodium bicarbonate, separated using a Phase-Separator®, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 85:15 to 65:35) to give the title compound (4.6 g) as a colorless oil. MS (ESI) m / z: 225.9 [M+H]+

[0167] Reference Example 26: Synthesis of 2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide To a solution of N-[(1R,2S)-2-fluorocyclopropyl]-2-hydroxy-6-methoxybenzamide (4.6 g) described in Reference Example 25 in acetonitrile (23 mL) and water (23 mL), potassium hydroxide (11 g) was added portionwise under ice cooling, and the mixture was stirred for 5 minutes. Diethyl (bromodifluoromethyl)phosphonate (7.2 mL) was added dropwise under ice cooling, and the mixture was stirred at room temperature for 40 minutes. Ethyl acetate was added to the reaction solution for extraction, and the organic layer was washed with saturated brine, followed by addition of magnesium sulfate and filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=0:100) and then suspended and washed with diisopropyl ether to give the title compound (4.3 g) as a colorless powder. MS (ESI) m / z: 276.0 [M+H]+

[0168] Reference Example 27: Synthesis of 2-(difluoromethoxy)-4-(1,3,6,2-dioxazaborocan-2-yl)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide To a suspension of 2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (4.3 g) described in Reference Example 26 in tetrahydrofuran (5.0 mL), bis(pinacolato)diboron (4.2 g), 4,4'-di-tert-butyl-2,2'-bipyridyl (84 mg), and bis(1,5-cyclooctadiene)di-μ-methoxydiiridium(I) (104 mg) were added and the mixture was stirred under nitrogen atmosphere and refluxed for 1.5 hours. Further, bis(1,5-cyclooctadiene)di-μ-methoxydiiridium(I) (208 mg) and 4,4'-di-tert-butyl-2,2'-bipyridyl (169 mg) were added to the reaction mixture, and the mixture was stirred under reflux for 3 hours. Subsequently, THF (20 mL) and 2-(2-hydroxyethylamino)ethanol (3.3 g) were added to the reaction solution at room temperature, and the mixture was stirred for 14 hours. The reaction solution was filtered and washed with THF (approximately 40 mL) to obtain the title compound (5.5 g) as a gray powder. MS (ESI) m / z: 319.9 [M+H—C4H7N]+

[0169] Reference Example 28: Synthesis of [3-(difluoromethoxy)-4-[[(1R,2S)-2-fluorocyclopropyl]carbamoyl]-5-methoxyphenyl]boronic acid 1N hydrochloric acid (30 mL) was added to 2-(difluoromethoxy)-4-(1,3,6,2-dioxazaborocan-2-yl)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (5.5 g) described in Reference Example 27, and the mixture was stirred at room temperature for 2 hours. The reaction solution was filtered and washed twice with a total of approximately 50 mL of water to obtain the title compound (3.7 g) as a gray powder. MS (ESI) m / z: 319.9 [M+H]+

[0170] Reference Example 29: Synthesis of 6-bromo-4-(difluoromethyl)-1H-indazole 1-Acetyl-6-bromoindazole-4-carbaldehyde (2.3 g) described in Reference Example 1 was suspended in dichloromethane (43 mL), and diethylaminosulfur trifluoride (2.3 mL) was added under ice-cooling. The mixture was stirred for 1 hour under ice-cooling and then overnight at room temperature. After completion of the reaction, the reaction solution was added dropwise to saturated aqueous sodium bicarbonate (150 mL), followed by addition of water (100 mL) and extraction with chloroform twice. The organic layers were combined and concentrated, and the residue was dissolved in a mixed solvent of methanol (43 mL) and tetrahydrofuran (43 mL), and 1N aqueous sodium hydroxide solution (17 mL) was added and stirred at room temperature for 1 hour. After completion of the reaction, 1N hydrochloric acid (17 mL) was added to the reaction solution and extracted with chloroform. The organic layer was separated using a Phase-separator (registered trademark) and then concentrated under reduced pressure to obtain the title compound (2.6 g) as a yellow powder. MS (ESI) m / z: 246.7 / 248.7 [M+H]+

[0171] Reference Example 30: Synthesis of 6-bromo-4-(difluoromethyl)-3-iodo-1H-indazole 6-Bromo-4-(difluoromethyl)-1H-indazole (229 mg) described in Reference Example 29 was dissolved in N,N-dimethylformamide (2.1 mL), and potassium hydroxide (182 mg) and iodine (471 mg) were added, followed by stirring at room temperature for 5 hours. After completion of the reaction, aqueous sodium thiosulfate solution and an excess amount of water were added to the reaction solution under ice cooling, and the mixture was stirred at room temperature for 10 minutes. The solid was collected by filtration and washed with an excess amount of water to obtain the title compound (328 mg) as a pale brown powder. MS (ESI) m / z: 373.0 / 375.0 [M+H]+

[0172] Reference Example 31: Synthesis of 6-bromo-4-(difluoromethyl)-3-iodo-2-methylindazole 6-Bromo-4-(difluoromethyl)-3-iodo-1H-indazole (202 mg) described in Reference Example 30 was dissolved in ethyl acetate (2.6 mL), and trimethyloxonium tetrafluoroborate (99 mg) was added, followed by stirring at room temperature for 2 hours. After completion of the reaction, saturated aqueous sodium bicarbonate solution and chloroform were added to the reaction mixture, and the organic layer was separated using a Phase-Separator (registered trademark) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 95:5 to 75:25) to obtain the title compound (148 mg) as a white powder. MS (ESI) m / z: 386.8 / 388.8 [M+H]+

[0173] Reference Example 32: Synthesis of 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide A mixture of 6-bromo-4-(difluoromethyl)-3-iodo-2-methylindazole (40 mg) described in Reference Example 31, [3-(difluoromethoxy)-4-[[(1R,2S)-2-fluorocyclopropyl]carbamoyl]-5-methoxyphenyl]boronic acid (33 mg) described in Reference Example 28, water (0.17 mL), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (8.4 mg), potassium carbonate (43 mg), and 1,4-dioxane (0.69 mL) was heated and stirred for 1 hour at 100°C under a nitrogen atmosphere. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was then separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=60:40 to 20:80) to obtain the title compound (24 mg) as a white powder. MS (ESI) m / z: 534.3 / 536.3 [M+H]

[0174] Reference Example 33: Synthesis of 6-bromo-3-iodo-2-methylindazol-4-ol 6-Bromo-3-iodo-4-methoxy-2-methylindazole (1.0 g) described in Reference Example 23 was dissolved in dichloromethane (25 mL), and 1 M boron tribromide dichloromethane solution (14 mL) was added dropwise over 20 minutes under ice-cooling, followed by stirring at room temperature for 46 hours. After completion of the reaction, water was added to the reaction mixture under ice-cooling, and the precipitate was collected by filtration and washed with water to obtain the title compound (1.2 g) as a pale gray powder. MS (ESI) m / z: 353.0 / 355.0 [M+H]+

[0175] Reference Example 34: Synthesis of 6-bromo-3-iodo-2-methyl-4-[3-(oxan-2-yloxy)propoxy]indazole 6-Bromo-3-iodo-2-methylindazol-4-ol (100 mg) and potassium carbonate (117 mg) described in Reference Example 33 were suspended in N,N-dimethylformamide (3.0 mL), and 2-(3-bromopropoxy)tetrahydropyran (95 mg) was added, followed by stirring at 80°C under a nitrogen atmosphere for 45 hours. After completion of the reaction, water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed twice with saturated brine. The organic layer was filtered through a Phase-Separator® and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate = 95:5 to 80:20) to obtain the title compound (129 mg) as a colorless viscous material. MS (ESI) m / z: 495.1 / 497.2 [M+H]+

[0176] Reference Example 35: Synthesis of 4-[6-bromo-2-methyl-4-[3-(oxan-2-yloxy)propoxy]indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide A mixture of 6-bromo-3-iodo-2-methyl-4-[3-(oxan-2-yloxy)propoxy]indazole (125 mg) described in Reference Example 34, [3-(difluoromethoxy)-4-[[(1R,2S)-2-fluorocyclopropyl]carbamoyl]-5-methoxyphenyl]boronic acid (97 mg) described in Reference Example 28, potassium carbonate (70 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (21 mg), 1,4-dioxane (5.0 mL), and water (0.50 mL) was heated and stirred at 100°C for 2 hours under a nitrogen atmosphere. After completion of the reaction, ethyl acetate was added to the reaction solution and the mixture was filtered. Water was added to the filtrate and the mixture was extracted with ethyl acetate, and the organic layer was washed with saturated brine. Sodium sulfate was added to the organic layer, insoluble matter was removed by filtration, and the mixture was concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=70:30 to 30:70) to obtain the title compound (108 mg) as a colorless powder. MS (ESI) m / z: 642.0 / 643.9 [M+H]

[0177] Reference Example 36: Synthesis of 2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxy-4-[2-methyl-6-(1-methylpyrazol-4-yl)-4-[3-(oxan-2-yloxy)propoxy]indazol-3-yl]benzamide A mixture of 4-[6-bromo-2-methyl-4-[3-(oxan-2-yloxy)propoxy]indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (104 mg) described in Reference Example 35, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (51 mg), potassium carbonate (45 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (13 mg), 1,4-dioxane (3.0 mL), and water (0.30 mL) was heated and stirred at 100°C for 2 hours under a nitrogen atmosphere. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was separated using a Phase-separator (registered trademark), concentrated under reduced pressure, and then purified by NH silica gel column chromatography (hexane:ethyl acetate=50:50 to 0:100) to obtain the title compound (80 mg) as a pale yellow powder. MS (ESI) m / z: 644.5 [M+H]

[0178] Reference Example 37: Synthesis of 6-bromo-3-iodo-2-methyl-4-phenylmethoxyindazole 6-Bromo-3-iodo-2-methylindazol-4-ol (100 mg) and potassium carbonate (117 mg) described in Reference Example 33 were suspended in N,N-dimethylformamide (3.0 mL), bromomethylbenzene (73 mg) was added, and the mixture was stirred at 80°C under a nitrogen atmosphere for 6 hours. After completion of the reaction, water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed twice with saturated brine. The organic layer was filtered through a Phase-Separator® and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 99:1 to 90:10) to obtain the title compound (75 mg) as a colorless powder. MS (ESI) m / z: 443.1 / 445.1 [M+H]+

[0179] Reference Example 38: Synthesis of 4-(6-bromo-2-methyl-4-phenylmethoxyindazol-3-yl)-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide A mixture of 6-bromo-3-iodo-2-methyl-4-phenylmethoxyindazole (72 mg) described in Reference Example 37, [3-(difluoromethoxy)-4-[[(1R,2S)-2-fluorocyclopropyl]carbamoyl]-5-methoxyphenyl]boronic acid (62 mg) described in Reference Example 28, potassium carbonate (45 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (13 mg), 1,4-dioxane (3.0 mL), and water (0.30 mL) was heated and stirred under a nitrogen atmosphere at 100°C for 4 hours. After completion of the reaction, water was added to the reaction solution, and the mixture was extracted with chloroform. The organic layer was then separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=80:20 to 50:50) to obtain the title compound (55 mg) as a colorless powder. MS (ESI) m / z: 590.3 / 592.3 [M+H]

[0180] Reference Example 39: Synthesis of 6-bromo-4-(difluoromethoxy)-3-iodo-2-methylindazole 6-Bromo-3-iodo-2-methylindazol-4-ol (1.0 g) described in Reference Example 33 was dissolved in a mixed solvent of acetonitrile (10 mL) and water (5.0 mL), and potassium hydroxide (1.6 g) was added under ice-cooling. The mixture was stirred for 10 minutes under ice-cooling. Acetonitrile (5.0 mL) and diethyl (bromodifluoromethyl)phosphonate (0.70 mL) were added under ice-cooling, and the mixture was stirred for 1 hour and 40 minutes under ice-cooling. After completion of the reaction, water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 85:15 to 60:40) to obtain the title compound (737 mg) as a colorless powder. MS (ESI) m / z: 402.9 / 404.9 [M+H]+

[0181] Reference Example 40: Synthesis of 4-[6-bromo-4-(difluoromethoxy)-2-methylindazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide A mixture of 6-bromo-4-(difluoromethoxy)-3-iodo-2-methylindazole (65 mg) described in Reference Example 39, [3-(difluoromethoxy)-4-[[(1R,2S)-2-fluorocyclopropyl]carbamoyl]-5-methoxyphenyl]boronic acid (51 mg) described in Reference Example 28, water (0.27 mL), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (13 mg), potassium carbonate (45 mg), and 1,4-dioxane (1.1 mL) was heated and stirred at 100 ° C. for 2 hours under a nitrogen atmosphere. After completion of the reaction, the reaction solution was purified by silica gel column chromatography (hexane:ethyl acetate = 50:50 to 20:80) to obtain the title compound (41 mg) as a pale yellow powder. MS (ESI) m / z: 550.2 / 552.3 [M + H] +

[0182] Reference Example 41: Synthesis of tert-butyl 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoate A mixture of tert-butyl 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoate (4.5 g) described in Reference Example 44, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (2.2 g), potassium carbonate (2.5 g), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (725 mg), 1,4-dioxane (59 mL), and water (15 mL) was heated and stirred under a nitrogen atmosphere at 100°C for 2.5 hours. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The combined organic layers were passed through a Phase-Separator (registered trademark), concentrated under reduced pressure, and purified by NH silica gel column chromatography (hexane:ethyl acetate=90:10 to 30:70) to obtain the title compound (4.3 g) as a pale yellow powder. MS (ESI) m / z: 510.0 [M+H]+

[0183] Reference Example 42: Synthesis of 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid TFA (21 mL) was added dropwise to a dichloromethane (21 mL) solution of tert-butyl 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoate (4.3 g) described in Reference Example 41 under ice-cooling, and the mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and then azeotroped with toluene. The resulting residue was suspended and washed with diethyl ether to obtain the title compound (3.4 g) as a white powder. MS (ESI) m / z: 454.0 [M+H]+

[0184] Reference Example 43: Synthesis of tert-butyl 2-(difluoromethoxy)-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate A suspension of tert-butyl 4-bromo-2-(difluoromethoxy)-6-methoxybenzoate (6.0 g), bis(pinacolato)diboron (5.2 g), potassium acetate (5.0 g), and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (1.4 g) in 1,4-dioxane (42 mL) was stirred under a nitrogen atmosphere at 100°C for 6 hours. Ethyl acetate was added to the reaction solution, and insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 80:20 to 50:50) to give the title compound (7.3 g) as a pale yellow oil. MS (ESI) m / z: 345.3 [M+H-tBu]+

[0185] Reference Example 44: Synthesis of tert-butyl 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoate A mixture of 6-bromo-3-iodo-2-methylindazole-4-carbonitrile (5.0 g) described in Reference Example 19, tert-butyl 2-(difluoromethoxy)-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (6.3 g) described in Reference Example 43, [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (1.1 g), potassium carbonate (3.8 g), water (12 mL), and 1,4-dioxane (46 mL) was heated and stirred for 2 hours and 30 minutes at 100°C under a nitrogen atmosphere. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layer was then separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=90:10 to 50:50) to obtain the title compound (4.5 g) as a pale yellow powder. MS (ESI) m / z: 507.9 / 509.8 [M+H]

[0186] Reference Example 45: Synthesis of tert-butyl 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoate A mixture of 6-bromo-4-(difluoromethyl)-3-iodo-2-methylindazole (1.7 g) described in Reference Example 31, tert-butyl 2-(difluoromethoxy)-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (1.9 g) described in Reference Example 43, potassium carbonate (1.8 g), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (361 mg), water (7.4 mL), and 1,4-dioxane (29 mL) was heated and stirred under a nitrogen atmosphere at 100°C for 1 hour. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was then separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=90:10 to 50:50) to obtain the title compound (1.6 g) as a pale yellow powder. MS (ESI) m / z: 532.8 / 534.8 [M+H]

[0187] Reference Example 46: Synthesis of 2-(difluoromethoxy)-4-[4-(difluoromethyl)-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzoic acid A mixture of tert-butyl 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoate (1.6 g) described in Reference Example 45, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (695 mg), potassium carbonate (1.3 g), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (248 mg), 1,4-dioxane (20 mL), and water (5.1 mL) was heated and stirred under a nitrogen atmosphere at 100°C for 2 hours. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was separated using a Phase-separator (registered trademark), concentrated under reduced pressure, and then purified by silica gel column chromatography (chloroform:methanol = 100:0 to 95:5). The resulting intermediate product was dissolved in dichloromethane (19 mL), and TFA (4.6 mL) was added, followed by stirring overnight at room temperature. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and then subjected to azeotropic distillation twice with toluene. The resulting crude product was suspended and washed with diethyl ether to obtain the title compound (1.1 g) as a pale red powder. MS (ESI) m / z: 479.2 [M+H]+

[0188] Reference Example 47: Synthesis of [4-bromo-2-(difluoromethoxy)-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone To a mixture of 4-bromo-2-(difluoromethoxy)-6-methoxybenzoic acid (2.4 g), HATU (4.6 g), N,N-diisopropylethylamine (4.2 mL), and N,N-dimethylformamide (12 mL) described in Reference Example 15, 3-(trifluoromethyl)azetidin-3-ol hydrochloride (2.2 g) was added and stirred at room temperature for 30 minutes. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with water and saturated brine, then sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 65:35 to 30:70) to give the title compound (3.5 g) as a pale yellow powder. MS (ESI) m / z: 419.8 / 421.7 [M+H]

[0189] Reference Example 48: Synthesis of [2-(difluoromethoxy)-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone A suspension of [4-bromo-2-(difluoromethoxy)-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (1.7 g) described in Reference Example 47, bis(pinacolato)diboron (1.3 g), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (339 mg), and potassium acetate (1.2 g) in 1,4-dioxane (10 mL) was stirred at 100°C for 155 minutes under a nitrogen atmosphere. Ethyl acetate was added to the reaction mixture, and insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 90:10 to 34:66) to give the title compound (1.9 g) as a brown viscous material. MS (ESI) m / z: 467.8 [M+H]+

[0190] Reference Example 49: Synthesis of tert-butyl 4-(6-bromo-4-methoxy-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoate A mixture of 6-bromo-3-iodo-4-methoxy-2-methylindazole (1.8 g) described in Reference Example 23, tert-butyl 2-(difluoromethoxy)-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (2.2 g) described in Reference Example 43, [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (400 mg), potassium carbonate (1.4 g), water (6.1 mL), and 1,4-dioxane (25 mL) was heated and stirred at 100°C for 1 hour under a nitrogen atmosphere. After completion of the reaction, the reaction mixture was filtered, saturated brine was added to the filtrate, and the mixture was extracted with chloroform. Sodium sulfate was added to the organic layer, and the mixture was stirred. Insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a Si silica gel column and an NH silica gel column in series (hexane:ethyl acetate=75:25 to 50:50) to obtain the title compound (1.8 g) as a white powder. MS (ESI) m / z: 512.9 / 514.8 [M+H]+

[0191] Reference Example 50: Synthesis of tert-butyl 2-(difluoromethoxy)-6-methoxy-4-[4-methoxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]benzoate A mixture of tert-butyl 4-(6-bromo-4-methoxy-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoate (1.8 g) described in Reference Example 49, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (732 mg), potassium carbonate (884 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (261 mg), 1,4-dioxane (16 mL), and water (4.0 mL) was heated and stirred under a nitrogen atmosphere at 100°C for 2 hours. After completion of the reaction, the reaction mixture was diluted with chloroform and then dried by adding sodium sulfate. After removing the insoluble matter by filtration, the filtrate was concentrated under reduced pressure and purified by NH silica gel column chromatography (hexane:ethyl acetate=90:10 to 30:70) to obtain the title compound (2.1 g) as a pale yellow oil. MS (ESI) m / z: 515.3 [M+H]

[0192] Reference Example 51: Synthesis of 2-(difluoromethoxy)-6-methoxy-4-[4-methoxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]benzoic acid TFA (7.1 mL) was added to a dichloromethane (7.1 mL) solution of tert-butyl 2-(difluoromethoxy)-6-methoxy-4-[4-methoxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]benzoate (2.1 g) described in Reference Example 50 under ice-cooling, and the mixture was stirred overnight at room temperature. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and then azeotroped with toluene. The resulting crude product was suspended and washed with diethyl ether to obtain the title compound (1.1 g) as a pale yellow powder. MS (ESI) m / z: 459.2 [M+H]+

[0193] Reference Example 52: Synthesis of [3-(difluoromethoxy)-5-methoxy-4-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]boronic acid To a suspension of tert-butyl 2-(difluoromethoxy)-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (200 mg) and sodium periodate (802 mg) described in Reference Example 43 in acetone (3.0 mL) was added 1M aqueous ammonium acetate solution (1.5 mL), and the mixture was stirred at room temperature for 5 hours. After 1N hydrochloric acid (4 mL) was added to the reaction mixture and stirred for 10 minutes, water and ethyl acetate were added for extraction. The organic layer was washed twice with water and once with saturated brine, then separated using a Phase-Separator®, and concentrated under reduced pressure. The concentrated residue was suspended and washed with diisopropyl ether to obtain the title compound (72 mg) as a white powder. MS (ESI) m / z: 263.0 [M+H-tBu]+

[0194] Reference Example 53: Synthesis of [4-(6-bromo-4-hydroxy-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone A mixture of 6-bromo-3-iodo-2-methylindazol-4-ol (2.0 g) described in Reference Example 33, [2-(difluoromethoxy)-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (2.9 g) described in Reference Example 48, potassium carbonate (1.6 g), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (463 mg), 1,4-dioxane (50 mL), and water (5.0 mL) was heated and stirred at 100°C for 2 hours and 30 minutes under a nitrogen atmosphere. After completion of the reaction, 1N hydrochloric acid was added to the reaction mixture, and the mixture was extracted three times with a mixed solvent of chloroform and methanol. The organic layer was separated using a Phase-Separator (registered trademark) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 95:5) to obtain the title compound (1.8 g) as a brown powder. MS (ESI) m / z: 565.8 / 567.8 [M+H]+

[0195] Reference Example 54: Synthesis of [2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone A mixture of [4-(6-bromo-4-hydroxy-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (1.8 g) described in Reference Example 53, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (976 mg), potassium carbonate (864 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (255 mg), 1,4-dioxane (50 mL), and water (5.0 mL) was heated and stirred under a nitrogen atmosphere at 100°C for 2.5 hours. After completion of the reaction, the reaction mixture was neutralized with 1N hydrochloric acid and then extracted three times with chloroform containing methanol. The combined organic layers were passed through a Phase-Separator (registered trademark), concentrated under reduced pressure, and purified by silica gel column chromatography (chloroform:methanol=100:0 to 90:10) to obtain the title compound (1.3 g) as a brown powder. MS (ESI) m / z: 568.1 [M+H]+

[0196] Reference Example 55: Synthesis of [4-[6-bromo-4-(difluoromethoxy)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone 6-bromo-4- (difluoromethoxy) -3-iodo-2-methylindazole (110 mg) described in Reference Example 39, [2- (difluoromethoxy) -6-methoxy-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl] - [3-hydroxy-3- (trifluoromethyl) azetidin-1-yl] methanone (153 mg) described in Reference Example 48, water (0.34 mL), potassium carbonate (75 mg), [1,1'-bis (diphenylphosphino) ferrocene] palladium (II) dichloride dichloromethane adduct (22 mg), 1,4-dioxane (1.4 mL) mixture was heated and stirred for 2 hours at 100 ° C. under a nitrogen atmosphere. After completion of the reaction, the reaction solution was purified by silica gel column chromatography (hexane: ethyl acetate = 20:80 to 0:100) to obtain the title compound (111 mg) as a pale orange viscous substance. MS (ESI) m / z: 615.9 / 617.8 [M+H]+

[0197] Reference Example 56: Synthesis of 6-bromo-3-[3-(difluoromethoxy)-4-[3-hydroxy-3-(trifluoromethyl)azetidine-1-carbonyl]-5-methoxyphenyl]-2-methylindazole-4-carbonitrile 6-Bromo-3-iodo-2-methylindazole-4-carbonitrile (400 mg) described in Reference Example 19, [2-(difluoromethoxy)-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (671 mg) described in Reference Example 48, water (1.4 mL), potassium carbonate (305 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloride dichloromethane adduct (90 mg), 1,4-dioxane (5.5 mL) mixture was heated and stirred for 2 hours at 100 ° C. under a nitrogen atmosphere. After completion of the reaction, the reaction solution was purified by silica gel column chromatography (hexane: ethyl acetate = 20:80 to 0:100) to obtain the title compound (502 mg) as an orange viscous substance. MS (ESI) m / z: 575.6 / 577.7 [M+H]

[0198] Reference Example 57: Synthesis of [2-(difluoromethoxy)-6-methoxy-4-[2-methyl-6-(1-methylpyrazol-4-yl)-4-[3-(oxan-2-yloxy)propoxy]indazol-3-yl]phenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone To a mixture of [2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (77 mg), potassium carbonate (56 mg), and N,N-dimethylformamide (3.0 mL) described in Reference Example 54, 2-(3-bromopropoxy)tetrahydropyran (45 mg) was added and the mixture was heated and stirred at 80°C under a nitrogen atmosphere for 3 hours. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The separated organic layer was washed with saturated brine and dried over sodium sulfate, and then insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure and purified by NH silica gel column chromatography (chloroform:methanol = 100:0 to 97:3) to obtain the title compound (64 mg) as an orange viscous liquid. MS (ESI) m / z: 710.4 [M+H]+

[0199] Reference Example 58: Synthesis of tert-butyl 4-(6-bromo-4-hydroxy-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoate A mixture of 6-bromo-3-iodo-2-methylindazol-4-ol (3.0 g) described in Reference Example 33, [3-(difluoromethoxy)-5-methoxy-4-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]boronic acid (3.2 g) described in Reference Example 52, [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (694 mg), potassium carbonate (2.4 g), 1,4-dioxane (30 mL), and water (3.0 mL) was heated and stirred at 100°C for 1 hour and 30 minutes under a nitrogen atmosphere. After completion of the reaction, a saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with a mixed solvent of chloroform and methanol. Sodium sulfate was added to the organic layer and the mixture was stirred, after which insoluble matter was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 95:5) to obtain the title compound (4.2 g) as a brown powder. MS (ESI) m / z: 499.1 / 501.1 [M+H]

[0200] Reference Example 59: Synthesis of tert-butyl 2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzoate A mixture of tert-butyl 4-(6-bromo-4-hydroxy-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoate (4.2 g) described in Reference Example 58, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (2.7 g), potassium carbonate (2.4 g), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (693 mg), 1,4-dioxane (30 mL), and water (3.0 mL) was heated and stirred at 100°C for 3 hours under a nitrogen atmosphere. After completion of the reaction, the reaction mixture was diluted with saturated aqueous ammonium chloride and extracted with chloroform to which methanol had been added. Sodium sulfate was added to the organic layer, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 95:5) to obtain the title compound (1.7 g) as a brown powder. MS (ESI) m / z: 501.3 [M+H]

[0201] Reference Example 60: Synthesis of tert-butyl 2-(difluoromethoxy)-4-[4-ethoxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzoate A mixture of tert-butyl 2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzoate (165 mg), potassium carbonate (137 mg), N,N-dimethylformamide (3.3 mL), and iodoethane (77 mg) described in Reference Example 59 was heated and stirred at 80°C for 2 hours. After completion of the reaction, water, saturated brine, and chloroform were added to the reaction mixture and stirred for several minutes. The organic layer was then separated using a Phase-Separator (registered trademark) and concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to give the title compound (82 mg) as a brown powder. MS (ESI) m / z: 529.4 [M+H]+

[0202] Reference Example 61: Synthesis of [2-(difluoromethoxy)-6-methoxy-4-[2-methyl-6-(1-methylpyrazol-4-yl)-4-[4-(oxan-2-yloxy)butoxy]indazol-3-yl]phenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone To a mixture of [2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (68 mg), potassium carbonate (50 mg), and N,N-dimethylformamide (3.0 mL) described in Reference Example 54, 2-(4-bromobutoxy)tetrahydropyran (43 mg) was added and heated with stirring at 80°C under a nitrogen atmosphere for 2 hours. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, passed through a Phase-Separator®, and then concentrated under reduced pressure. The resulting residue was purified by NH silica gel column chromatography (chloroform:methanol = 100:0 to 97:3) to give the title compound (26 mg) as an orange powder. MS (ESI) m / z: 724.2 [M+H]+

[0203] Reference Example 62: Synthesis of 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoic acid To a mixture of tert-butyl 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoate (4.5 g) described in Reference Example 44 and dichloromethane (22 mL), TFA (22 mL) was added at room temperature and stirred for 2 hours. The reaction solution was concentrated under reduced pressure, and then subjected to azeotropic distillation twice with toluene to obtain the title compound (4.9 g) as a white powder. MS (ESI) m / z: 451.7 / 453.7 [M+H]+

[0204] Reference Example 63: Synthesis of 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-N-[(1-fluorocyclopropyl)methyl]-6-methoxybenzamide To a mixture of 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoic acid (2.0 g), (1-fluorocyclopropyl)methanamine hydrochloride (561 mg), and N,N-dimethylformamide (20 mL) described in Reference Example 62, N,N-diisopropylethylamine (2.8 mL) and HATU (1.7 g) were added at room temperature, and the mixture was stirred at the same temperature overnight. After completion of the reaction, water was added to the reaction solution, and the mixture was extracted twice with ethyl acetate. The organic layer was separated using a Phase-Separator (registered trademark) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 70:30 to 0:100) to obtain the title compound (1.7 g) as a white powder. MS (ESI) m / z: 522.8 / 524.8 [M+H]+

[0205] Reference Example 64: Synthesis of 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1-fluorocyclopropyl)methyl]-6-methoxybenzamide A mixture of 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-N-[(1-fluorocyclopropyl)methyl]-6-methoxybenzamide (1.7 g) described in Reference Example 63, bis(pinacolato)diboron (843 mg), potassium acetate (889 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (247 mg), and 1,4-dioxane (12 mL) was heated and stirred at 100°C for 1 hour under a nitrogen atmosphere. After completion of the reaction, ethyl acetate was added to the reaction mixture, and the mixture was filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform:ethyl acetate = 100:0 to 50:50) to obtain the title compound (1.7 g) as a brown powder. MS (ESI) m / z: 571.0 [M+H]+

[0206] Reference Example 65: Synthesis of tert-butyl 4-[6-bromo-4-(difluoromethoxy)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoate A mixture of 6-bromo-4-(difluoromethoxy)-3-iodo-2-methylindazole (1.6 g) described in Reference Example 39, [3-(difluoromethoxy)-5-methoxy-4-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]boronic acid (1.5 g) described in Reference Example 52, potassium carbonate (1.1 g), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (324 mg), 1,4-dioxane (20 mL), and water (2.0 mL) was heated and stirred at 100°C for 4 hours under a nitrogen atmosphere. After completion of the reaction, water was added to the reaction mixture, which was then extracted with chloroform. Sodium sulfate was added to the organic layer, and after stirring, insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure, and the residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=95:5 to 70:30) and silica gel column chromatography (hexane:ethyl acetate=95:5 to 70:30) to obtain the title compound (1.3 g) as a colorless powder. MS (ESI) m / z: 549.1 / 551.0 [M+H]+

[0207] Reference Example 66: Synthesis of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-6-methoxybenzoate A mixture of tert-butyl 4-[6-bromo-4-(difluoromethoxy)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoate (1.3 g) described in Reference Example 65, potassium acetate (708 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (196 mg), bis(pinacolato)diboron (671 mg), and 1,4-dioxane (20 mL) was heated and stirred at 100°C for 1 hour under a nitrogen atmosphere. After completion of the reaction, ethyl acetate was added to the reaction mixture, and the mixture was filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane:ethyl acetate = 80:20 to 50:50) to obtain the title compound (1.6 g) as a brown viscous material. MS (ESI) m / z: 597.3 [M+H]+

[0208] Reference Example 67: Synthesis of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(1-methyltriazol-4-yl)indazol-3-yl]-6-methoxybenzoate A mixture of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-6-methoxybenzoate (250 mg) described in Reference Example 66, 4-bromo-1-methyl-triazole (136 mg), potassium carbonate (174 mg), tetrakis(triphenylphosphine)palladium(0) (48 mg), 1,4-dioxane (2.0 mL), and water (0.50 mL) was stirred under microwave irradiation at 110° C. for 30 minutes. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was separated using a Phase-separator (registered trademark), concentrated under reduced pressure, and then purified by NH silica gel column chromatography (hexane:ethyl acetate=50:50 to 0:100) to obtain the title compound (153 mg) as a colorless viscous substance. MS (ESI) m / z: 552.3 [M+H]+

[0209] Reference Example 68: Synthesis of 2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(1-methyltriazol-4-yl)indazol-3-yl]-6-methoxybenzoic acid TFA (1.0 mL) was added to a dichloromethane (2.0 mL) solution of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(1-methyltriazol-4-yl)indazol-3-yl]-6-methoxybenzoate (150 mg) described in Reference Example 67, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and then subjected to azeotropic distillation twice with toluene. The resulting crude product was suspended and washed with diethyl ether to obtain the title compound (118 mg) as a colorless powder. MS (ESI) m / z: 496.1 [M+H]+

[0210] Reference Example 69: Synthesis of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(2-methyltriazol-4-yl)indazol-3-yl]-6-methoxybenzoate A mixture of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-6-methoxybenzoate (250 mg) described in Reference Example 66, 4-bromo-2-methyl-2H-1,2,3-triazole (136 mg), potassium carbonate (174 mg), tetrakis(triphenylphosphine)palladium(0) (48 mg), 1,4-dioxane (2.0 mL), and water (0.50 mL) was stirred under microwave irradiation at 110° C. for 30 minutes. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was separated using a Phase-separator (registered trademark), concentrated under reduced pressure, and then purified by NH silica gel column chromatography (hexane:ethyl acetate=80:20 to 50:50) to obtain the title compound (197 mg) as a colorless viscous substance. MS (ESI) m / z: 552.3 [M+H]+

[0211] Reference Example 70: Synthesis of 2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(2-methyltriazol-4-yl)indazol-3-yl]-6-methoxybenzoic acid TFA (1.0 mL) was added to a dichloromethane (2.0 mL) solution of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(2-methyltriazol-4-yl)indazol-3-yl]-6-methoxybenzoate (193 mg) described in Reference Example 69, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and then subjected to azeotropic distillation twice with toluene. The resulting crude product was suspended and washed with diethyl ether to obtain the title compound (134 mg) as a colorless powder. MS (ESI) m / z: 496.1 [M+H]+

[0212] Reference Example 71: Synthesis of 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid To a mixture of tert-butyl 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoate (1.5 g) described in Reference Example 45 and dichloromethane (10 mL), TFA (3.0 mL) was added at room temperature and stirred for 13 hours. The reaction solution was concentrated under reduced pressure, and the residue was suspended and washed with diethyl ether to obtain the title compound (1.1 g) as a colorless powder. MS (ESI) m / z: 476.7 / 478.7 [M+H]+

[0213] Reference Example 72: Synthesis of [4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone To a mixture of 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid (351 mg), 3-(trifluoromethyl)azetidin-3-ol hydrochloride (196 mg), HATU (419 mg), and N,N-dimethylformamide (5.0 mL) described in Reference Example 71, N,N-diisopropylethylamine (285 mg) was added at room temperature and stirred at 50°C for 2 hours and 30 minutes. After completion of the reaction, water was added to the reaction solution, which was extracted with ethyl acetate and washed twice with water. The organic layer was separated using a Phase-Separator (registered trademark) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 50:50 to 0:100) to obtain the title compound (385 mg) as an orange powder. MS (ESI) m / z: 599.8 / 601.8 [M+H]+

[0214] Reference Example 73: Synthesis of [4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxyphenyl]-[3-(difluoromethyl)-3-hydroxyazetidin-1-yl]methanone To a mixture of 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid (300 mg), HATU (359 mg), 3-(difluoromethyl)azetidin-3-ol hydrochloride (167 mg), and N,N-dimethylformamide (3.0 mL) described in Reference Example 71, N,N-diisopropylethylamine (0.33 mL) was added at room temperature and stirred at 50°C for 12 hours. After completion of the reaction, water was added to the reaction solution, which was then extracted with ethyl acetate and washed twice with water and once with saturated brine. The organic layer was separated using a Phase-Separator (registered trademark) and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (chloroform:methanol = 100:0 to 95:5 to 90:10) to obtain the title compound (375 mg) as a colorless powder. MS (ESI) m / z: 581.8 / 583.7 [M+H]+

[0215] Reference Example 74: Synthesis of 5-(hydroxymethyl)pyridine-3-carbonitrile trifluoroacetate 5-Cyanopyridine-3-carboxylic acid (300 mg) and N,N-dimethylformamide (16 μL) were dissolved in tetrahydrofuran (16 mL), and oxalyl dichloride (0.21 mL) was added under ice-cooling, followed by stirring for 2 hours. Further oxalyl dichloride (0.21 mL) was added under ice-cooling, and the mixture was stirred for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue obtained by azeotropic distillation with toluene was dissolved in a mixed solvent of tetrahydrofuran (7.8 mL) and 1,2-dimethoxyethane (7.8 mL). Sodium borohydride (268 mg) was added under ice-cooling, and the mixture was stirred for 2 hours. After completion of the reaction, methanol (2.3 mL) was added under ice-cooling, and the mixture was stirred for 30 minutes, followed by stirring at room temperature for 15 minutes. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over magnesium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (0.05% TFA aqueous solution-0.05% TFA acetonitrile solution) to give the title compound (60 mg) as a yellow viscous substance. MS (ESI) m / z: 133.0 [M−H]

[0216] Reference Example 75: Synthesis of N-[(2,2-difluorocyclopropyl)methyl]-1-(4-methoxyphenyl)methanamine (2,2-Difluorocyclopropyl)methanamine hydrochloride (1.1 g), 4-methoxybenzaldehyde (800 mg), N,N-diisopropylethylamine (1.3 mL), and acetic acid (0.34 mL) were dissolved in methanol (29 mL), and sodium triacetoxyborohydride (1.9 g) was added and stirred at room temperature overnight. After the reaction was completed, saturated aqueous sodium bicarbonate solution was added, and the mixture was extracted with chloroform. The organic layer was separated using a Phase-Separator® and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform:methanol = 97:3 to 88:12) to give the title compound (1.1 g) as a pale yellow oil. MS (ESI) m / z: 227.9 [M+H]+

[0217] Reference Example 76: Synthesis of hydrochloride of the isomer of 1-(4-methoxyphenyl)-N-[[rel-(1R)-2,2-difluorocyclopropyl]methyl]methanamine which elutes first under the chiral HPLC conditions described in the experimental section N-[(2,2-difluorocyclopropyl)methyl]-1-(4-methoxyphenyl)methanamine (700 mg) described in Reference Example 75 was separated using a chiral column [CHIRALPAK® IG-3 (30*250), hexane:ethanol:methanol:diethylamine=80:7.5:7.5:0.1]. The first fraction was collected and concentrated, and the residue was dissolved in diethyl ether (5.0 mL), and 4 M hydrochloric acid-dioxane (0.77 mL) was added dropwise at room temperature. The precipitated white solid was collected by filtration to obtain the title compound (370 mg) as a white powder. MS (ESI) m / z: 228.0 [M+H]+

[0218] Reference Example 77: Synthesis of methyl 2-(difluoromethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate A suspension of methyl 2-(difluoromethoxy)-4-iodobenzoate (1.4 g), bis(pinacolato)diboron (1.1 g), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (333 mg), and potassium acetate (1.2 g) in N,N-dimethylformamide (14 mL) was stirred at 100°C for 4 hours under a nitrogen atmosphere. Ethyl acetate was added to the reaction mixture, and then insoluble matter was removed by filtration. Water was added to the filtrate, followed by extraction with ethyl acetate. Sodium sulfate was added to the organic layer, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 70:30 to 0:100) to give the title compound (1.3 g) as a brown viscous material. MS (ESI) m / z: 329.1 [M+H]+

[0219] Reference Example 78: Synthesis of methyl 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)benzoate A mixture of methyl 2-(difluoromethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (377 mg) described in Reference Example 77, 6-bromo-3-iodo-2-methylindazole-4-carbonitrile (438 mg) described in Reference Example 19, tripotassium phosphate (494 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (76 mg), water (0.62 mL), and 1,4-dioxane (6.2 mL) was heated and stirred at 100°C for 2 hours under a nitrogen atmosphere. After completion of the reaction, water was added to the reaction mixture, which was then extracted with chloroform. Sodium sulfate was added to the organic layer, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using an NH silica gel column and a Si silica gel column in series (hexane:ethyl acetate=70:30 to 40:60) to obtain the title compound (254 mg) as a pale yellow viscous substance. MS (ESI) m / z: 435.8 / 437.7 [M+H]+

[0220] Reference Example 79: Synthesis of methyl 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)benzoate A mixture of methyl 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)benzoate (250 mg) described in Reference Example 78, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (122 mg), tripotassium phosphate (226 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (44 mg), 1,4-dioxane (3.6 mL), and water (0.36 mL) was heated and stirred at 100°C under a nitrogen atmosphere for 2.5 hours. After completion of the reaction, water was added to the reaction mixture, which was then extracted with chloroform. Sodium sulfate was added to the separated organic layer, and the mixture was filtered. The filtrate was concentrated under reduced pressure and then purified by NH silica gel column chromatography (hexane:ethyl acetate=50:50 to 30:70) to obtain the title compound (159 mg) as a pale yellow powder. MS (ESI) m / z: 438.2 [M+H]

[0221] Reference Example 80: Synthesis of 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)benzoic acid To a mixed solution of methyl 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)benzoate (155 mg) described in Reference Example 79, methanol (2.0 mL), and tetrahydrofuran (1.0 mL), 4N aqueous sodium hydroxide solution (0.30 mL) was added, and the mixture was stirred at room temperature for 10 minutes. After completion of the reaction, the reaction solution was concentrated under reduced pressure, and 1N hydrochloric acid was added until a precipitate appeared. The precipitate was collected by filtration, washed with water, and then dried to obtain the title compound (111 mg) as a white powder. MS (ESI) m / z: 423.9 [M+H]+

[0222] Reference Example 81: Synthesis of N,N-dimethyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]propanamide 3-(4-Bromopyrazol-1-yl)-N,N-dimethylpropanamide (800 mg), bis(pinacolato)diboron (1.2 g), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (266 mg), and potassium acetate (1.3 g) were suspended in 1,4-dioxane (10 mL) and stirred at 100°C under a nitrogen atmosphere for 2 hours. After completion of the reaction, water was added and the mixture was extracted with chloroform. The organic layer was separated using a Phase-Separator® and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate:methanol = 100:0 to 90:10) to give the title compound (342 mg) as a brown oil. MS (ESI) m / z: 293.8 [M+H]+

[0223] Reference Example 82: Synthesis of 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-6-methoxybenzamide To a solution of 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoic acid (150 mg) described in Reference Example 62 in tetrahydrofuran (1.7 mL), N,N-dimethylformamide (1 drop) and oxalyl dichloride (84 μL) were added, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure and subjected to azeotropic distillation with toluene. To the residue, dichloromethane (3.3 mL), (R)-2,2-difluorocyclopropan-1-amine hydrochloride (56 mg), and N,N-diisopropylethylamine (0.29 mL) were sequentially added at room temperature, and the mixture was stirred for 1 hour. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, and the residue was purified by NH silica gel column chromatography (hexane:ethyl acetate = 80:20 to 30:70) to obtain the title compound (123 mg) as a pale yellow powder. MS (ESI) m / z: 527.2 / 529.2 [M+H]+

[0224] Reference Example 83: Synthesis of 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-6-methoxybenzamide To a solution of 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid (450 mg) described in Reference Example 71 in tetrahydrofuran (4.7 mL), oxalyl dichloride (0.24 mL) and N,N-dimethylformamide (1 drop) were added, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure, and azeotropic distillation was performed three times with toluene. To the residue, dichloromethane (9.4 mL), (R)-2,2-difluorocyclopropan-1-amine hydrochloride (159 mg), and N,N-diisopropylethylamine (0.82 mL) were sequentially added at room temperature, and the mixture was stirred overnight. After completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, which was then extracted with chloroform. The organic layer was separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=75:25 to 40:60) to obtain the title compound (508 mg) as a colorless powder. MS (ESI) m / z: 551.9 / 553.9 [M+H]

[0225] Reference Example 84: Synthesis of 3-[(4-bromopyrazol-1-yl)methyl]thietane 1,1-dioxide (1,1-Dioxothietan-3-yl)methanol (145 mg), 4-bromo-1H-pyrazole (172 mg), and triphenylphosphine (419 mg) were dissolved in tetrahydrofuran (5.3 mL), and diisopropyl azodicarboxylate (40% toluene solution) (0.84 mL) was added dropwise under ice cooling. The mixture was stirred for 5 minutes and then at room temperature for an additional 4 hours. After completion of the reaction, the mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform:methanol = 100:0 to 90:10 to 80:20) to give the title compound (485 mg) as a white powder. MS (ESI) m / z: 264.7 / 266.6 [M+H]+

[0226] Reference Example 85: Synthesis of 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxy-N-[[rel-(1R)-2,2-difluorocyclopropyl]methyl]benzamide 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoic acid (450 mg) described in Reference Example 62 and the hydrochloride salt (289 mg) of the isomer of 1-(4-methoxyphenyl)-N-[[rel-(1R)-2,2-difluorocyclopropyl]methyl]methanamine described in Reference Example 76 that elutes earlier under the chiral HPLC conditions described in the Experimental section were dissolved in N,N-dimethylformamide (5.0 mL), and N,N-diisopropylethylamine (0.52 mL) and HATU (568 mg) were added, followed by stirring at room temperature for 2 hours. After completion of the reaction, water was added to the reaction solution, and the mixture was stirred at room temperature for 1 hour. The precipitate was collected by filtration and washed with water, and the resulting residue was dissolved in TFA (10 mL) and stirred at 60°C for 2 days. After completion of the reaction, the reaction solution was concentrated under reduced pressure and azeotroped with toluene. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=80:20 to 20:80) to give the title compound (463 mg) as a pale yellow powder. MS (ESI) m / z: 541.1 / 543.1 [M+H]

[0227] Reference Example 86: Synthesis of 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzamide 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoic acid (500 mg), WSC.HCl (318 mg), HOBt (224 mg), ammonium chloride (237 mg), and tetrahydrofuran (11 mL) were mixed as described in Reference Example 62, and triethylamine (0.93 mL) was added. The mixture was stirred overnight at room temperature. After completion of the reaction, saturated aqueous sodium bicarbonate solution and water were added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated brine and dried over magnesium sulfate. Insoluble matter was filtered off, and the filtrate was concentrated under reduced pressure. The residue was suspended and washed in a mixed solvent of ethyl acetate:diethyl ether=1:1 to give the title compound (178 mg) as a colorless powder. MS (ESI) m / z: 451.1 / 453.1 [M+H]+

[0228] Reference Example 87: Synthesis of 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxy-N-[[rel-(1R)-2,2-difluorocyclopropyl]methyl]benzamide 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxy-N-[[rel-(1R)-2,2-difluorocyclopropyl]methyl]benzamide (230 mg) described in Reference Example 85, bis(pinacolato)diboron (119 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (35 mg), and potassium acetate (125 mg) were suspended in 1,4-dioxane (1.7 mL) and stirred at 100°C under a nitrogen atmosphere for 1.5 hours. After completion of the reaction, the reaction mixture was diluted with ethyl acetate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:ethyl acetate = 90:10 to 50:50) to obtain the title compound (229 mg) as a brown powder. MS (ESI) m / z: 589.3 [M+H]+

[0229] Reference Example 88: Synthesis of 4-bromo-1-[2-(3,3-difluoroazetidin-1-yl)ethyl]pyrazole N,N-diisopropylethylamine (0.31 mL) was added to a mixture of 4-bromo-1-(2-bromoethyl)pyrazole (150 mg), 3,3-difluoroazetidine hydrochloride (191 mg), and acetonitrile (3.0 mL) synthesized by the method described in Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 1639-1648, at room temperature, and the mixture was stirred at 60 ° C. overnight. After completion of the reaction, saturated brine was added and the mixture was extracted twice with ethyl acetate. The organic layer was separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 90:10 to 40:60) to obtain the title compound (49 mg) as a colorless powder. MS (ESI) m / z: 266.0 / 268.0 [M+H]+

[0230] Reference Example 89: Synthesis of 2-bromo-6-methoxy-N-[(4-methoxyphenyl)methyl]benzamide HATU (2.7 g), 4-methoxybenzylamine (0.92 mL), and N,N-diisopropylethylamine (2.2 mL) were added to a mixture of 2-bromo-6-methoxybenzoic acid (1.5 g) and N,N-dimethylformamide (13 mL), and the mixture was stirred at room temperature for 30 minutes. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed with 1N hydrochloric acid, a saturated aqueous solution of sodium bicarbonate, and saturated brine. Sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The concentrated residue was purified by silica gel column chromatography (hexane:ethyl acetate = 70:30 to 30:70) to obtain the title compound (1.7 g) as a white powder. MS (ESI) m / z: 349.8 / 351.8 [M+H]+

[0231] Reference Example 90: Synthesis of 2-bromo-6-methoxy-N-[(4-methoxyphenyl)methyl]-N-(2-propenyl)benzamide To a solution of 2-bromo-6-methoxy-N-[(4-methoxyphenyl)methyl]benzamide (1.0 g) described in Reference Example 89 in tetrahydrofuran (5.7 mL), sodium hydride (60%, dispersed in liquid paraffin) (130 mg) was added portionwise under ice cooling and the mixture was stirred for 1.5 hours. Allyl bromide (380 mg) was then added and the mixture was stirred at 60°C for 1 hour. A saturated aqueous solution of ammonium chloride was added to the reaction mixture under ice cooling, followed by extraction twice with ethyl acetate. The organic layer was washed with saturated brine. Sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 75:25 to 55:45) to give the title compound (1.0 g) as a colorless oil. MS (ESI) m / z: 390.1 / 392.0 [M+H]+

[0232] Reference Example 91: Synthesis of 8-methoxy-2-[(4-methoxyphenyl)methyl]-4-methylisoquinolin-1-one A suspension of 2-bromo-6-methoxy-N-[(4-methoxyphenyl)methyl]-N-(2-propenyl)benzamide (700 mg) described in Reference Example 90, palladium(II) acetate (18 mg), tetrabutylammonium chloride (490 mg), sodium formate (120 mg), and triethylamine (406 mg) in N,N-dimethylformamide (6.4 mL) was stirred at 80°C for 3 hours under a nitrogen atmosphere. Water was added to the reaction solution, and the mixture was extracted three times with ethyl acetate. Sodium sulfate was added to the organic layer, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by NH silica gel column chromatography (hexane:ethyl acetate = 50:50 to 20:80) to give the title compound (513 mg) as a colorless oil. MS (ESI) m / z: 310.0 [M+H]+

[0233] Reference Example 92: Synthesis of 8-methoxy-2-[(4-methoxyphenyl)methyl]-4-methyl-3,4-dihydroisoquinolin-1-one To a solution of 8-methoxy-2-[(4-methoxyphenyl)methyl]-4-methylisoquinolin-1-one (2.7 g) described in Reference Example 91 in acetic acid (25 mL) was added 7.5% Pd / C (500 mg), and the mixture was stirred under a hydrogen atmosphere at 50°C for 4.5 hours and at 60°C for 3 hours. The reaction mixture was diluted with chloroform and insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure, and the concentrated residue was again dissolved in acetic acid (25 mL), and 10% Pd / C (500 mg) was added, and the mixture was stirred overnight under a hydrogen atmosphere at 50°C. The reaction mixture was diluted with chloroform and insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure. The concentrated residue was purified by silica gel column chromatography (chloroform:methanol = 100:0 to 95:5) and NH silica gel column chromatography (hexane:ethyl acetate = 50:50 to 20:80) to obtain the title compound (297 mg) as a white viscous substance. MS (ESI) m / z: 312.2 [M+H]+

[0234] Reference Example 93: Synthesis of 8-methoxy-2-[(4-methoxyphenyl)methyl]-4-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinolin-1-one A suspension of 8-methoxy-2-[(4-methoxyphenyl)methyl]-4-methyl-3,4-dihydroisoquinolin-1-one (812 mg), bis(pinacolato)diboron (650 mg), bis(1,5-cyclooctadiene)di-μ-methoxydiiridium(I) (81 mg), and 4,4'-di-tert-butyl-2,2'-bipyridyl (65 mg) in tetrahydrofuran (4.9 mL) was stirred overnight at 70°C under a nitrogen atmosphere. 1N hydrochloric acid was added to the reaction solution, which was then extracted with chloroform. The organic layer was separated using a Phase-Separator® and concentrated under reduced pressure. The concentrated residue was purified by silica gel column chromatography (chloroform:methanol = 100:0 to 93:7) to give the title compound (986 mg) as an orange viscous liquid. MS (ESI) m / z: 438.4 [M+H]+

[0235] Reference Example 94: Synthesis of 3-[8-methoxy-2-[(4-methoxyphenyl)methyl]-4-methyl-1-oxo-3,4-dihydroisoquinolin-6-yl]-2-methyl-6-(1-methylpyrazol-4-yl)indazole-4-carbonitrile A mixture of 8-methoxy-2-[(4-methoxyphenyl)methyl]-4-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinolin-1-one (215 mg) described in Reference Example 93, 6-bromo-3-iodo-2-methylindazole-4-carbonitrile (167 mg) described in Reference Example 19, potassium carbonate (98 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (29 mg), 1,4-dioxane (2.4 mL), and water (0.59 mL) was heated and stirred under a nitrogen atmosphere at 100°C for 3 hours. After completion of the reaction, the reaction mixture was diluted with chloroform, dried over sodium sulfate, and insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure and then purified by NH silica gel column chromatography (hexane:ethyl acetate = 50:50 to 20:80). The resulting residue was mixed with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (47 mg), potassium carbonate (57 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (17 mg), 1,4-dioxane (1.4 mL), and water (0.34 mL) and heated with stirring at 100°C for 1.5 hours under a nitrogen atmosphere. After completion of the reaction, the reaction mixture was diluted with chloroform and then dried over sodium sulfate. Insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure and purified by NH silica gel column chromatography (ethyl acetate:methanol = 100:0 to 90:10) to give the title compound (112 mg) as a gray powder. MS (ESI) m / z: 547.1 [M+H]+

[0236] Reference Example 95: Synthesis of 6-bromo-3-[8-methoxy-2-[(4-methoxyphenyl)methyl]-4-methyl-1-oxo-3,4-dihydroisoquinolin-6-yl]-2-methylindazole-4-carbonitrile A mixture of 8-methoxy-2-[(4-methoxyphenyl)methyl]-4-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinolin-1-one (980 mg) described in Reference Example 93, 6-bromo-3-iodo-2-methylindazole-4-carbonitrile (808 mg) described in Reference Example 19, potassium carbonate (588 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (174 mg), 1,4-dioxane (14 mL), and water (3.5 mL) was stirred at 100°C for 2 hours under a nitrogen atmosphere. After completion of the reaction, chloroform was added to the reaction mixture, and the organic layer was separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=50:50 to 20:80) to obtain the title compound (494 mg) as an orange powder. MS (ESI) m / z: 545.3 / 547.3 [M+H]

[0237] Reference Example 96: Synthesis of 6-bromo-3-(8-methoxy-4-methyl-1-oxo-3,4-dihydro-2H-isoquinolin-6-yl)-2-methylindazole-4-carbonitrile 6-Bromo-3-[8-methoxy-2-[(4-methoxyphenyl)methyl]-4-methyl-1-oxo-3,4-dihydroisoquinolin-6-yl]-2-methylindazole-4-carbonitrile (490 mg) described in Reference Example 95 was dissolved in a mixed solvent of TFA (1.9 mL) and anisole (0.44 mL) and stirred at 100°C for 8 hours under microwave irradiation. After completion of the reaction, the reaction solution was concentrated under reduced pressure, saturated aqueous sodium bicarbonate solution was added, and the mixture was extracted with chloroform. The organic layer was concentrated, and the residue was purified by NH silica gel column chromatography (ethyl acetate:methanol = 100:0 to 90:10) to obtain the title compound (213 mg) as a pale yellow powder. MS (ESI) m / z: 424.9 / 426.9 [M+H]+

[0238] Reference Example 97: Synthesis of the isomer of 6-bromo-2-methyl-3-[rel-(4R)-8-methoxy-4-methyl-1-oxo-3,4-dihydro-2H-isoquinolin-6-yl]indazole-4-carbonitrile which elutes first under the chiral HPLC conditions described in the experimental section 6-Bromo-3-(8-methoxy-4-methyl-1-oxo-3,4-dihydro-2H-isoquinolin-6-yl)-2-methylindazole-4-carbonitrile (210 mg) described in Reference Example 96 was separated using a chiral column [CHIRALPAK® IC (30*250), ethanol:acetonitrile = 80:20]. The front fraction was collected and concentrated to obtain the title compound (91 mg) as a white powder. MS (ESI) m / z: 425.2 / 427.1 [M+H]+

[0239] Reference Example 98: Synthesis of [2-(difluoromethoxy)-4-[4-(difluoromethyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone A mixture of [4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (129 mg) described in Reference Example 72, [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (18 mg), bis(pinacolato)diboron (60 mg), potassium acetate (63 mg), and 1,4-dioxane (3.0 mL) was heated and stirred at 100°C for 3 hours under a nitrogen atmosphere. After completion of the reaction, ethyl acetate was added to the reaction mixture, and the mixture was filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane:ethyl acetate = 50:50 to 0:100) to obtain the title compound (105 mg) as a pale brown powder. MS (ESI) m / z: 648.2 [M+H]+

[0240] Reference Example 99: Synthesis of 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-6-methoxybenzamide 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-6-methoxybenzamide (75 mg) described in Reference Example 82, bis(pinacolato)diboron (54 mg), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloride (9.3 mg), and potassium acetate (42 mg) were suspended in 1,4-dioxane (2.0 mL) and stirred at 50°C under a nitrogen atmosphere for 16 hours. After completion of the reaction, the reaction mixture was diluted with ethyl acetate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:ethyl acetate = 100:0 to 40:60) to obtain the title compound (78 mg) as a brown oil. MS (ESI) m / z: 575.1 [M+H]+

[0241] Reference Example 100: Synthesis of 1-[(4-iodopyrazol-1-yl)methyl]cyclobutan-1-ol 1-(Hydroxymethyl)cyclobutan-1-ol (150 mg) was dissolved in ethyl acetate (4.9 mL), and methanesulfonic anhydride (307 mg) and triethylamine (0.41 mL) were added under ice-cooling, followed by stirring for 30 minutes. After completion of the reaction, saturated aqueous sodium bicarbonate solution was added under ice-cooling, and the mixture was extracted with chloroform. The organic layer was separated using a Phase-Separator® and concentrated under reduced pressure. The resulting residue was dissolved in N,N-dimethylformamide (6.2 mL), and 4-iodopyrazole (240 mg) and cesium carbonate (806 mg) were added at room temperature, followed by stirring at 90°C for 6 hours. Water was added to the reaction solution under ice-cooling, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting mixture was purified by silica gel column chromatography (hexane:ethyl acetate=72:25 to 50:50) to give the title compound (163 mg) as a colorless powder. MS (ESI) m / z: 279.1 [M+H]

[0242] Reference Example 101: Synthesis of 4-(4-iodopyrazol-1-yl)-2-methylbutan-2-ol 3-Hydroxy-3-methylbutyl methanesulfonate (416 mg), 4-iodopyrazole (295 mg), and cesium carbonate (991 mg) were suspended in N,N-dimethylformamide (7.6 mL) and stirred at 90°C for 3 hours. After completion of the reaction, water (30 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL). The organic layer was washed successively with water and saturated brine, dried over sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 75:25 to 50:50) to give the title compound (343 mg) as a colorless oil. MS (ESI) m / z: 281.1 [M+H]+

[0243] Reference Example 102: Synthesis of N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-4-[4-(difluoromethyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-6-methoxybenzamide 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-6-methoxybenzamide (404 mg) described in Reference Example 83, bis(pinacolato)diboron (212 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (57 mg), potassium acetate (273 mg) were suspended in 1,4-dioxane (3.5 mL) and stirred overnight at 45 ° C. under a nitrogen atmosphere. To the reaction mixture, bis(pinacolato)diboron (53 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (57 mg), potassium acetate (136 mg) were added and the mixture was stirred at 40 ° C. under a nitrogen atmosphere for 4 hours. To the reaction mixture, [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (57 mg) was added and stirred at 100°C under a nitrogen atmosphere for 1 hour. After completion of the reaction, magnesium sulfate was added to the reaction mixture, which was then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:chloroform = 100:0 to 45:55) to obtain the title compound (561 mg) as a brown viscous material. MS (ESI) m / z: 600.2 [M+H]+

[0244] Reference Example 103: Synthesis of cis-3-[(4-iodopyrazol-1-yl)methyl]cyclobutan-1-ol Under ice cooling, a 1M borane-tetrahydrofuran complex solution (10 mL) in tetrahydrofuran was added dropwise over 15 minutes to a solution of cis-3-hydroxycyclobutanecarboxylic acid (517 mg) in tetrahydrofuran (10 mL), followed by stirring at room temperature. After 13 hours, the insoluble matter in the reaction mixture was crushed with a spatula and stirred for an additional hour. After completion of the reaction, methanol (5.0 mL) was added to the reaction mixture under ice cooling, and the mixture was stirred for 10 minutes. The mixture was then concentrated under reduced pressure and purified by silica gel column chromatography (chloroform:methanol = 100:0 to 90:10). The resulting intermediate product was dissolved in dichloromethane (10 mL), and p-toluenesulfonyl chloride (810 mg) and triethylamine (0.81 mL) were added under ice cooling, followed by stirring at room temperature for 18 hours. After completion of the reaction, water was added to the reaction mixture, followed by extraction with chloroform. The organic layer was separated using a Phase-separator®, concentrated under reduced pressure, and then purified by silica gel column chromatography (hexane:ethyl acetate = 80:20 to 25:75). 4-iodo-1H-pyrazole (150 mg), cesium carbonate (504 mg), and N,N-dimethylformamide (3.9 mL) were added to 218 mg of the resulting intermediate product (377 mg), and the mixture was stirred at 90°C for 3 hours. After completion of the reaction, water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over magnesium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 70:30 to 25:75) to give the title compound (156 mg) as a colorless oil. MS (ESI) m / z: 279.0 [M+H]+

[0245] Reference Example 104: Synthesis of (2R)-4-(4-iodopyrazol-1-yl)butan-2-ol The 4-methylbenzenesulfonate [(3R)-3-hydroxybutyl] (302 mg) described in Reference Example 2, 4-iodo-1H-pyrazole (200 mg), and cesium carbonate (672 mg) were suspended in N,N-dimethylformamide (5.2 mL) and stirred at 90°C for 2 hours. After completion of the reaction, water was added to the reaction solution, and the mixture was extracted with chloroform. The organic layer was separated using a Phase-Separator (registered trademark) and concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to give the title compound (237 mg) as a colorless oil. MS (ESI) m / z: 267.0 [M+H]+

[0246] Reference Example 105: Synthesis of 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzamide 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzamide (275 mg) described in Reference Example 86, bis(pinacolato)diboron (166 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (45 mg), and potassium acetate (160 mg) were suspended in 1,4-dioxane (2.7 mL) and stirred at 100°C for 1 hour. After completion of the reaction, ethyl acetate was added to the reaction mixture, which was then filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol = 100:0 to 90:10) to obtain the title compound (265 mg) as a brown powder. MS (ESI) m / z: 499.3 [M+H]+

[0247] Reference Example 106: Synthesis of 2-methylidenethietane 1,1-dioxide (1,1-Dioxothietan-2-yl)methanol (129 mg), 4-iodo-1H-pyrazole (202 mg), and triphenylphosphine (373 mg) were dissolved in tetrahydrofuran (4.7 mL), and diisopropyl azodicarboxylate (40% toluene solution) (0.75 mL) was added at room temperature and stirred for 4 hours. After completion of the reaction, the mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate=40:60 to 30:70) to give the title compound (69 mg) as a colorless oil. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 5.93-5.89 (m, 1H), 5.57-5.53 (m, 1H), 4.01-3.95 (m, 2H), 2.88-2.81 (m, 2H)

[0248] Reference Example 107: Synthesis of 2-[(4-iodopyrazol-1-yl)methyl]thietane 1,1-dioxide 2-Methylidenethietane 1,1-dioxide (62 mg) and 4-iodo-1H-pyrazole (153 mg) described in Reference Example 106 were dissolved in N,N-dimethylformamide (5.2 mL), and sodium hydride (60%, dispersed in liquid paraffin) (25 mg) was added under ice-cooling, followed by stirring at room temperature for 2 hours. After completion of the reaction, water (30 mL) and saturated aqueous ammonium chloride solution (5 mL) were added under ice-cooling, and the mixture was extracted twice with ethyl acetate (10 mL). The combined organic layer was washed with saturated brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 60:40 to 35:65) to give the title compound (32 mg) as a white powder. MS (ESI) m / z: 313.0 [M+H]+

[0249] Reference Example 108: Synthesis of 2-[(4-iodopyrazol-1-yl)methyl]thiolane 1,1-dioxide (1,1-Dioxothiolan-2-yl)methyl methanesulfonate (353 mg) synthesized by the method described in US20200079772 and 4-iodo-1H-pyrazole (599 mg) were dissolved in acetonitrile (7.7 mL), and potassium carbonate (1.1 g) was added at room temperature and stirred at 75°C for 20 hours. After completion of the reaction, water (20 mL) was added, and the mixture was extracted twice with ethyl acetate (20 mL). The organic layers were combined, washed with saturated brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 60:40 to 35:65) to give the title compound (360 mg) as a white powder. MS (ESI) m / z: 327.0 [M+H]+

[0250] Reference Example 109: Synthesis of (2S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]butan-2-ol 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (250 mg), (2S)-2-ethyloxirane (0.27 mL), and cesium carbonate (630 mg) were suspended in acetonitrile (2.6 mL) and stirred at 130°C for 1 hour under microwave irradiation. After completion of the reaction, the reaction solution was filtered, and the filtrate was concentrated under reduced pressure. Dichloromethane (10 mL) was added to the resulting residue, and the mixture was stirred at room temperature for 30 minutes. After filtering again, the filtrate was concentrated under reduced pressure to obtain the title compound (300 mg) as a colorless oil. MS (ESI) m / z: 267.3 [M+H]+

[0251] Reference Example 110: Synthesis of tert-butyl 2-[4-[4-cyano-3-[3-(difluoromethoxy)-4-[(1-fluorocyclopropyl)methylcarbamoyl]-5-methoxyphenyl]-2-methylindazol-6-yl]pyrazol-1-yl]acetate A mixture of 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]tert-butyl acetate (276 mg), 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-N-[(1-fluorocyclopropyl)methyl]-6-methoxybenzamide described in Reference Example 63 (312 mg), tripotassium phosphate (253 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (49 mg), 1,4-dioxane (6.0 mL), and water (0.60 mL) was heated and stirred at 100°C for 2 hours under a nitrogen atmosphere. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted three times with chloroform. The combined organic layer was concentrated under reduced pressure and then purified by NH silica gel column chromatography (hexane:ethyl acetate=90:10 to 0:100) to obtain the title compound (392 mg) as a pale yellow viscous substance. MS (ESI) m / z: 625.5 [M+H]

[0252] Reference Example 111: Synthesis of 2-[4-[4-cyano-3-[3-(difluoromethoxy)-4-[(1-fluorocyclopropyl)methylcarbamoyl]-5-methoxyphenyl]-2-methylindazol-6-yl]pyrazol-1-yl]acetic acid To a solution of tert-butyl 2-[4-[4-cyano-3-[3-(difluoromethoxy)-4-[(1-fluorocyclopropyl)methylcarbamoyl]-5-methoxyphenyl]-2-methylindazol-6-yl]pyrazol-1-yl]acetate (385 mg) described in Reference Example 110 in 1,4-dioxane (2.0 mL), 4M hydrochloric acid in dioxane (4.0 mL) and tetrahydrofuran (1.0 mL) were added and the mixture was stirred at room temperature for 17 hours. After completion of the reaction, the reaction mixture was concentrated, and ethyl acetate was added to the residue. The precipitated solid was collected by filtration and dried to obtain the title compound (354 mg) as a colorless powder. MS (ESI) m / z: 569.1 [M+H]+

[0253] Reference Example 112: Synthesis of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethyl)-6-(1-ethylpyrazol-4-yl)-2-methylindazol-3-yl]-6-methoxybenzoate A mixture of tert-butyl 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoate (303 mg) described in Reference Example 45, 1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (189 mg), tripotassium phosphate (362 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (46 mg), 1,4-dioxane (6.0 mL), and water (0.60 mL) was heated and stirred for 3 hours at 100°C under a nitrogen atmosphere. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted three times with chloroform. The combined organic layer was concentrated under reduced pressure and then purified by NH silica gel column chromatography (hexane:ethyl acetate=95:5 to 40:60) to obtain the title compound (398 mg) as a pale yellow oil. MS (ESI) m / z: 549.1 [M+H]

[0254] Reference Example 113: Synthesis of 2-(difluoromethoxy)-4-[4-(difluoromethyl)-6-(1-ethylpyrazol-4-yl)-2-methylindazol-3-yl]-6-methoxybenzoic acid TFA (3.0 mL) was added to a dichloromethane (3.0 mL) solution of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethyl)-6-(1-ethylpyrazol-4-yl)-2-methylindazol-3-yl]-6-methoxybenzoate (354 mg) described in Reference Example 112, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, and then ethyl acetate was added and the mixture was stirred at room temperature for 2 hours. The precipitated solid was collected by filtration and dried to obtain the title compound (190 mg) as a colorless powder. MS (ESI) m / z: 493.0 [M+H]+

[0255] Reference Example 114: Synthesis of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethyl)-2-methyl-6-(1-propylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzoate A mixture of tert-butyl 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoate (150 mg) described in Reference Example 45, 1-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (100 mg), tripotassium phosphate (179 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (23 mg), 1,4-dioxane (3.0 mL), and water (0.30 mL) was heated and stirred for 3 hours at 100°C under a nitrogen atmosphere. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted three times with chloroform. The combined organic layer was concentrated under reduced pressure and then purified by NH silica gel column chromatography (hexane:ethyl acetate=95:5 to 50:50) to obtain the title compound (145 mg) as a colorless oil. MS (ESI) m / z: 563.1 [M+H]

[0256] Reference Example 115: Synthesis of 2-(difluoromethoxy)-4-[4-(difluoromethyl)-2-methyl-6-(1-propylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzoic acid TFA (1.0 mL) was added to a dichloromethane (2.0 mL) solution of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethyl)-2-methyl-6-(1-propylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzoate (135 mg) described in Reference Example 114, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, and then ethyl acetate was added and the mixture was concentrated under reduced pressure again. Diethyl ether was added to the residue, and the precipitated solid was collected by filtration and dried to obtain the title compound (96 mg) as a colorless powder. MS (ESI) m / z: 507.0 [M+H]+

[0257] Reference Example 116: Synthesis of 1-[2-(4-iodopyrazol-1-yl)ethyl]cyclobutan-1-ol 2-(1-hydroxycyclobutyl)ethyl 4-methylbenzenesulfonate (501 mg), synthesized by the method described in WO2013144191, 4-iodopyrazole (360 mg), and cesium carbonate (1.8 g) were suspended in N,N-dimethylformamide (9.0 mL) and stirred at 60°C for 2 hours. After the reaction was completed, water was added and the mixture was extracted three times with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 95:5 to 75:25 to 70:30) to give the title compound (545 mg) as a colorless oil. MS (ESI) m / z: 292.8 [M+H]+

[0258] Reference Example 117: Synthesis of 4-[4-cyano-2-methyl-6-[1-(oxan-2-yl)pyrazol-4-yl]indazol-3-yl]-N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-6-methoxybenzamide A mixture of 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-6-methoxybenzamide (90 mg) described in Reference Example 82, 1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (57 mg), tripotassium phosphate (72 mg), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloride (5.6 mg), 1,4-dioxane (1.5 mL), and water (0.15 mL) was heated and stirred under a nitrogen atmosphere at 50°C for 1.5 hours. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted three times with chloroform. The combined organic layer was concentrated under reduced pressure and then purified by NH silica gel column chromatography (hexane:ethyl acetate=95:5 to 15:85) to obtain the title compound (96 mg) as a colorless powder. MS (ESI) m / z: 599.0 [M+H]

[0259] Reference Example 118: Synthesis of 4-[4-cyano-2-methyl-6-[1-(oxan-2-yl)pyrazol-3-yl]indazol-3-yl]-N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-6-methoxybenzamide A mixture of 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-6-methoxybenzamide (96 mg) described in Reference Example 82, 1-(tetrahydro-2H-pyran-2-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (61 mg), tripotassium phosphate (77 mg), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloride (5.9 mg), 1,4-dioxane (2.0 mL), and water (0.20 mL) was heated and stirred under a nitrogen atmosphere at 50°C for 1.5 hours. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted three times with chloroform. The combined organic layer was concentrated under reduced pressure and then purified by NH silica gel column chromatography (hexane:ethyl acetate=95:5 to 0:100 to ethyl acetate:methanol=97:3) to obtain the title compound (107 mg) as a pale yellow powder. MS (ESI) m / z: 599.0 [M+H]

[0260] Reference Example 119: Synthesis of N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-4-[4-(difluoromethyl)-2-methyl-6-[1-(oxan-2-yl)pyrazol-4-yl]indazol-3-yl]-6-methoxybenzamide A mixture of 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-6-methoxybenzamide (118 mg) described in Reference Example 83, 1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (71 mg), tripotassium phosphate (91 mg), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloride (7.0 mg), 1,4-dioxane (2.0 mL), and water (0.20 mL) was heated and stirred for 2 hours at 50 ° C. under a nitrogen atmosphere. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted three times with chloroform. The combined organic layer was concentrated under reduced pressure and then purified by NH silica gel column chromatography (hexane:ethyl acetate=95:5 to 0:100) to obtain the title compound (127 mg) as a pale yellow viscous substance. MS (ESI) m / z: 624.3 [M+H]

[0261] Reference Example 120: Synthesis of 2-bromo-6-methoxy-N-(2-propenyl)benzamide To a mixture of 2-bromo-6-methoxybenzoic acid (10 g) and toluene (87 mL), oxalyl dichloride (7.4 mL) and N,N-dimethylformamide (10 μL) were added in that order, and the mixture was stirred at 60°C under a nitrogen atmosphere for 1 hour. The reaction mixture was concentrated under reduced pressure, and toluene was added to the concentrated residue, followed by further concentration under reduced pressure. Tetrahydrofuran (87 mL) was added to the concentrated residue, and allylamine hydrochloride (4.3 g) and triethylamine (24 mL) were added in that order under ice cooling, and the mixture was stirred at room temperature for 1.5 hours under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure, and water was added to the concentrated residue, followed by filtration and washing with water. The product collected by filtration was dissolved in ethyl acetate, followed by addition of sodium sulfate and filtration, and the filtrate was concentrated under reduced pressure. The mixture was suspended and washed with hexane (approximately 30 mL) to obtain the title compound (10 g) as a white powder. MS (ESI) m / z: 269.9 / 271.8 [M+H]+

[0262] Reference Example 121: Synthesis of 2-bromo-6-methoxy-N-(2-propenyl)-N-(2-trimethylsilylethoxymethyl)benzamide To a solution of 2-bromo-6-methoxy-N-(2-propenyl)benzamide (5.1 g) described in Reference Example 120 in N,N-dimethylformamide (40 mL), sodium hydride (60%, dispersed in liquid paraffin) (824 mg) was added under ice cooling, and the mixture was stirred for 5 minutes, followed by stirring at room temperature for 15 minutes. 2-(Chloromethoxy)ethyltrimethylsilane (3.7 g) was added under ice cooling, and the mixture was stirred at room temperature under a nitrogen atmosphere for 3 hours. Water was added to the reaction mixture under ice cooling, and the mixture was extracted twice with ethyl acetate. The organic layer was washed with saturated brine, sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure to obtain the title compound (8.6 g) as a pale yellow oil. MS (ESI) m / z: 399.9 / 401.9 [M+H]+

[0263] Reference Example 122: Synthesis of 8-methoxy-4-methyl-2-(2-trimethylsilylethoxymethyl)isoquinolin-1-one A mixture of 2-bromo-6-methoxy-N-(2-propenyl)-N-(2-trimethylsilylethoxymethyl)benzamide (7.5 g), palladium(II) acetate (210 mg), triethylamine (6.5 mL), tetrabutylammonium chloride (5.7 g), and N,N-dimethylformamide (40 mL) described in Reference Example 121 was stirred at 80°C for 1 hour under a nitrogen atmosphere. Water (100 mL) and ethyl acetate (70 mL) were added to the reaction mixture, which was then filtered. The filtrate was extracted twice with ethyl acetate. The organic layer was washed with 1N hydrochloric acid, saturated aqueous sodium bicarbonate, and saturated brine, followed by addition of sodium sulfate and filtration. The filtrate was concentrated under reduced pressure. The concentrated residue was purified by column chromatography using an NH silica gel column and a Si silica gel column in series (hexane:ethyl acetate = 90:10 to 20:80) to give the title compound (5.2 g) as a colorless powder. MS (ESI) m / z: 320.0 [M+H]+

[0264] Reference Example 123: Synthesis of 8-methoxy-4-methyl-2-(2-trimethylsilylethoxymethyl)-3,4-dihydroisoquinolin-1-one To a solution of 8-methoxy-4-methyl-2-(2-trimethylsilylethoxymethyl)isoquinolin-1-one (5.2 g) described in Reference Example 122 in ethanol (140 mL) was added 10% Pd / C (3.7 g), and the mixture was stirred overnight at room temperature under a hydrogen atmosphere. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The concentrated residue was purified by silica gel column chromatography (hexane:ethyl acetate=90:10 to 50:50) to obtain the title compound (3.7 g) as a pale yellow oil. MS (ESI) m / z: 322.0 [M+H]+

[0265] Reference Example 124: Synthesis of the isomer of rel-(4R)-8-methoxy-4-methyl-2-(2-trimethylsilylethoxymethyl)-3,4-dihydroisoquinolin-1-one which elutes first under the chiral HPLC conditions described in the experimental section 8-Methoxy-4-methyl-2-(2-trimethylsilylethoxymethyl)-3,4-dihydroisoquinolin-1-one (206 mg) described in Reference Example 123 was separated using a chiral column [CHIRALPAK (registered trademark) ID (30*250), hexane:2-propanol=80:20]. The front fraction was collected and concentrated to obtain the title compound (72 mg) as a colorless oil. MS (ESI) m / z: 322.0 [M+H]+

[0266] Reference Example 125: Synthesis of rel-(4R)-8-methoxy-4-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(2-trimethylsilylethoxymethyl)-3,4-dihydroisoquinolin-1-one A mixture of the isomer (70 mg) of rel-(4R)-8-methoxy-4-methyl-2-(2-trimethylsilylethoxymethyl)-3,4-dihydroisoquinolin-1-one described in Reference Example 124 that elutes first under the chiral HPLC conditions described in the Experimental section, bis(pinacolato)diboron (66 mg), bis(1,5-cyclooctadiene)di-μ-methoxydiiridium(I) (4.3 mg), 4,4′-di-tert-butyl-2,2′-bipyridyl (3.5 mg), and heptane (0.22 mL) was stirred at 80°C under a nitrogen atmosphere for 2 hours. The reaction solution was diluted with ethyl acetate and purified by silica gel column chromatography (hexane:ethyl acetate = 70:30 to 30:70) to obtain the title compound (95 mg) as a pale yellow oil. MS (ESI) m / z: 448.4 [M+H]+

[0267] Reference Example 126: Synthesis of tert-butyl 8-methoxy-4,4-dimethyl-1-oxo-3H-isoquinoline-2-carboxylate A mixture of tert-butyl N-(2-bromo-6-methoxybenzoyl)-N-(2-methyl-2-propenyl)carbamate (1.3 g) described in Reference Example 130, tetrabutylammonium chloride (909 mg), sodium formate (303 mg), triethylamine (1.0 mL), palladium(II) acetate (67 mg), and N,N-dimethylformamide (12 mL) was stirred at 80°C for 4 hours under a nitrogen atmosphere. Water was added to the reaction solution, and the mixture was extracted three times with ethyl acetate. Sodium sulfate was added to the organic layer, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform:methanol = 100:0 to 93:7) to give the title compound (597 mg) as a pale yellow powder. MS (ESI) m / z: 249.9 [M+H-tBu]+

[0268] Reference Example 127: Synthesis of tert-butyl 8-methoxy-4,4-dimethyl-1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-isoquinoline-2-carboxylate Tetrahydrofuran (1.2 mL) was added to tert-butyl 8-methoxy-4,4-dimethyl-1-oxo-3H-isoquinoline-2-carboxylate (380 mg), bis(pinacolato)diboron (379 mg), 4,4'-di-tert-butyl-2,2'-bipyridyl (20 mg), and bis(1,5-cyclooctadiene)di-μ-methoxydiiridium(I) (25 mg) described in Reference Example 126, and the mixture was stirred at 70°C under a nitrogen atmosphere for 2 hours. The reaction solution was diluted with ethyl acetate and purified directly by silica gel column chromatography (hexane:ethyl acetate = 50:50 to 25:75) to obtain the title compound (534 mg) as a pale yellow powder. MS (ESI) m / z: 376.3 [M+H-tBu]+

[0269] Reference Example 128: Synthesis of 6-bromo-3-(8-methoxy-4,4-dimethyl-1-oxo-2,3-dihydroisoquinolin-6-yl)-2-methylindazole-4-carbonitrile 8-Methoxy-4,4-dimethyl-1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-isoquinoline-2-carboxylate tert-butyl (900 mg) described in Reference Example 127 and 6-bromo-3-iodo-2-methylindazole-4-carbonitrile (700 mg) described in Reference Example 19 were suspended in a mixed solvent of 1,4-dioxane (13 mL) and water (3.2 mL) and stirred for 10 minutes at 100° C. under a nitrogen atmosphere. After the suspension was allowed to cool to room temperature, potassium carbonate (535 mg) and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (158 mg) were added and the mixture was stirred for 3 hours at 100° C. under a nitrogen atmosphere. After completion of the reaction, chloroform was added to the reaction mixture, and the organic layer separated using a Phase-Separator® was concentrated under reduced pressure. The residue was dissolved in dichloromethane (9.7 mL), and TFA (1.5 mL) was added and stirred at room temperature for 30 minutes. After completion of the reaction, the reaction solution was concentrated under reduced pressure, and to the resulting residue, saturated aqueous sodium bicarbonate and chloroform were added, and the organic layer separated using a Phase-Separator® was concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (ethyl acetate:methanol = 100:0 to 93:7) and washed by suspension with diethyl ether to obtain the title compound (536 mg) as a white powder. MS (ESI) m / z: 439.2 / 441.2 [M+H]+

[0270] Reference Example 129: Synthesis of 2-bromo-6-methoxy-N-(2-methyl-2-propenyl)benzamide To a solution of 2-bromo-6-methoxybenzoic acid (10 g) in dichloromethane (144 mL), oxalyl dichloride (7.4 mL) was added under ice cooling, and the mixture was stirred at 60°C for 3 hours. The reaction mixture was concentrated under reduced pressure. Toluene was added to the concentrated residue, and the mixture was concentrated under reduced pressure again. This procedure was repeated three times. To a mixture of the concentrated residue and triethylamine (18 mL) in dichloromethane (144 mL), a solution of 2-methylallylamine (4.7 mL) in dichloromethane (20 mL) was added dropwise under ice cooling, and the mixture was stirred at room temperature for 2 days. The reaction mixture was concentrated under reduced pressure, then diluted with ethyl acetate, and extracted with water. The organic layer was washed three times with 1N hydrochloric acid and three times with saturated aqueous sodium bicarbonate. After washing with saturated brine, sodium sulfate was added, followed by filtration, and the filtrate was concentrated under reduced pressure. The concentrated residue was suspended and washed with diisopropyl ether to obtain the title compound (8.1 g) as a white powder. MS (ESI) m / z: 284.1 / 286.1 [M+H]+

[0271] Reference Example 130: Synthesis of tert-butyl N-(2-bromo-6-methoxybenzoyl)-N-(2-methyl-2-propenyl)carbamate To a solution of 2-bromo-6-methoxy-N-(2-methyl-2-propenyl)benzamide (1.0 g) described in Reference Example 129 and triethylamine (0.50 mL) in dichloromethane (6.0 mL), di-tert-butyl dicarbonate (1.3 g) and 4-dimethylaminopyridine (37 mg) were added in this order under ice cooling, and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure, and the concentrated residue was purified by silica gel column chromatography (hexane:ethyl acetate=80:20 to 50:50) to obtain the title compound (1.3 g) as a white powder. MS (ESI) m / z: 328.1 / 330.1 [M+H-tBu]+

[0272] Reference Example 131: Synthesis of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzoate A mixture of tert-butyl 2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-6-methoxybenzoate (200 mg) described in Reference Example 66, 4-iodo-1-methyl-pyrazole (84 mg), potassium carbonate (139 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (27 mg), 1,4-dioxane (2.0 mL), and water (0.40 mL) was heated and stirred at 100 ° C. under a nitrogen atmosphere. After 1 hour, the reaction mixture was allowed to cool to room temperature, and to this was added [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (27 mg), followed by heating and stirring overnight at 100°C under a nitrogen atmosphere. After completion of the reaction, the reaction mixture was diluted with ethyl acetate and dried by adding sodium sulfate. After removing the insoluble matter by filtration, the filtrate was concentrated under reduced pressure and purified by preparative HPLC (10 mM aqueous ammonium carbonate-acetonitrile) to obtain the title compound (41 mg) as a gray powder. MS (ESI) m / z: 551.3 [M+H]+

[0273] Reference Example 132: Synthesis of 4-[6-bromo-4-(difluoromethoxy)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzamide Tert-butyl 4-[6-bromo-4-(difluoromethoxy)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoate (302 mg) described in Reference Example 65 was dissolved in dichloromethane (1.0 mL), TFA (1.0 mL) was added, and the mixture was stirred at room temperature for 1.5 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure and azeotroped twice with toluene. The residue, ammonium chloride (118 mg), WSC.HCl (158 mg), and HOBt (111 mg) were suspended in tetrahydrofuran (5.5 mL), triethylamine (0.46 mL) was added, and the mixture was stirred at room temperature for 2 days. After completion of the reaction, saturated aqueous sodium bicarbonate solution and water were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine and dried over magnesium sulfate. The residue obtained by filtration and concentration of the filtrate under reduced pressure was purified by silica gel column chromatography (ethyl acetate:methanol=100:0 to 95:5) to obtain the title compound (209 mg) as a colorless powder. MS (ESI) m / z: 492.1 / 494.1 [M+H]

[0274] Reference Example 133: Synthesis of 6-bromo-4-ethoxy-3-iodo-2-methylindazole 6-Bromo-3-iodo-2-methylindazol-4-ol (356 mg), iodoethane (0.40 mL), and potassium carbonate (279 mg) described in Reference Example 33 were suspended in N,N-dimethylformamide (4.0 mL) and stirred at 80°C under a nitrogen atmosphere for 2 hours. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The combined organic layers were washed with saturated brine, sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate = 95:5 to 75:25) to obtain the title compound (363 mg) as a pale yellow powder. MS (ESI) m / z: 380.7 / 382.7 [M+H]+

[0275] Reference Example 134: Synthesis of 2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzamide TFA (1.6 mL) was added to a dichloromethane (1.6 mL) solution of tert-butyl 2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzoate (330 mg) described in Reference Example 59, and the mixture was stirred at room temperature for 21 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and then azeotroped three times with toluene. The resulting residue was dissolved in N,N-dimethylformamide (3.3 mL), and HATU (301 mg) and N,N-diisopropylethylamine (0.50 mL) were added, followed by stirring at room temperature for 10 minutes. Ammonium carbonate (76 mg) was then added, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, water and 1N hydrochloric acid were added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed successively with water and saturated brine, magnesium sulfate was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 80:20) to obtain the title compound (129 mg) as a brown powder. MS (ESI) m / z: 444.3 [M+H]

[0276] Reference Example 135: Synthesis of 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzamide 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid (400 mg), WSC.HCl (241 mg), HOBt (170 mg), and ammonium chloride (179 mg) described in Reference Example 71 were dissolved in tetrahydrofuran (8.4 mL), and triethylamine (0.70 mL) was added. The mixture was stirred overnight at room temperature. After completion of the reaction, saturated aqueous sodium bicarbonate solution and water were added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated brine and dried over magnesium sulfate. After filtration, the filtrate was concentrated under reduced pressure, and the resulting residue was suspended and washed with diethyl ether to give the title compound (361 mg) as a colorless powder. MS (ESI) m / z: 475.8 / 477.8 [M+H]+

[0277] Reference Example 136: Synthesis of 4-(6-bromo-4-hydroxy-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzamide Tert-butyl 4-(6-bromo-4-hydroxy-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzoate (680 mg) described in Reference Example 58 was dissolved in dichloromethane (3.4 mL), TFA (3.4 mL) was added, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was concentrated under reduced pressure and azeotroped three times with toluene. The residue was mixed with ammonium chloride (291 mg), WSC.HCl (392 mg), HOBt (276 mg), and tetrahydrofuran (14 mL), and triethylamine (1.1 mL) was added and the mixture was stirred at room temperature overnight. After completion of the reaction, 1N hydrochloric acid was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over magnesium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain a residue. The title compound (368 mg) was obtained as a pale yellow powder by purifying it by silica gel column chromatography (ethyl acetate:methanol = 100:0 to 90:10). MS (ESI) m / z: 441.8 / 443.8 [M+H]+

[0278] Reference Example 137: Synthesis of 4-[6-bromo-4-(2,2-difluoroethoxy)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzamide 4-(6-bromo-4-hydroxy-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzamide (50 mg) described in Reference Example 136 and potassium carbonate (47 mg) were suspended in N,N-dimethylformamide (0.57 mL) and stirred at room temperature for 5 minutes. 2,2-difluoroethyl trifluoromethanesulfonate (23 μL) was then added and the mixture was stirred at 80°C for 1 hour. After completion of the reaction, chloroform and water were added to the reaction mixture, which was then separated using a Phase-Separator (registered trademark). The organic layer was concentrated under reduced pressure. The residue was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) and column chromatography using an NH silica gel column and a Si silica gel column in series (hexane:ethyl acetate = 50:50 to 0:100 to ethyl acetate:methanol = 95:5) to obtain the title compound (36 mg) as a colorless powder. MS (ESI) m / z: 506.1 / 508.1 [M+H]+

[0279] Reference Example 138: Synthesis of 4-[6-bromo-2-methyl-4-(2,2,2-trifluoroethoxy)indazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzamide 4-(6-bromo-4-hydroxy-2-methylindazol-3-yl)-2-(difluoromethoxy)-6-methoxybenzamide (50 mg) described in Reference Example 136 and potassium carbonate (47 mg) were suspended in N,N-dimethylformamide (0.57 mL) and stirred at room temperature for 5 minutes. After stirring, 2,2,2-trifluoroethyl trifluoromethanesulfonate (25 μL) was added and the mixture was stirred at 80°C for 1 hour. After completion of the reaction, chloroform and water were added to the reaction mixture, which was separated using a Phase-Separator®, and the organic layer was concentrated under reduced pressure. The residue was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) and column chromatography using an NH silica gel column and a Si silica gel column in series (hexane:ethyl acetate = 50:50 to 0:100 to ethyl acetate:methanol = 95:5) to obtain the title compound (35 mg) as a brown powder. MS (ESI) m / z: 524.1 / 526.1 [M+H]+

[0280] Reference Example 139: Synthesis of tert-butyl 8-(difluoromethoxy)-4-methyl-1-oxo-3,4-dihydroisoquinoline-2-carboxylate Tert-butyl 8-(difluoromethoxy)-4-methyl-1-oxoisoquinoline-2-carboxylate (324 mg) described in Reference Example 11 was dissolved in tetrahydrofuran (5.0 mL), and 10% Pd / C (100 mg) was added under a nitrogen atmosphere. The mixture was stirred at room temperature under a hydrogen atmosphere for 7 hours. After completion of the reaction, the reaction mixture was diluted with chloroform and then filtered. The filtrate was concentrated and dried to obtain the title compound (318 mg) as a colorless oil. MS (ESI) m / z: 272.1 [M-tBu+H]+

[0281] Reference Example 140: Synthesis of tert-butyl 8-(difluoromethoxy)-4-methyl-1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2-carboxylate A suspension of tert-butyl 8-(difluoromethoxy)-4-methyl-1-oxo-3,4-dihydroisoquinoline-2-carboxylate (315 mg), bis(pinacolato)diboron (285 mg), 4,4'-di-tert-butyl-2,2'-bipyridyl (15 mg), and bis(1,5-cyclooctadiene)di-μ-methoxydiiridium(I) (19 mg) in heptane (0.94 mL) was stirred at 80°C for 2 hours under a nitrogen atmosphere. The reaction solution was diluted with ethyl acetate and purified directly by silica gel column chromatography (hexane:ethyl acetate = 70:30 to 30:70) to obtain the title compound (389 mg) as an orange oil. MS (ESI) m / z: 398.2 [M+H-tBu]+

[0282] Reference Example 141: Synthesis of 6-bromo-3-[8-(difluoromethoxy)-4-methyl-1-oxo-3,4-dihydro-2H-isoquinolin-6-yl]-2-methylindazole-4-carbonitrile A mixture of 8-(difluoromethoxy)-4-methyl-1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2-carboxylate tert-butyl (189 mg) described in Reference Example 140, 6-bromo-3-iodo-2-methylindazole-4-carbonitrile (125 mg) described in Reference Example 19, potassium carbonate (95 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (28 mg), 1,4-dioxane (2.3 mL), and water (0.58 mL) was stirred for 3 hours at 100°C under a nitrogen atmosphere. After completion of the reaction, chloroform and water were added to the reaction mixture, and the organic layer was separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The residue was dissolved in dichloromethane (0.86 mL), and TFA (0.86 mL) was added, followed by stirring at room temperature for 3 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure and then azeotroped with toluene. A saturated aqueous solution of sodium bicarbonate and chloroform were added to the residue, and the organic layer was separated using a Phase-Separator (registered trademark) and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (ethyl acetate:methanol = 100:0 to 94:6) and then suspended and washed with diisopropyl ether to obtain the title compound (57 mg) as a yellow powder. MS (ESI) m / z: 460.9 / 462.8 [M+H]+

[0283] Reference Example 142: Synthesis of 6-(6-bromo-4-methoxy-2-methylindazol-3-yl)-8-(difluoromethoxy)-4-methyl-3,4-dihydro-2H-isoquinolin-1-one The title compound was obtained by carrying out the same reaction and treatment as in Reference Example 141 using 6-bromo-3-iodo-4-methoxy-2-methylindazole described in Reference Example 23 as the starting material. MS (ESI) m / z: 465.9 / 467.8 [M+H]+

[0284] Reference Example 143: Synthesis of rel-(4R)-6-(6-bromo-4-ethoxy-2-methylindazol-3-yl)-8-methoxy-4-methyl-2-(2-trimethylsilylethoxymethyl)-3,4-dihydroisoquinolin-1-one A mixture of 6-bromo-4-ethoxy-3-iodo-2-methylindazole (100 mg) described in Reference Example 133, rel-(4R)-8-methoxy-4-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(2-trimethylsilylethoxymethyl)-3,4-dihydroisoquinolin-1-one (149 mg) described in Reference Example 125, [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (21 mg), potassium carbonate (73 mg), 1,4-dioxane (1.6 mL), and water (0.40 mL) was stirred at 100°C under a nitrogen atmosphere for 2 hours and 30 minutes. After completion of the reaction, chloroform and water were added to the reaction mixture, and the organic layer separated using a Phase-separator (registered trademark) was concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=70:30 to 30:70) to give the title compound (126 mg) as a pale yellow viscous substance. MS (ESI) m / z: 574.0 / 576.0 [M+H]

[0285] Reference Example 144: Synthesis of rel-(4R)-6-(6-bromo-4-ethoxy-2-methyl-indazol-3-yl)-8-methoxy-4-methyl-3,4-dihydro-2H-isoquinolin-1-one rel-(4R)-6-(6-bromo-4-ethoxy-2-methylindazol-3-yl)-8-methoxy-4-methyl-2-(2-trimethylsilylethoxymethyl)-3,4-dihydroisoquinolin-1-one (125 mg) described in Reference Example 143 was dissolved in dichloromethane (0.98 mL), TFA (0.45 mL) was added, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was added to a 4N aqueous sodium hydroxide solution (2.0 mL) and stirred, and the organic layer separated using a Phase-Separator (registered trademark) was concentrated under reduced pressure. The residue was dissolved in methanol (2.0 mL), potassium carbonate (81 mg) was added, and the mixture was stirred at 60°C for 1 hour. After completion of the reaction, ethyl acetate was added to the reaction mixture, which was then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (ethyl acetate:methanol=100:0 to 94:6) to give the title compound (70 mg) as a white powder. MS (ESI) m / z: 444.2 / 446.2 [M+H]

[0286] Reference Example 145: Synthesis of 2-bromo-6-(difluoromethoxy)-N-(2-methylallyl)benzamide To a solution of 2-bromo-6-(difluoromethoxy)benzoic acid (443 mg) in N,N-dimethylformamide (3.8 mL), N,N-diisopropylethylamine (0.39 mL), 2-methylallylamine (0.16 mL), and HATU (690 mg) were added sequentially, and the mixture was stirred at room temperature for 5 hours. After completion of the reaction, ethyl acetate and 1N hydrochloric acid were added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed sequentially with saturated aqueous sodium bicarbonate and saturated brine, sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 80:20 to 60:40) to give the title compound (404 mg) as a white powder. MS (ESI) m / z: 320.1 / 322.1 [M+H]+

[0287] Reference Example 146: Synthesis of tert-butyl N-[2-bromo-6-(difluoromethoxy)benzoyl]-N-(2-methylallyl)carbamate To a dichloromethane (2.5 mL) solution of 2-bromo-6-(difluoromethoxy)-N-(2-methylallyl)benzamide (400 mg) described in Reference Example 145, di-tert-butyl dicarbonate (545 mg), triethylamine (0.21 mL), and 4-dimethylaminopyridine (15 mg) were added sequentially under ice cooling, and the mixture was stirred at room temperature for 20 hours. After completion of the reaction, ethyl acetate was added to the reaction mixture, which was then washed sequentially with saturated aqueous ammonium chloride solution and saturated brine. Sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure to obtain the title compound (544 mg) as a yellow oil. MS (ESI) m / z: 320.1 / 322.1 [M-Boc+H]+

[0288] Reference Example 147: Synthesis of tert-butyl 8-(difluoromethoxy)-4,4-dimethyl-1-oxo-3H-isoquinoline-2-carboxylate A mixture of tert-butyl N-[2-bromo-6-(difluoromethoxy)benzoyl]-N-(2-methylallyl)carbamate (525 mg), sodium formate (128 mg), tetrabutylammonium chloride (382 mg), palladium(II) acetate (28 mg), N,N-dimethylformamide (5.0 mL), and triethylamine (0.44 mL) described in Reference Example 146 was heated and stirred at 80°C for 2 hours. After completion of the reaction, ethyl acetate and water were added to the reaction mixture, which was then filtered and extracted twice with ethyl acetate. The combined organic layer was washed sequentially with saturated aqueous ammonium chloride, saturated aqueous sodium bicarbonate, and saturated brine, sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 85:15 to 70:30) to give the title compound (397 mg) as a colorless oil. MS (ESI) m / z: 286.1 [M-tBu+H]+

[0289] Reference Example 148: Synthesis of tert-butyl 8-(difluoromethoxy)-4,4-dimethyl-1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-isoquinoline-2-carboxylate A mixture of tert-butyl 8-(difluoromethoxy)-4,4-dimethyl-1-oxo-3H-isoquinoline-2-carboxylate (396 mg), bis(pinacolato)diboron (343 mg), 4,4'-di-tert-butyl-2,2'-bipyridyl (18 mg), bis(1,5-cyclooctadiene)di-μ-methoxydiiridium(I) (22 mg), and tetrahydrofuran (1.1 mL) described in Reference Example 147 was heated and stirred at 70°C for 2 hours. After completion of the reaction, the reaction mixture was ice-cooled, and ethanol was added in small portions until bubbling ceased, followed by quenching. The resulting mixture was purified by silica gel column chromatography (hexane:ethyl acetate = 50:50 to 25:75), and then suspended and washed with hexane to obtain the title compound (392 mg) as a white powder. MS (ESI) m / z: 412.0 [M-tBu+H]+

[0290] Reference Example 149: Synthesis of rel-(4R)-6-[6-bromo-4-(difluoromethoxy)-2-methyl-indazol-3-yl]-8-methoxy-4-methyl-2-(2-trimethylsilylethoxymethyl)-3,4-dihydroisoquinolin-1-one A mixture of 6-bromo-4-(difluoromethoxy)-3-iodo-2-methylindazole (150 mg) described in Reference Example 39, rel-(4R)-8-methoxy-4-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(2-trimethylsilylethoxymethyl)-3,4-dihydroisoquinolin-1-one (200 mg) described in Reference Example 125, potassium carbonate (103 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (30 mg), 1,4-dioxane (2.4 mL), and water (0.48 mL) was heated and stirred at 100°C under a nitrogen atmosphere. After 1 hour, the reaction mixture was allowed to cool to room temperature, and then [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (30 mg) was added, followed by heating and stirring under a nitrogen atmosphere at 100°C for an additional 2.5 hours. After completion of the reaction, chloroform and water were added to the reaction mixture, and the organic layer was separated using a Phase-Separator® and then concentrated under reduced pressure. The resulting residue was purified by NH silica gel column chromatography (hexane:ethyl acetate = 70:30 to 25:75) to obtain the title compound (143 mg) as a colorless viscous material. MS (ESI) m / z: 596.2 / 598.2 [M+H]+

[0291] Reference Example 150: Synthesis of 6-bromo-3-[8-(difluoromethoxy)-4,4-dimethyl-1-oxo-2,3-dihydroisoquinolin-6-yl]-2-methyl-indazole-4-carbonitrile A mixture of 6-bromo-3-iodo-2-methylindazole-4-carbonitrile (100 mg) described in Reference Example 19, 8-(difluoromethoxy)-4,4-dimethyl-1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-isoquinoline-2-carboxylate (190 mg) described in Reference Example 148, potassium carbonate (76 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (23 mg), 1,4-dioxane (1.8 mL), and water (0.46 mL) was heated and stirred for 2.5 hours at 100°C under a nitrogen atmosphere. After completion of the reaction, chloroform was added to the reaction mixture, and the organic layer was separated using a Phase-separator (registered trademark) and then concentrated under reduced pressure. The resulting residue was dissolved in dichloromethane (0.69 mL), TFA (0.69 mL) was added, and the mixture was stirred at room temperature for 30 minutes. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and then azeotroped with toluene. The resulting residue was purified by NH silica gel column chromatography (hexane:ethyl acetate = 30:70 to 0:100) and then suspended and washed with diisopropyl ether to obtain the title compound (30 mg) as a pale yellow powder. MS (ESI) m / z: 474.9 / 476.8 [M+H]+

[0292] Reference Example 151: Synthesis of rel-(4R)-6-[6-bromo-4-(difluoromethoxy)-2-methyl-indazol-3-yl]-8-methoxy-4-methyl-3,4-dihydro-2H-isoquinolin-1-one TFA (0.48 mL) was added to a dichloromethane (1.0 mL) solution of rel-(4R)-6-[6-bromo-4-(difluoromethoxy)-2-methyl-indazol-3-yl]-8-methoxy-4-methyl-2-(2-trimethylsilylethoxymethyl)-3,4-dihydroisoquinolin-1-one (141 mg) described in Reference Example 149, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was added to a 4N aqueous sodium hydroxide solution (2.1 mL) and stirred for 5 minutes. The organic layer was separated using a Phase-Separator (registered trademark) and concentrated under reduced pressure. To the resulting residue, methanol (2.1 mL) and potassium carbonate (86 mg) were added, and the mixture was heated and stirred at 60°C for 1 hour. After completion of the reaction, ethyl acetate was added to the reaction mixture, which was then filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by NH silica gel column chromatography (ethyl acetate:methanol=100:0 to 90:10) to obtain the title compound (84 mg) as a colorless viscous substance. MS (ESI) m / z: 465.8 / 467.8 [M+H]

[0293] Reference Example 152: Synthesis of tert-butyl 6-(6-bromo-4-cyano-2-methyl-indazol-3-yl)-8-(difluoromethoxy)-4-methyl-1-oxo-3,4-dihydroisoquinoline-2-carboxylate A mixture of 6-bromo-3-iodo-2-methylindazole-4-carbonitrile (2400 mg) described in Reference Example 19, tert-butyl 8-(difluoromethoxy)-4-methyl-1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2-carboxylate (3156 mg) described in Reference Example 140, potassium phosphate (2815 mg), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloride (432 mg), 1,4-dioxane (35 mL), and water (5.0 mL) was stirred at 100°C under a nitrogen atmosphere for 2.5 hours. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted three times with chloroform. The organic layers were combined, sodium sulfate was added, and the mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=90:10 to 40:60) to give the title compound (982 mg) as a yellow powder. MS (ESI) m / z: 504.8 / 506.8 [M+H]

[0294] Reference Example 153: Synthesis of tert-butyl 6-[4-cyano-6-[1-(2-methoxyethyl)pyrazol-4-yl]-2-methyl-indazol-3-yl]-8-(difluoromethoxy)-4-methyl-1-oxo-3,4-dihydroisoquinoline-2-carboxylate A mixture of tert-butyl 6-(6-bromo-4-cyano-2-methyl-indazol-3-yl)-8-(difluoromethoxy)-4-methyl-1-oxo-3,4-dihydroisoquinoline-2-carboxylate (325 mg) described in Reference Example 152, 1-(2-methoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (175 mg), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloride (38 mg), potassium phosphate (369 mg), 1,4-dioxane (3.0 mL), and water (0.40 mL) was heated and stirred for 2 hours at 100°C under a nitrogen atmosphere. After completion of the reaction, water and chloroform were added to the reaction mixture, and the organic layer was separated using a Phase-separator (registered trademark) and then concentrated under reduced pressure. The residue was purified sequentially by NH silica gel column chromatography (hexane:ethyl acetate=70:30 to 30:70) and preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to give the title compound (226 mg) as a colorless powder. MS (ESI) m / z: 507.3 [M-Boc+H]

[0295] Reference Example 154: Synthesis of tert-butyl 6-[4-cyano-6-(1-ethylpyrazol-4-yl)-2-methyl-indazol-3-yl]-8-(difluoromethoxy)-4-methyl-1-oxo-3,4-dihydroisoquinoline-2-carboxylate A mixture of tert-butyl 6-(6-bromo-4-cyano-2-methyl-indazol-3-yl)-8-(difluoromethoxy)-4-methyl-1-oxo-3,4-dihydroisoquinoline-2-carboxylate (325 mg) described in Reference Example 152, 1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (257 mg), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloride (38 mg), potassium phosphate (369 mg), 1,4-dioxane (3.0 mL), and water (0.40 mL) was heated and stirred for 2 hours at 100°C under a nitrogen atmosphere. After completion of the reaction, water and chloroform were added to the reaction mixture, and the organic layer was separated using a Phase-separator (registered trademark) and then concentrated under reduced pressure. The residue was purified sequentially by NH silica gel column chromatography (hexane:ethyl acetate=75:25 to 40:60) and preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to give the title compound (64 mg) as a colorless oil. MS (ESI) m / z: 577.3 [M+H]

[0296] Reference Example 155: Synthesis of 3-[8-(difluoromethoxy)-4-methyl-1-oxo-3,4-dihydro-2H-isoquinolin-6-yl]-6-[1-(2-methoxyethyl)pyrazol-4-yl]-2-methyl-indazole-4-carbonitrile Tert-butyl 6-[4-cyano-6-[1-(2-methoxyethyl)pyrazol-4-yl]-2-methyl-indazol-3-yl]-8-(difluoromethoxy)-4-methyl-1-oxo-3,4-dihydroisoquinoline-2-carboxylate (223 mg) described in Reference Example 153 was dissolved in dichloromethane (2.0 mL), and TFA (2.0 mL) was added, followed by stirring at room temperature for 50 minutes. After completion of the reaction, saturated aqueous sodium bicarbonate solution was added to the reaction solution, and the mixture was extracted three times with chloroform. The combined organic layers were concentrated under reduced pressure and then purified by NH silica gel column chromatography (ethyl acetate:methanol = 100:0 to 98:2 to 95:5) to obtain the title compound (173 mg) as a colorless powder. MS (ESI) m / z: 507.0 [M+H]+

[0297] Reference Example 156: Synthesis of 3-[8-(difluoromethoxy)-4-methyl-1-oxo-3,4-dihydro-2H-isoquinolin-6-yl]-6-(1-ethylpyrazol-4-yl)-2-methyl-indazole-4-carbonitrile Tert-butyl 6-[4-cyano-6-(1-ethylpyrazol-4-yl)-2-methyl-indazol-3-yl]-8-(difluoromethoxy)-4-methyl-1-oxo-3,4-dihydroisoquinoline-2-carboxylate (61 mg) described in Reference Example 154 was dissolved in dichloromethane (1.0 mL), and TFA (1.0 mL) was added, followed by stirring at room temperature for 45 minutes. After completion of the reaction, saturated aqueous sodium bicarbonate solution was added to the reaction solution, and the mixture was extracted three times with chloroform. The combined organic layers were concentrated under reduced pressure and then purified by NH silica gel column chromatography (ethyl acetate:methanol = 100:0 to 98:2 to 95:5) to obtain the title compound (46 mg) as a pale yellow powder. MS (ESI) m / z: 477.0 [M+H]+

[0298] Reference Example 157: Synthesis of 8-(difluoromethoxy)-6-[6-[1-[(2S)-2-hydroxypropyl]pyrazol-4-yl]-4-methoxy-2-methyl-indazol-3-yl]-4-methyl-3,4-dihydro-2H-isoquinolin-1-one 6- (6-bromo-4-methoxy-2-methylindazol-3-yl) -8- (difluoromethoxy) -4-methyl-3,4-dihydro-2H-isoquinolin-1-one (200 mg) described in Reference Example 142, (2S)-1- [4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) pyrazol-1-yl] propan-2-ol (130 mg) synthesized by the method described in WO2022081627, [1,1'-bis (di -tert- butylphosphino) ferrocene] palladium (II) dichloride (28 mg), potassium phosphate (273 mg), 1,4-dioxane (2.1 mL), a mixture of water (0.20 mL) was heated and stirred at 100 ° C. under a nitrogen atmosphere for 2 hours. After the reaction was completed, water and chloroform were added to the reaction mixture, and the organic layer was separated using a Phase-Separator (registered trademark) and then concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (ethyl acetate:methanol=100:0 to 90:10) to obtain the title compound (198 mg) as a beige powder. MS (ESI) m / z: 512.0 [M+H]+

[0299] Reference Example 158: Synthesis of 8-(difluoromethoxy)-6-[4-methoxy-6-[1-(2-methoxyethyl)pyrazol-4-yl]-2-methyl-indazol-3-yl]-4-methyl-3,4-dihydro-2H-isoquinolin-1-one A mixture of 6-(6-bromo-4-methoxy-2-methylindazol-3-yl)-8-(difluoromethoxy)-4-methyl-3,4-dihydro-2H-isoquinolin-1-one (200 mg) described in Reference Example 142, 1-(2-methoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (130 mg), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium (II) dichloride (28 mg), potassium phosphate (273 mg), 1,4-dioxane (2.1 mL), and water (0.20 mL) was heated and stirred at 100 ° C. for 2 hours under a nitrogen atmosphere. After the reaction was completed, water and chloroform were added to the reaction mixture, and the organic layer was separated using a Phase-Separator®. After concentrating under reduced pressure, the organic layer was purified by NH silica gel column chromatography (ethyl acetate:methanol = 100:0 to 93:7). The crude product obtained was suspended and washed in a 1:1 mixed solvent of ethyl acetate and diethyl ether to obtain the title compound (190 mg) as a beige powder. MS (ESI) m / z: 512.3 [M+H]+

[0300] Reference Example 159: Synthesis of 8-(difluoromethoxy)-6-[6-(1-ethylpyrazol-4-yl)-4-methoxy-2-methyl-indazol-3-yl]-4-methyl-3,4-dihydro-2H-isoquinolin-1-one A mixture of 6-(6-bromo-4-methoxy-2-methylindazol-3-yl)-8-(difluoromethoxy)-4-methyl-3,4-dihydro-2H-isoquinolin-1-one (300 mg) described in Reference Example 142, 1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (172 mg), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium (II) dichloride (42 mg), potassium phosphate (410 mg), 1,4-dioxane (2.0 mL), and water (0.40 mL) was heated and stirred at 100 ° C. under a nitrogen atmosphere for 1.5 hours. After the reaction was completed, water and chloroform were added to the reaction mixture, and the organic layer was separated using a Phase-separator®. After concentration under reduced pressure, the mixture was purified by column chromatography using an NH silica gel column and a Si silica gel column in series (ethyl acetate:methanol=100:0 to 90:10). The crude product obtained was suspended and washed in a 1:1 mixed solvent of ethyl acetate and diethyl ether to obtain the title compound (292 mg) as a pale yellow powder. MS (ESI) m / z: 482.0 [M+H]+

[0301] Reference Example 160: Synthesis of tert-butyl N-[(1R)-2,2-difluorocyclopropyl]carbamate Diphenylphosphoryl azide (58 mL) was added dropwise over 2 hours to a solution of (1S)-2,2-difluorocyclopropanecarboxylic acid (30 g) and triethylamine (34 mL) in tert-butyl alcohol (360 mL) at 75-80°C, and the mixture was stirred for 2.5 hours. After the reaction was completed, the reaction mixture was cooled to room temperature, and saturated aqueous sodium bicarbonate solution (300 mL) and water (1200 mL) were added, followed by stirring for 2.5 hours. The resulting suspension was left standing overnight at room temperature, and the precipitated solid was collected by filtration and washed three times with water (150 mL) to obtain the title compound (32 g) as a pale yellow powder. 1H NMR (400 MHz, CDCl 3 ) δ ppm 4.83 (brs, 1H), 3.16 (brs, 1H), 1.79-1.65 (m, 1H), 1.46 (s, 9H), 1.41-1.29 (m, 1H)

[0302] Reference Example 161: Synthesis of (1R)-2,2-difluorocyclopropan-1-amine hydrochloride A solution of (1S)-2,2-difluorocyclopropanecarboxylic acid (20 g) in tert-butyl alcohol (360 mL) was concentrated under reduced pressure to approximately 120 mL, tert-butyl alcohol (200 mL) was added, and the solution was again concentrated under reduced pressure to approximately 120 mL. Diphenylphosphoryl azide (47 g) was added to the resulting solution at 75°C, and triethylamine (17 g) was added dropwise at the same temperature over 2 hours, followed by stirring for 4 hours. After completion of the reaction, the reaction mixture was cooled to room temperature, and an aqueous solution of sodium bicarbonate (14 g) dissolved in water (280 mL) and tert-butyl N-[(1R)-2,2-difluorocyclopropyl]carbamate described in Reference Example 160 were added as seed crystals (10 mg), followed by stirring at room temperature for 30 minutes. Water (200 mL) was then added dropwise at room temperature over 30 minutes, followed by stirring at 5°C or below for 2 hours. The precipitated solid was collected by filtration and washed with cold water (140 mL). The resulting powder was dissolved in ethyl acetate (36 mL) and washed with 10% brine (40 mL). 4M hydrochloric acid-ethyl acetate (98 mL) was added dropwise to the organic layer at 20-30°C over 40 minutes, and the mixture was stirred at the same temperature for 2 hours. The precipitated solid was collected by filtration and washed three times with ethyl acetate (60 mL) to obtain the title compound (16 g) as a colorless powder. 1H NMR (400 MHz, CD 3 OD) δ ppm 3.44-3.38 (m, 1H), 2.10-2.00 (m, 1H), 1.87-1.78 (m, 1H), Enantiomeric excess >99.8% ee

[0303] Reference Example 162: Measurement of enantiomeric excess of (1R)-2,2-difluorocyclopropan-1-amine hydrochloride (100 mg) described in Reference Example 161 was suspended in chloroform (2.0 mL), and benzoyl chloride (0.13 mL) and triethylamine (0.28 mL) were added at room temperature, followed by stirring overnight at the same temperature. After completion of the reaction, 1N hydrochloric acid was added to the reaction mixture, which was then extracted three times with chloroform. The organic layers were combined and concentrated under reduced pressure, and purified by column chromatography using an NH silica gel column and a Si silica gel column in series (hexane:ethyl acetate=95:5 to 60:40 to 50:50) to obtain N-[(1R)-2,2-difluorocyclopropyl]benzamide (86 mg) as a colorless powder. MS (ESI) m / z: 197.9 [M+H]+ N-[(1R)-2,2-difluorocyclopropyl]benzamide was analyzed by chiral column chromatography [CHIRALPAK (registered trademark) IA-3 (4.6*150), hexane:2-propanol=88:12, column temperature: 25°C, injection solution: 2 mg / mL ethanol solution, injection volume: 0.7 μL, flow rate: 0.5 ml / min, detection wavelength: 227 nm, retention time: 9.8 min (1R isomer), 11.1 min (1S isomer)] to calculate the enantiomeric excess of (1R)-2,2-difluorocyclopropan-1-amine hydrochloride.

[0304] Example 1: Synthesis of 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide A mixture of 4-(6-bromo-4-cyano-2-methylindazol-3-yl)-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (70 mg), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (43 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (11 mg), potassium carbonate (38 mg), 1,4-dioxane (1.4 mL), and water (0.14 mL) described in Reference Example 20 was heated and stirred at 100°C for 3 hours under a nitrogen atmosphere. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted three times with chloroform. The organic layer was separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to give the title compound (48 mg) as a gray powder. MS (ESI) m / z: 511.0 [M+H]

[0305] Example 2 Synthesis of 2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxy-4-[4-methoxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]benzamide The title compound was obtained by carrying out the same reaction and treatment as in Example 1 using 4-(6-bromo-4-methoxy-2-methylindazol-3-yl)-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide described in Reference Example 24. MS (ESI) m / z: 516.0 [M+H]

[0306] Example 3 Synthesis of 2-(difluoromethoxy)-4-[4-(difluoromethyl)-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide 4-[6-bromo-4-(difluoromethyl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (24 mg), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (9.5 mg), potassium carbonate (17 mg), and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (3.4 mg) were suspended in a mixed solvent of 1,4-dioxane (0.28 mL) and water (69 μL), and the mixture was heated and stirred at 100° C. for 2 hours under a nitrogen atmosphere. After completion of the reaction, the reaction mixture was diluted with ethyl acetate, sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography using an NH silica gel column and a Si silica gel column in series (ethyl acetate:methanol=100:0 to 90:10) to obtain the title compound (18 mg) as a pale yellow powder. MS (ESI) m / z: 536.1 [M+H]

[0307] Example 4 Synthesis of 2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-4-[4-(3-hydroxypropoxy)-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzamide Under a nitrogen atmosphere, 1N hydrochloric acid (0.35 mL) was added to a methanol (2.0 mL) solution of 2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxy-4-[2-methyl-6-(1-methylpyrazol-4-yl)-4-[3-(oxan-2-yloxy)propoxy]indazol-3-yl]benzamide (75 mg) described in Reference Example 36, and the mixture was stirred at room temperature for 2 hours. A 1N aqueous sodium hydroxide solution (0.35 mL) was added to the reaction mixture, and the mixture was concentrated under reduced pressure. Water was added to the concentrated residue, and the mixture was extracted with chloroform. The organic layer was separated using a Phase-Separator (registered trademark) and concentrated again under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform:methanol = 100:0 to 97:3 to 95:5) and then suspended and washed with diethyl ether to give the title compound (45 mg) as a pale yellow powder. MS (ESI) m / z: 560.4 [M+H]+

[0308] Example 5 Synthesis of 2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide 4-[6-bromo-4-(difluoromethoxy)-2-methylindazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (40 mg), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (18 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (6.0 mg), and potassium carbonate (20 mg) were suspended in a mixed solvent of 1,4-dioxane (0.49 mL) and water (0.12 mL), and the mixture was heated and stirred at 100°C for 80 minutes under a nitrogen atmosphere. The reaction solution was purified directly by silica gel column chromatography (ethyl acetate:methanol = 100:0 to 85:15). The resulting crude product was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to give the title compound (31 mg) as a gray powder. MS (ESI) m / z: 552.3 [M+H]

[0309] Example 6 Synthesis of 2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxy-4-[2-methyl-6-(1-methylpyrazol-4-yl)-4-phenylmethoxyindazol-3-yl]benzamide 4-(6-bromo-2-methyl-4-phenylmethoxyindazol-3-yl)-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (52 mg), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (27 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (7.2 mg), and potassium carbonate (24 mg) were suspended in a mixed solvent of 1,4-dioxane (3.0 mL) and water (0.30 mL), and the mixture was heated and stirred for 3 hours at 100°C under a nitrogen atmosphere. The reaction solution was extracted with water and chloroform, and the organic layer was separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=50:50 to 0:100) and then again by silica gel column chromatography (hexane:ethyl acetate=50:50 to 0:100 to chloroform:methanol=97:3), and then suspended and washed with diethyl ether to give the title compound (29 mg) as a colorless powder. MS (ESI) m / z: 592.4 [M+H]+

[0310] Example 7 Synthesis of 3-[3-(difluoromethoxy)-4-[3-hydroxy-3-(trifluoromethyl)azetidine-1-carbonyl]-5-methoxyphenyl]-2-methyl-6-(1-methylpyrazol-4-yl)indazole-4-carbonitrile 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid (40 mg), HATU (49 mg), and N,N-diisopropylethylamine (44 μL) described in Reference Example 42 were suspended in N,N-dimethylformamide (1.0 mL), and 3-(trifluoromethyl)azetidin-3-ol hydrochloride (23 mg) was added at room temperature and stirred for 18 minutes. After completion of the reaction, the reaction solution was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to obtain the title compound (49 mg) as a white powder. MS (ESI) m / z: 577.1 [M+H]+

[0311] Example 8 Synthesis of 3-[3-(difluoromethoxy)-4-[3-(difluoromethyl)-3-methylazetidine-1-carbonyl]-5-methoxyphenyl]-2-methyl-6-(1-methylpyrazol-4-yl)indazole-4-carbonitrile The title compound was obtained by carrying out the same reaction and treatment as in Example 7 using 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid and 3-(difluoromethyl)-3-methylazetidine hydrochloride described in Reference Example 42. MS (ESI) m / z: 557.2 [M+H]+

[0312] Example 9 Synthesis of 3-[3-(difluoromethoxy)-4-[3-(difluoromethoxy)azetidine-1-carbonyl]-5-methoxyphenyl]-2-methyl-6-(1-methylpyrazol-4-yl)indazole-4-carbonitrile The title compound was obtained by carrying out the same reaction and treatment as in Example 7 using 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid and 3-(difluoromethoxy)azetidine hydrochloride described in Reference Example 42. MS (ESI) m / z: 559.3 [M+H]

[0313] Example 10: Synthesis of 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-N-[(2,2-difluorocyclopropyl)methyl]-2-(difluoromethoxy)-6-methoxybenzamide The title compound was obtained by carrying out the same reaction and treatment as in Example 7 using 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid and (2,2-difluorocyclopropyl)methanamine hydrochloride described in Reference Example 42. MS (ESI) m / z: 543.3 [M+H]+

[0314] Example 11: Synthesis of N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-4-[4-(difluoromethyl)-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzamide To a suspension of 2-(difluoromethoxy)-4-[4-(difluoromethyl)-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxybenzoic acid (30 mg) described in Reference Example 46 in tetrahydrofuran (0.31 mL) was added oxalyl dichloride (24 mg) and N,N-dimethylformamide (1 drop) in that order at room temperature, and the mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and toluene was then added to the resulting residue, which was then concentrated under reduced pressure again. Dichloromethane (1.0 mL) and (R)-2,2-difluorocyclopropan-1-amine hydrochloride (11 mg) were added to the residue, and the mixture was suspended. N,N-diisopropylethylamine (54 μL) was added, and the mixture was stirred at room temperature for 10 minutes. The reaction solution was concentrated again, and the residue was dissolved in DMSO and purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to obtain the title compound (27 mg) as a white powder. MS (ESI) m / z: 554.4 [M+H]+

[0315] Example 12: Synthesis of 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1-fluorocyclopropyl)methyl]-6-methoxybenzamide To a solution of 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid (100 mg) and (1-fluorocyclopropyl)methanamine hydrochloride (30 mg) in N,N-dimethylformamide (2.2 mL) described in Reference Example 42, N,N-diisopropylethylamine (0.11 mL) and HATU (92 mg) were added in that order at room temperature, and the mixture was stirred for 1.5 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, which was then extracted twice with ethyl acetate. The organic layer was separated using a Phase-Separator (registered trademark) and concentrated under reduced pressure. The concentrated residue was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to obtain the title compound (80 mg) as a white powder. MS (ESI) m / z: 525.1 [M+H]+

[0316] Example 13: Synthesis of [2-(difluoromethoxy)-6-methoxy-4-[4-methoxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]phenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone To a solution of 2-(difluoromethoxy)-6-methoxy-4-[4-methoxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]benzoic acid (100 mg), HATU (100 mg), and 3-(trifluoromethyl)azetidin-3-ol hydrochloride (46 mg) described in Reference Example 51 in N,N-dimethylformamide (1.1 mL), N,N-diisopropylethylamine (0.11 mL) was added and stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to obtain the title compound (86 mg) as a colorless powder. MS (ESI) m / z: 582.3 [M+H]+

[0317] Example 14: Synthesis of [2-(difluoromethoxy)-4-[4-(difluoromethoxy)-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone [4-[6-bromo-4-(difluoromethoxy)-2-methylindazol-3-yl]-2-(difluoromethoxy)-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (106 mg), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (43 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (14 mg), and potassium carbonate (48 mg) were suspended in a mixed solvent of 1,4-dioxane (0.86 mL) and water (0.22 mL), and the mixture was heated and stirred at 100°C for 95 minutes under a nitrogen atmosphere. The reaction solution was purified directly by silica gel column chromatography (chloroform:methanol = 100:0 to 85:15). The resulting crude product was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to give the title compound (53 mg) as a pale brown powder. MS (ESI) m / z: 618.1 [M+H]

[0318] Example 15: Synthesis of 3-[3-(difluoromethoxy)-4-[3-hydroxy-3-(trifluoromethyl)azetidine-1-carbonyl]-5-methoxyphenyl]-6-(1-ethylpyrazol-4-yl)-2-methylindazole-4-carbonitrile 6-Bromo-3-[3-(difluoromethoxy)-4-[3-hydroxy-3-(trifluoromethyl)azetidine-1-carbonyl]-5-methoxyphenyl]-2-methylindazole-4-carbonitrile (90 mg), 1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (42 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (13 mg), and potassium carbonate (43 mg) were suspended in a mixed solvent of 1,4-dioxane (0.78 mL) and water (0.20 mL), and the mixture was heated and stirred at 100°C for 175 minutes under a nitrogen atmosphere. The reaction solution was purified directly by silica gel column chromatography (chloroform:methanol = 100:0 to 91:9). The resulting crude product was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to give the title compound (44 mg) as a pale brown powder. MS (ESI) m / z: 591.3 [M+H]

[0319] Example 16: Synthesis of 3-[3-(difluoromethoxy)-4-[3-hydroxy-3-(trifluoromethyl)azetidine-1-carbonyl]-5-methoxyphenyl]-6-[1-(2-hydroxy-2-methylpropyl)pyrazol-4-yl]-2-methylindazole-4-carbonitrile 6-Bromo-3-[3-(difluoromethoxy)-4-[3-hydroxy-3-(trifluoromethyl)azetidine-1-carbonyl]-5-methoxyphenyl]-2-methylindazole-4-carbonitrile (85 mg), 2-methyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]propan-2-ol (47 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (12 mg), and potassium carbonate (41 mg) were suspended in a mixed solvent of 1,4-dioxane (0.74 mL) and water (0.18 mL) and heated with stirring at 100°C for 70 minutes under a nitrogen atmosphere. The reaction solution was purified directly by silica gel column chromatography (chloroform:methanol = 100:0 to 85:15). The resulting crude product was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to give the title compound (49 mg) as a pale brown powder. MS (ESI) m / z: 635.4 [M+H]

[0320] Example 17: Synthesis of 2-[4-[4-cyano-3-[3-(difluoromethoxy)-4-[3-hydroxy-3-(trifluoromethyl)azetidine-1-carbonyl]-5-methoxyphenyl]-2-methylindazol-6-yl]pyrazol-1-yl]-N,N-dimethylacetamide 6-Bromo-3-[3-(difluoromethoxy)-4-[3-hydroxy-3-(trifluoromethyl)azetidine-1-carbonyl]-5-methoxyphenyl]-2-methylindazole-4-carbonitrile (90 mg), N,N-dimethyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]acetamide (52 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (13 mg), and potassium carbonate (43 mg) were suspended in a mixed solvent of 1,4-dioxane (0.78 mL) and water (0.20 mL) and heated with stirring at 100°C for 70 minutes under a nitrogen atmosphere. The reaction solution was purified directly by silica gel column chromatography (chloroform:methanol = 100:0 to 85:15). The resulting crude product was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) to give the title compound (54 mg) as a pale brown powder. MS (ESI) m / z: 648.4 [M+H]

[0321] Example 18: Synthesis of 4-[4-cyano-6-(1-ethylpyrazol-4-yl)-2-methylindazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide To a suspension of 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (50 mg) described in Reference Example 21 and 1-ethyl-4-iodopyrazole (24 mg) in N,N-dimethylformamide (1.0 mL), a solution of sodium carbonate (19 mg) in water (0.20 mL) and tetrakis(triphenylphosphine)palladium(0) (10 mg) were added and stirred overnight at 80° C. SiliaMetS DMT (registered trademark) was added and the mixture was shaken for 1 hour, after which insoluble matter was removed by filtration and washed with N,N-dimethylformamide. The filtrate was purified by preparative HPLC (0.1% TFA aqueous solution-acetonitrile) and then by NH silica gel column chromatography (dichloromethane:methanol=4:1) to obtain the title compound (14 mg) as a yellow powder. MS (ESI) m / z: 525.1 [M+H]

[0322] Example 19: Synthesis of 4-[4-cyano-6-[1-[2-(dimethylamino)ethyl]pyrazol-4-yl]-2-methylindazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide The title compound was obtained by the same reaction and treatment as in Example 18 using 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide and 2-(4-iodopyrazol-1-yl)-N,N-dimethylethanamine described in Reference Example 21. MS (ESI) m / z: 568.1 [M+H]+

[0323] Example 20: Synthesis of 4-[6-(1-tert-butylpyrazol-4-yl)-4-cyano-2-methylindazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide The title compound was obtained by the same reaction and treatment as in Example 18 using 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide and 1-tert-butyl-4-iodopyrazole described in Reference Example 21. MS (ESI) m / z: 553.1 [M+H]+

[0324] Example 21: Synthesis of 4-[4-cyano-2-methyl-6-(3-methyl-1,2-thiazol-5-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide The title compound was obtained by the same reaction and treatment as in Example 18 using 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide and 5-iodo-3-methyl-1,2-thiazole described in Reference Example 21. MS (ESI) m / z: 528.0 [M+H]+

[0325] Example 22: Synthesis of 4-[4-cyano-2-methyl-6-[1-(oxolan-3-yl)pyrazol-4-yl]indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide To a suspension of 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (50 mg) and 4-iodo-1-(oxolan-3-yl)pyrazole (29 mg) in N,N-dimethylformamide (1.0 mL), a solution of sodium carbonate (19 mg) in water (0.20 mL) and tetrakis(triphenylphosphine)palladium(0) (10 mg) were added and stirred overnight at 80°C. SiliaMetS DMT (registered trademark) was added and the mixture was shaken for 1 hour, after which insoluble material was removed by filtration and washed with N,N-dimethylformamide. The filtrate was purified by preparative HPLC (0.1% TFA aqueous solution - acetonitrile). The fractions containing the target compound were extracted with saturated aqueous sodium bicarbonate and dichloromethane, and concentrated under reduced pressure to give the title compound (15 mg) as a yellow powder. MS (ESI) m / z: 567.1 [M+H]

[0326] Example 23: Synthesis of 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-N-[(1R)-2,2-difluorocyclopropyl]-2-(difluoromethoxy)-6-methoxybenzamide To a solution of 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid (40 mg) described in Reference Example 42 in tetrahydrofuran (0.44 mL) were added oxalyl dichloride (34 mg) and N,N-dimethylformamide (1 drop) in that order at room temperature, and the mixture was stirred at room temperature for 7 hours. The reaction solution was concentrated under reduced pressure, and toluene was then added to the resulting residue, followed by further concentration under reduced pressure. The residue was suspended in (1S)-2,2-difluorocyclopropanamine hydrochloride (15 mg) and dichloromethane (2.0 mL), and N,N-diisopropylethylamine (76 μL) was added and the mixture was stirred overnight at room temperature. 1N hydrochloric acid was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was separated using a Phase-Separator®, sodium sulfate was added, and the mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified sequentially by NH silica gel column chromatography (ethyl acetate:methanol=100:0 to 95:5) and silica gel column chromatography (chloroform:methanol=100:0 to 90:10 to 80:20 to 70:30) to obtain the title compound (29 mg) as a white powder. MS (ESI) m / z: 529.3 [M+H]

[0327] Example 24: Synthesis of 4-[4-cyano-2-methyl-6-(1H-pyrazol-3-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide To a suspension of 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (50 mg) described in Reference Example 21 and 3-iodo-1H-pyrazole (21 mg) in N,N-dimethylformamide (1.0 mL), a solution of sodium carbonate (19 mg) in water (0.20 mL) and tetrakis(triphenylphosphine)palladium(0) (10 mg) were added and stirred overnight at 100° C. SiliaMetS DMT (registered trademark) was added and the mixture was shaken for 1 hour, after which insoluble material was removed by filtration and washed with N,N'-dimethylformamide. The filtrate was purified by preparative HPLC (0.1% TFA aqueous solution-acetonitrile), and the fraction containing the target compound was concentrated and purified by NH silica gel column chromatography (dichloromethane:methanol=4:1) to obtain the title compound (5.6 mg) as a white powder. MS (ESI) m / z: 497.0 [M+H]

[0328] Example 25: Synthesis of 3-[3-(difluoromethoxy)-4-[3-(difluoromethyl)-3-hydroxyazetidine-1-carbonyl]-5-methoxyphenyl]-2-methyl-6-(1-methylpyrazol-4-yl)indazole-4-carbonitrile To 3-(difluoromethyl)azetidin-3-ol hydrochloride (26 mg), 4-[4-cyano-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxybenzoic acid (50 mg) described in Reference Example 42, N,N-diisopropylethylamine (77 μL), and a solution of HATU (63 mg) in N,N-dimethylformamide (1.0 mL) were added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was filtered, and the filtrate was purified by preparative HPLC (0.1% TFA aqueous solution-acetonitrile). A saturated aqueous solution of sodium bicarbonate was added to the fraction containing the target product, followed by extraction with dichloromethane. The organic layer was washed with saturated brine and then concentrated under reduced pressure to obtain the title compound (21 mg) as a white powder. MS (ESI) m / z: 559.1 [M+H]+

[0329] Example 26: Synthesis of [2-(difluoromethoxy)-6-methoxy-4-[2-methyl-6-(1-methylpyrazol-4-yl)-4-(oxetan-3-ylmethoxy)indazol-3-yl]phenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone To a suspension of [2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (40 mg) described in Reference Example 54 and potassium carbonate (29 mg) in N,N-dimethylformamide (3.0 mL), 3-(bromomethyl)oxetane (16 mg) was added at room temperature under a nitrogen atmosphere, and the mixture was stirred at 80°C for 3 hours. After allowing the reaction solution to cool, water was added and the mixture was extracted with ethyl acetate. The organic layer was washed twice with saturated brine, and then the organic layer was separated using a Phase-separator (registered trademark) and concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (10 mM aqueous ammonium carbonate solution-acetonitrile) and then by NH silica gel column chromatography (chloroform:methanol=100:0 to 97:3), followed by suspension washing with diethyl ether to give the title compound (13 mg) as a pale yellow powder. MS (ESI) m / z: 638.3 [M+H]+

[0330] Example 27: Synthesis of [4-[4-(cyclobutylmethoxy)-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone The title compound was obtained by the same reaction and treatment as in Example 26 using [2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone and bromomethylcyclobutane described in Reference Example 54. MS (ESI) m / z: 636.4 [M+H]

[0331] Example 28: Synthesis of [2-(difluoromethoxy)-4-[4-(3-hydroxypropoxy)-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone Under a nitrogen atmosphere, 1N hydrochloric acid (0.14 mL) was added to a methanol (2.0 mL) solution of [2-(difluoromethoxy)-6-methoxy-4-[2-methyl-6-(1-methylpyrazol-4-yl)-4-[3-(oxan-2-yloxy)propoxy]indazol-3-yl]phenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (34 mg) described in Reference Example 57, and the mixture was stirred at room temperature for 20 hours. A 1N aqueous sodium hydroxide solution (0.14 mL) was added to the reaction mixture, and the mixture was concentrated under reduced pressure. Water was added to the concentrated residue, and the mixture was extracted with chloroform. The organic layer was separated using a Phase-Separator (registered trademark) and again concentrated under reduced pressure. The resulting residue was purified by NH silica gel column chromatography (chloroform:methanol = 100:0 to 95:5) and then suspended and washed with diethyl ether to give the title compound (21 mg) as an orange powder. MS (ESI) m / z: 626.3 [M+H]+

[0332] Example 29: Synthesis of [4-[4-(cyclopropylmethoxy)-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone To a solution of [2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (40 mg) described in Reference Example 54 and potassium carbonate (29 mg) in N,N-dimethylformamide (3.0 mL), bromomethylcyclopropane (14 mg) was added at room temperature under a nitrogen atmosphere, and the mixture was stirred at 80°C for 2 hours. Water was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was washed twice with saturated brine. The organic layer was separated using a Phase-Separator® and concentrated under reduced pressure. The resulting residue was purified by NH silica gel column chromatography (chloroform:methanol = 100:0 to 97:3) and then suspended and washed with diethyl ether to give the title compound (21 mg) as a pale yellow powder. MS (ESI) m / z: 622.3 [M+H]+

[0333] Example 30: Synthesis of [2-(difluoromethoxy)-6-methoxy-4-[2-methyl-6-(1-methylpyrazol-4-yl)-4-(2,2,2-trifluoroethoxy)indazol-3-yl]phenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone The title compound was obtained by the same reaction and treatment as in Example 29 using [2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone described in Reference Example 54 and 2,2,2-trifluoroethyl trifluoromethanesulfonate. MS (ESI) m / z: 650.3 [M+H]+

[0334] Example 31: Synthesis of 4-[4-cyano-6-[1-(2,2-difluoroethyl)pyrazol-4-yl]-2-methylindazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide (50 mg) described in Reference Example 21, 1-(2,2-difluoroethyl)-4-iodopyrazole (28 mg) in N,N-dimethylformamide (1.0 mL) suspension was added with a solution of sodium carbonate (19 mg) in water (0.20 mL) and tetrakis(triphenylphosphine)palladium(0) (10 mg), and the mixture was stirred overnight at 80 ° C. SiliaMetS DMT (registered trademark) was added and the mixture was shaken for 1 hour, after which insoluble matter was removed by filtration and washed with N,N-dimethylformamide. The filtrate was purified by preparative HPLC (0.1% TFA aqueous solution-acetonitrile), and the fraction containing the target product was concentrated and purified by NH silica gel column chromatography (dichloromethane:methanol=4:1). The crude product was purified again by preparative HPLC (10 mM ammonium carbonate aqueous solution-acetonitrile) to obtain the title compound (9.2 mg) as a white powder. MS (ESI) m / z: 561.0 [M+H]+

[0335] Example 32: Synthesis of 4-[4-cyano-6-[1-(cyclopropylmethyl)pyrazol-4-yl]-2-methylindazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide The title compound was obtained by the same reaction and treatment as in Example 31 using 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide and 1-(cyclopropylmethyl)-4-iodopyrazole described in Reference Example 21. MS (ESI) m / z: 551.1 [M+H]+

[0336] Example 33: Synthesis of 4-[4-cyano-2-methyl-6-(1-propan-2-ylpyrazol-4-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide The title compound was obtained by the same reaction and treatment as in Example 31 using 4-[4-cyano-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]-2-(difluoromethoxy)-N-[(1R,2S)-2-fluorocyclopropyl]-6-methoxybenzamide and 4-iodo-1-propan-2-ylpyrazole described in Reference Example 21. MS (ESI) m / z: 539.1 [M+H]+

[0337] Example 34: Synthesis of [2-(difluoromethoxy)-6-methoxy-4-[2-methyl-6-(1-methylpyrazol-4-yl)-4-(pyridin-3-ylmethoxy)indazol-3-yl]phenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone To a suspension of [2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (60 mg) and potassium carbonate (73 mg) in N,N-dimethylformamide (3.0 mL) described in Reference Example 54, 3-(bromomethyl)pyridine hydrobromide (32 mg) was added at room temperature under a nitrogen atmosphere, and the mixture was heated and stirred at 80°C for 1 hour. After completion of the reaction, water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed twice with saturated brine. The organic layer was separated using a Phase-Separator® and concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (0.05% TFA aqueous solution-0.05% TFA acetonitrile solution). A saturated aqueous sodium bicarbonate solution was added to the fraction containing the target product, and the mixture was extracted with ethyl acetate. The organic layer was separated using a Phase-Separator (registered trademark) and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (chloroform:methanol=100:0 to 97:3), and the resulting crude product was suspended and washed with diethyl ether to obtain the title compound (10 mg) as a colorless powder. MS (ESI) m / z: 659.4 [M+H]+

[0338] Example 35: Synthesis of [2-(difluoromethoxy)-6-methoxy-4-[2-methyl-6-(1-methylpyrazol-4-yl)-4-(pyridin-4-ylmethoxy)indazol-3-yl]phenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone To a suspension of [2-(difluoromethoxy)-4-[4-hydroxy-2-methyl-6-(1-methylpyrazol-4-yl)indazol-3-yl]-6-methoxyphenyl]-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]methanone (40 mg) described in Reference Example 54 and potassium carbonate (49 mg) in N,N-dimethylformamide (3.0 mL), 4-(bromomethyl)pyridine hydrobromide (27 mg) was added at room temperature under a nitrogen atmosphere, and the mixture was heated and stirred at 80°C for 2 hours. After completion of the reaction, water was added to the reaction mixture, which was then extracted with ethyl acetate, and the organic layer was washed twice with saturated brine. The organ...

Claims

1. A compound represented by the following formula (I): [In the formula, R 1 is a cyano group, C optionally substituted with 1 to 3 halogen atoms 1-4 Alkyl group or R 1a C optionally substituted with 1 to 3 substituents independently selected from 1-4 an alkoxy group, where R 1a is a halogen atom; a cyano group, a halogen atom, and C 1-4 a 5- or 6-membered monocyclic aromatic heterocyclic group which may be substituted by 1 to 3 substituents independently selected from the group consisting of alkyl groups; a 4-membered monocyclic aliphatic heterocyclic group; a hydroxyl group; 3-4 a cycloalkyl group; and a phenyl group; L is a single bond, C 1-4 Alkylene group or C 2-4 is an alkenylene group, R 2 is R 2a is a 5-membered monocyclic aromatic heterocyclic group optionally substituted with 2a is R 2b C, which may be substituted with 1 to 4 substituents independently selected from 1-5 an alkyl group, or a 5-membered monocyclic aliphatic heterocyclic group, where R 2b is a hydroxyl group; C optionally substituted with a hydroxyl group 3-4 Cycloalkyl group; halogen atom; C 1- 4 an alkoxy group; a 4- to 6-membered monocyclic aliphatic heterocyclic group which may be substituted with 1 to 3 substituents independently selected from the group consisting of a halogen atom and an oxo group; an oxo group; 1-4 an amino group optionally substituted with an alkyl group; a phenyl group; a 5-membered monocyclic aromatic heterocyclic group; and 1-4 an alkylsulfonyl group, R 3 is a hydrogen atom or C optionally substituted with 1 to 3 halogen atoms 1-4 is an alkoxy group, R 4 is C optionally substituted with 1 to 3 halogen atoms 1-4 ​is an alkoxy group, R 5 is a hydrogen atom; R 6 is a hydrogen atom; C substituted with a halocyclopropyl group 1-4 an alkyl group; or a cyclopropyl group substituted with 1 to 2 halogen atoms; or R 5 and R 6 together with the nitrogen atom to which they are attached form an azetidine ring, wherein the azetidine ring is a C 1-4 C which may be substituted with an alkyl group, a hydroxyl group, or 1 to 2 halogen atoms 1-4 substituted with 1 to 2 substituents independently selected from the group consisting of an alkoxy group, a cyano group, and an amino group; or 4 and R 6 is R 4 is attached to a benzene ring to form a tetrahydroisoquinolin-1-one ring, which ring is 1-4 or a pharma- ceutical acceptable salt thereof.

2. R 1 C optionally substituted with 1 to 3 halogen atoms 1-4 C optionally substituted with an alkyl group or 1 to 3 halogen atoms 1-4 L is a single bond; R 2 is a substituent R 2b’ C optionally substituted with 1-4 A pyrazolyl group optionally substituted with an alkyl group, 2b’ represents a hydroxyl group, 1 to 3 halogen atoms, C 1-4 R is independently selected from the group consisting of an alkoxy group, and a hydroxyl-substituted cyclobutyl group; 3 C optionally substituted with 1 to 3 halogen atoms 1-4 is an alkoxy group, R 4 C optionally substituted with 1 to 3 halogen atoms 1-4 is an alkoxy group, R 5 is a hydrogen atom; R 6 is a hydrogen atom; C substituted with a halocyclopropyl group 1-4 an alkyl group; or a cyclopropyl group substituted with 1 to 2 halogen atoms; or R 4 and R 6 is R 4 is attached to a benzene ring, to form a tetrahydroisoquinolin-1-one ring, 1-4 2. The compound according to claim 1, wherein the compound is substituted with an alkyl group, or a pharma- ceutical acceptable salt thereof.

3. R 1 C optionally substituted with 1 to 3 fluorine atoms 1-2 C optionally substituted with an alkyl group or 1 to 3 fluorine atoms 1-2 an alkoxy group; L is a single bond; R 2 is a substituent R 2b’’ C optionally substituted with 1-3 A pyrazolyl group optionally substituted with an alkyl group, 2b’’ is independently selected from the group consisting of a hydroxyl group, 1 to 3 fluorine atoms, a methoxy group, and a hydroxyl-substituted cyclobutyl group; R 3 is a methoxy group optionally substituted with 1 to 3 fluorine atoms, R 4 is a methoxy group optionally substituted with 1 to 3 fluorine atoms, R 5 is a hydrogen atom; R 6 is a hydrogen atom; a methyl group substituted with a fluorocyclopropyl group; or a cyclopropyl group substituted with one to two fluorine atoms; or R 4 and R 6 is R 4 is taken together with the benzene ring to which it is attached to form a tetrahydroisoquinolin-1-one ring (wherein the 4-position of the ring is substituted with 1 to 2 methyl groups), or a pharma- ceutically acceptable salt thereof.

4. R 1 is a cyano group, -CHF 2 , -OCHF 2 , or -OC 2 H 5 The compound according to any one of claims 1 to 3, or a pharma- cologically acceptable salt thereof.

5. R 2 -L-, where R 2a But -CH 3 , -CHF 2 , -CH 2 CH 3 , -CH 2 CF 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 OCH 3 , -CH 2 CH (CH 3 5. The compound according to claim 1, or a pharmacologically acceptable salt thereof, wherein R is 0, R is 1, R is 2, R is 3, R is 4, R is 5, R is 6, R is 7, R is 8, R is 9, R is 10, R is 11, R is 12, R is 13, R is 14, R is 15, R is 16, R is 17, R is 18, 6. R 3 But, -OCH 3 , or -OCHF 2 The compound according to any one of claims 1 to 5, or a pharma- ceutical acceptable salt thereof.

7. R 4 But, -OCH 3 , or -OCHF 2 And R 5 is a hydrogen atom; R 6 is a hydrogen atom, or or R 4 and R 6 is R 4 is attached to a benzene ring to form a tetrahydroisoquinolin-1-one ring (wherein the 4-position of the ring is 3 The compound according to any one of claims 1 to 6, wherein the compound forms a ring structure substituted with 8. R 1 is a cyano group, -CHF 2 , or -OCHF 2 , or -OC 2 H 5 And R 2 -L-, where R 2a But -CH 3 , -CHF 2 , -CH 2 CH 3 , -CH 2 CF 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 OCH 3 , -CH 2 CH (CH 3 ) OH, or a 3-hydroxycyclobutylmethyl group; R 3 But, -OCH 3 , or -OCHF 2 And R 4 But, -OCH 3 , or -OCHF 2 And R 5 is a hydrogen atom; R 6 is a hydrogen atom, or or R 4 and R 6 is R 4 is attached to a benzene ring to form a tetrahydroisoquinolin-1-one ring (wherein the 4-position of the ring is 3 4. The compound according to claim 3, wherein the compound is substituted with 9. The following: A compound selected from the group consisting of: or a pharmacologically acceptable salt thereof.

10. A pharmaceutical composition comprising the compound according to any one of claims 1 to 9 or a pharmacologically acceptable salt thereof as an active ingredient.

11. The pharmaceutical composition according to claim 10, which is used for the prevention or treatment of various diseases and / or symptoms associated therewith that can be improved by inhibition of salt-inducible kinase (SIK), or for improving the prognosis of such diseases and / or symptoms associated therewith.

12. The pharmaceutical composition according to claim 10, which is an agent for the prevention or treatment of a disease selected from inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases associated with impaired cartilage metabolic turnover, congenital cartilage malformations, diseases associated with impaired bone metabolic turnover, diseases associated with excessive secretion of TNF-α, interferon, IL-6, IL-12, and / or IL-23, respiratory diseases, endocrine and / or metabolic diseases, cardiovascular diseases, skin diseases, and diseases associated with abnormal angiogenesis.

13. Rheumatoid arthritis, osteoarthritis, psoriatic arthritis, chronic inflammatory demyelinating polyneuropathy, ulcerative colitis, Crohn's disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, type 1 diabetes, type 2 diabetes, pancreatitis, systemic lupus erythematosus, cutaneous lupus erythematosus, central nervous system lupus, lupus nephritis, antiphospholipid syndrome, chronic renal failure, acute kidney injury, sarcoidosis, systemic sclerosis, localized scleroderma, Sjogren's syndrome, ANCA-associated vasculitis, immune complex-mediated small vasculitis, polyarteritis nodosa, Kawasaki disease, Takayasu's vasculitis, giant cell arteritis, idiopathic inflammatory myopathy (polymyositis, dermatomyositis, inclusion body myositis), IgG4-related disease, juvenile Still's disease, pelvic inflammatory disease, psoriasis, pustular psoriasis, atopic dermatitis, asthma, allergies 11. The pharmaceutical composition according to claim 10, which is an agent for the prevention or treatment of a disease selected from the group consisting of chronic pulmonary fibrosis, relapsing polychondritis, mixed connective tissue disease, graft-versus-host disease, idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, chronic obstructive pulmonary disease, myelofibrosis, multiple sclerosis, cerebral infarction, ischemic stroke, Alzheimer's disease, Parkinson's disease, depression, developmental epilepsy, Meniere's disease, narcolepsy, macrophage activation syndrome, sepsis, pulmonary hypertension, dyslipidemia, Behcet's disease, uveitis, osteoporosis, bone fracture, osteosarcoma, heart failure, hypertrophic cardiomyopathy, atherosclerosis, female pregnancy, ovarian cancer, breast cancer, prostate cancer, malignant lymphoma, leukemia, multiple myeloma, lung cancer, granuloma annulare, esophageal cancer, colon cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, melanoma, and secondary hemophagocytic lymphohistiocytosis.

14. The pharmaceutical composition according to claim 10, which is an agent for preventing or treating a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, primary biliary cholangitis, primary sclerosing cholangitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjogren's syndrome, psoriasis, pustular psoriasis, Behcet's disease, ovarian cancer, and acute myeloid leukemia.

15. The pharmaceutical composition according to claim 10, which is an agent for preventing or treating a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjogren's syndrome, pustular psoriasis, and Behcet's disease.

16. The compound according to any one of claims 1 to 9 or a pharmacologic acceptable salt thereof, for use in the prevention or treatment of various diseases and / or symptoms associated therewith that can be ameliorated by inhibition of salt-inducible kinase (SIK), or for use in improving the prognosis of such diseases and / or symptoms associated therewith.

17. The compound according to any one of claims 1 to 9 or a pharmacologic acceptable salt thereof, for use in the prevention or treatment of a disease selected from inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases associated with impaired cartilage metabolic turnover, congenital cartilage malformations, diseases associated with impaired bone metabolic turnover, diseases associated with excessive secretion of TNF-α, interferon, IL-6, IL-12, and / or IL-23, respiratory diseases, endocrine and / or metabolic diseases, cardiovascular diseases, skin diseases, and diseases associated with abnormal angiogenesis.

18. Rheumatoid arthritis, osteoarthritis, psoriatic arthritis, chronic inflammatory demyelinating polyneuropathy, ulcerative colitis, Crohn's disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, type 1 diabetes, type 2 diabetes, pancreatitis, systemic lupus erythematosus, cutaneous lupus erythematosus, central nervous system lupus, lupus nephritis, antiphospholipid syndrome, chronic kidney disease, acute renal failure, sarcoidosis, systemic sclerosis, localized scleroderma, Sjogren's syndrome, ANCA-associated vasculitis, immune complex-mediated small vasculitis, polyarteritis nodosa, Kawasaki disease, Takayasu's vasculitis, giant cell arteritis, idiopathic inflammatory myopathies (polymyositis, dermatomyositis, inclusion body myositis), IgG4-related disease, juvenile Still's disease, pelvic inflammatory disease, psoriasis, pustular psoriasis, atopic dermatitis, asthma, allergic rhinitis, recurrent polyarteritis, The compound according to any one of claims 1 to 9, or a pharmacologically acceptable salt thereof, for use in the prevention or treatment of a disease selected from chondritis, mixed connective tissue disease, graft-versus-host disease, idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, chronic obstructive pulmonary disease, myelofibrosis, multiple sclerosis, cerebral infarction, ischemic stroke, Alzheimer's disease, Parkinson's disease, depression, developmental epilepsy, Meniere's disease, narcolepsy, macrophage activation syndrome, sepsis, pulmonary hypertension, dyslipidemia, Behcet's disease, uveitis, osteoporosis, bone fracture, osteosarcoma, heart failure, hypertrophic cardiomyopathy, atherosclerosis, female pregnancy, ovarian cancer, breast cancer, prostate cancer, malignant lymphoma, leukemia, multiple myeloma, lung cancer, granuloma annulare, esophageal cancer, colon cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, melanoma, and secondary hemophagocytic lymphohistiocytosis.

19. The compound according to any one of claims 1 to 9 or a pharmacologic acceptable salt thereof, for use in the prevention or treatment of a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, primary biliary cholangitis, primary sclerosing cholangitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjogren's syndrome, psoriasis, pustular psoriasis, Behcet's disease, ovarian cancer, and acute myeloid leukemia.

20. The compound according to any one of claims 1 to 9 or a pharmacologic acceptable salt thereof, for use in the prevention or treatment of a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjogren's syndrome, pustular psoriasis, and Behcet's disease.

21. A method for preventing or treating various diseases and / or symptoms associated therewith that can be improved by inhibition of salt-inducible kinase (SIK), comprising administering to a patient a therapeutically effective amount of a compound according to any one of claims 1 to 9 or a pharmacologically acceptable salt thereof.

22. A method for preventing or treating a disease selected from inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases associated with impaired cartilage turnover, congenital cartilage malformations, diseases associated with impaired bone turnover, diseases associated with excessive secretion of TNF-α, interferon, IL-6, IL-12, and / or IL-23, respiratory diseases, endocrine and / or metabolic diseases, cardiovascular diseases, skin diseases, and diseases associated with abnormal angiogenesis, comprising administering to a patient a therapeutically effective amount of a compound according to any one of claims 1 to 9 or a pharmacologically acceptable salt thereof.

23. A method for treating rheumatoid arthritis, osteoarthritis, psoriatic arthritis, chronic inflammatory demyelinating polyneuropathy, ulcerative colitis, Crohn's disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, type 1 diabetes, type 2 diabetes, pancreatitis, systemic steatohepatitis, rheumatoid arthritis, osteoarthritis, psoriatic arthritis, chronic inflammatory demyelinating polyneuropathy, ulcerative colitis, Crohn's disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, type 1 diabetes, type 2 diabetes, pancreatitis, systemic steatohepatitis, rheumatoid arthritis, osteoarthritis, osteoporosis ... Lupus erythematosus, cutaneous lupus erythematosus, central nervous system lupus, lupus nephritis, antiphospholipid syndrome, chronic kidney disease, acute kidney injury, sarcoidosis, systemic sclerosis, localized scleroderma, Sjogren's syndrome, ANCA-associated vasculitis, immune complex-mediated small vasculitis, polyarteritis nodosa, Kawasaki disease, Takayasu's vasculitis, giant cell arteritis, idiopathic inflammatory myopathy (polymyositis, dermatomyositis, inclusion body myositis), IgG4-related disease, juvenile Still's disease, pelvic inflammatory disease, psoriasis, pustular psoriasis, atopic dermatitis, asthma, allergic rhinitis, relapsing polychondritis, mixed connective tissue disease, graft-versus-host disease, idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, chronic obstructive pulmonary disease, myelofibrosis, multiple sclerosis, cerebral infarction, ischemic stroke, Alzheimer's disease, Parkinson's disease, depression, developmental epilepsy, Meniere's disease, narcolepsy, macrophage activation syndrome, A method for preventing or treating a disease selected from sepsis, pulmonary hypertension, dyslipidemia, Behcet's disease, uveitis, osteoporosis, fracture, osteosarcoma, heart failure, hypertrophic cardiomyopathy, atherosclerosis, female pregnancy, ovarian cancer, breast cancer, prostate cancer, malignant lymphoma, leukemia, multiple myeloma, lung cancer, granuloma annulare, esophageal cancer, colon cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, melanoma, and secondary hemophagocytic lymphohistiocytosis.

24. A method for preventing or treating a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, primary biliary cholangitis, primary sclerosing cholangitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjogren's syndrome, psoriasis, pustular psoriasis, Behcet's disease, ovarian cancer, and acute myeloid leukemia, comprising administering to a patient a therapeutically effective amount of a compound according to any one of claims 1 to 9 or a pharmacologically acceptable salt thereof.

25. A method for preventing or treating a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, pancreatitis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, Sjogren's syndrome, pustular psoriasis, and Behcet's disease, comprising administering to a patient a therapeutically effective amount of a compound according to any one of claims 1 to 9 or a pharmacologically acceptable salt thereof.

Citation Information

Patent Citations

  • Method for manufacturing resin molded article

    JP2023085585A

  • Compounds for the treatment of inflammatory disorders

    US20070219218A1

  • Compositions useful for treating disorders related to kit

    US20160031892A1

  • Antiviral pyridopyrazinedione compounds

    US20200079772A1

  • Substituted 2-amino-3-cyanopyridines as inhibitors of sodium-calcium exchange and use thereof for cardiovascular diseases

    WO2013144191A1

Cited By

  • Heterocyclic SIK inhibitors

    JP2025532626A

  • Heterocyclic SIK inhibitors

    JP7826572B2